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Abstract
Major histocompatability complex class I (MHC-I) proteins present short fragments of
pathogenic or cancerous proteins (peptides) on the surface of infected cells for recogni-
tion by T lymphocytes which are stimulated upon recognition of foreign peptides. Due
to the diversity of peptide sequences and the sequence-specificity of MHC-I alleles, be-
ing able to determine which peptides will be presented by which MHC-I alleles and in
what proportion could be important for the development of vaccines and treatments based
on the presented peptiodome. Machine learning tools, trained on experimental data, are
widely used to predict immunogenic peptides. However they are unable to account for the
impact the intracellular kinetics of the pathogenic or cancerous protein which will greatly
influence the resultant peptidome. Here we describe a mechanistic model of peptide pre-
sentation, validated against experimental data, which accounts for intracellular peptide
concentration, and can predict the relative cell surface presentation of competing peptides
with varying affinities for MHC-I proteins. We demonstrate how combining this mecha-
nistic model with the intracellular kinetics of HIV proteins can provide insight in to the
experimentally reported immunogenicity of the viral protein Gag, and show how such a
model can be used to predict the most abundant viral peptides presented on the cell sur-
face. Similarly, we predict the HeLa cell peptidome and demonstrate how a simple metric
can be used to approximate the abundance of a peptide based solely on protein synthesis
and degradation, peptide-MHC affinity and proteasomal cleavage.
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Chapter 1
Introduction
1.1 The Immune System
The immune system is a complex network of organs, cells and proteins working together
to protect the body from infection by pathogens, such as viruses and bacteria, as well
as seeking out and destroying the body’s own cells that may have become cancerous
due to mutations. In general, the immune system is split in to two: the adaptive immune
system and the innate immune system. Although these two systems are largely considered
separately, there is evidence of an interface between them[1, 2, 3]. In this thesis, however
we will be focussing solely on the adaptive immune system.
During initial infection by a pathogen the first line of defence is the innate immune
system. The responses of the innate immune system are not pathogen specific, but in-
stead recognise general conserved pathogen features, known as pathogen-associated im-
munostimulants. The recognition of these molecules results in inflammatory responses
and phagocytosis, where cells such as neutrophils and macrophages “eat” an infected
cell[4].
In contrast, the response of the adaptive immune system is pathogen specific and
can provide long lasting immunity to the pathogen in question. Something that triggers a
response from the adaptive immune system is known as an antibody generator or antigen,
usually in the form of a pathogenic protein. There are two classes of adaptive immune re-
sponse once an antigen has been detected - antibody responses and cell mediated immune
responses - and they both involve white blood cells called lymphocytes. Lymphocytes
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known as B-cells, which are produced in the bone marrow, are responsible for antibody
responses, whereas another type of lymphocyte known as T-cells or cytotoxic T lympho-
cytes (CTLs), are produced in the thymus and are responsible for cell mediated responses.
When B-cells are activated they produce antibodies known as immunoglobulins
which bind to the antigen responsible for activating the B-cell and inactivate the pathogen.
T-cells are activated by foreign antigens presented on the surface of cells, and once acti-
vated they work to directly destroy the infected cell.
In this thesis we will focus on the cell mediated immune response of the adaptive im-
mune system, specifically on the intracellular or endogenous antigen processing pathway.
1.2 The Antigen Processing Pathway
When a human cell is infected by viruses or bacteria, the adaptive immune system is
alerted to its presence by the presentation of short lengths of pathogenic proteins, known
as peptides, on the cell surface. These peptides are presented by proteins encoded by
the Major Histocompatability Complex (MHC) region of the genome, which encodes for
three classes of genes that make up part of the innate immune system: MHC Class I,
Class II, and Class III molecules. The presentation of peptides by these MHC molecules
alerts T-cells to the presence of the infection. The immune system will focus its response
on only a few peptides out of the many possible sequences in a process known as im-
munodominance[5]. Immunodominance is when the immune response is directed at only
a few of the possible antigenic peptides. Peptides that are recognised by the immune
system are known as epitopes, and more specifically, peptides recognised by T-cells are
known as T-cell epitopes. The immunodominance of the set of epitopes and the efficiency
of the T-cell (thymus cell) response are determined by the cell surface abundance of the
MHC-I-peptide complex[6, 7], the affinity of the complex with the T-cell Receptor (TCR),
and the frequency of the T-cell precursor[8].
1.2.1 The T-cell receptor
The TCR is a complex of proteins found on the surface of T-cells that binds with the
pMHC complex on the surface of the cell. Stimulation of the TCR results in a signalling
cascade that activates the T-cell response against the cell infected with the pathogen. The
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co-receptors CD4 and CD8 enhance the T-cell signal by simultaneously binding to sur-
face peptide bound MHC-II and MHC-I respectively. TCRs are generally specific to the
peptide-MHC complex as they are produced by gene rearrangement during T-cell de-
velopment in the thymus, meaning each TCR receptor can be very different from one
another, and therefore each person produces a very large number of TCRs. This results in
TCRs that are very sensitive to only a small number of pMHC complexes out of the many
thousands of possibilities, and are highly specific to certain pMHC combinations.
The nature of T-cell antigen recognition is subject to much debate. Wu et al 2002[9]
provide evidence that the initial docking between the pMHC complex and the TCR is dic-
tated by the contacts of the MHC, whilst the peptide contacts stabilize the binding. How-
ever Burrows et al. 2010[10] report that the TCR is able to maintain peptide recognition
following mutations in three important MHC contacts, suggesting the peptide contacts are
more important than the MHC.
When a TCR binds with pMHC a structure termed the immunological synapse (IS)
is formed. Kupfer and collegues first viewed this structure as two concentric rings
of molecules[11], that were named the central supramolecular activation cluster (cS-
MAC) and peripheral supramolecular activation cluster (pSMAC). These bullseye shaped
synapses are observed between CD4+ T-cells and B-cell lymphoma tumour cells, and
when CD8+ T-cells interact with target cells. It was initially thought that this bullseye
formation was crucial for sustained TCR signalling. However, this bullseye structure is
not universal to immunological synapses, as T-cells contacting dendritic cells (DCs) in-
stead have a multifocal IS, and T-cell activation is possible before the fully mature IS is
formed. The formation of this synapse initiates down-stream signalling, including cal-
cium release, actin remodelling and finally T-cell activation.
A single pMHC complex is able to stimulate the release of intracellular calcium
within the T-cell[12]; however, several hundreds of complexes are required for full T-
cell activation and Lavoie et al. [13] report a quantitative relationship between pMHC
concentration and the magnitude of T-cell activation. T-cells are activated in peripheral
lymphoid organs when they recognise a cell infected with a pathogen, where they then
proliferate and differentiate in to effector cells, which can then kill the cells infected with
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that specific pathogen.
1.2.2 Peptide-MHC binding
Peptides can be presented by both MHC class I and class II proteins. Both MHC Class
I and II binding grooves are structurally similar, made up of two α helices and eight β
strands. The MHC class I binding groove, however, is closed, whereas the MHC class II
binding groove is open. This means MHC class I proteins can only form stable complexes
with peptides of length 8-13 amino acids long, although nonamers are most preferred as
this is the length of the binding groove, whereas MHC class II can bind peptides between
14-20 amino acids long. Different MHC proteins will preferentially bind different peptide
sequences, due to the polymorphism of the amino acids that make up the peptide-binding
groove. Both MHC class I and II present both pathogenic and ‘self’ peptides (derived
from degradation of the own host cell protein). Autoimmune diseases result from T-
cells recognizing self peptides and mounting a T-cell response against them. The innate
immune system discriminates self from non-self by positive selection for TCRs with a
low affinity for self-peptide-MHC complexes and negative selection for TCRs with high
affinity for self-peptide-MHC complexes[14].
Human Leukyocyte Antigens (HLA) are the human MHC proteins. The MHC Class
I loci are split in to three genes HLA-A, HLA-B and HLA-C, all of which are highly
polymorphic and so are associated with many different alleles, differing by one or more
amino acid substitution. There are six genes in the MHC Class II loci: HLA-DPA1,
HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA and HLA-DRB1. Each individual
can express up to two different alleles from each of the three HLA loci, inherited from
their parents, and the HLA loci are the most polymorphic in the human genome, with
HLA-B alone having more than 400 alleles, whilst in entirety, the Class I and II loci are
associated with over 1300 possible alleles.
1.2.3 The exogenous and endogenous pathways
In general, peptides which are produced via intracellular processing of pathogenic pro-
teins bind to MHC class I protein, as part of what is known as the endogenous antigen
processing pathway. Peptides in complex with MHC class I interact with the CD8 recep-
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tors of T-cells known as cytotoxic T-lymphocytes.
In the exogenous or extracellular pathway, extracellular antigens are taken in to the
cell via intracellular vesicles known as endosomes. As the endosomes progress further
in to the cell, the antigen is broken down in to peptides and made available for binding
to MHC Class II molecules for cell surface presentation. Peptides in complex with MHC
class II molecules interact with the CD4 receptors of T-cells known as T-helper (Th)
cells. MHC Class II molecules are expressed in professional antigen presenting cells
(APC) such as macrophages, B cells and dendritic cells. When CD4+ T-cells are activated
they produce a range of cytokines and chemokines. One type of CD4+ T-helper cell
known as Th1 is known to produce the cytokine inferon gamma (IFN-γ), which increases
intracellular production of MHC and enhance the cytotoxic function of CD8+ T-cells.
In this work we will focus on mathematically modelling the endogenous or intra-
cellular antigen processing pathway (Figure 1.1), by approximately solving a system of
coupled differential equations to simulate the concentration of each species present in
the system (see Chapter 2 for more details). In the endogenous pathway, peptides are
produced when ubiquitin tagged cytoplasmic proteins are degraded by the proteasome.
Peptides not only derive from the degradation of mature proteins (retirees), but also from
other sources such as Defective Ribosomal Products (DRiPs)[15, 16]. DRiPs are de-
fined as “prematurely terminated polypeptides and misfolded polypeptides produced from
translation of bona fide mRNAs in the proper reading frame”[15], and are thought to be
a significant source of peptide. In this work however, we will not consider the impact of
DRiPs on antigen presentation as the exact nature of DRiPs remains highly controversial,
and the data we require to include them in the models presented in this thesis are so far
not available. We include a section in Chapter 6 discussing how future work could include
DRiPs.
Peptides are transported to the endoplasmic reticulum (ER), via the transporter as-
sociated with antigen processing (TAP), where they are available for binding to MHC
molecules. Peptides compete for binding to the peptide loading complex (PLC), which is
made up of TAP, along with the chaperon molecules tapasin, calreticulin and ERp57[17].
Tapasin acts as a filtering mechanism by increasing the unbinding rate of the peptide from
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the MHC-I molecule, and so only peptides with a high affinity for the MHC in ques-
tion stay bound long enough to be presented on the cell surface, thus influencing peptide
immunodominance[18]. Recently, another chaperone molecule TAPBPR (a tapasin ho-
mologue), has also been found to act like tapasin to enhance peptide optimization[19, 20].
The unbinding rate of the peptide from the MHC complex is therefore an important factor
in determining the cell surface abundance, and thus the immunogenicity of the peptide.
Another prerequisite for presentation is a high abundance of the peptide in the ER,
as this will increase the likelihood of successful MHC-I binding when competing against
thousands of other self and pathogenic peptides. The abundance of a peptide in the ER
is determined by the synthesis and degradation of the protein from which the sequence is
cleaved, the probability of cleavage of that sequence by the proteasome, and the affinity
of that peptide with TAP.
Furthermore, the timing of the appearance of viral peptides on the cell surface fol-
lowing infection, and thus the intracellular kinetics of the viral proteins, also influences
the T-cell response[21]. When a CD8 T-cell recognises a foreign antigen it is activated in
the draining lymph nodes and releases cytotoxic granules to induce apoptosis and kill the
infected cell. CD8 T-cells also induce the production of IFN-γ . Some cross-presentation
can occur between the exogenous and endogenous pathways, such as presentation of pep-
tides taken up from the extracellular environment being presented by MHC-I.
1.2.4 T-cell epitopes
The development of T-cell vaccines for viruses such as HIV, or immunotherapy for dis-
eases such as cancer, requires mapping of the peptide hierarchies and identification of
immunodominant peptides, known as epitopes, and so epitope discovery is an important
area of research. For example, Livingston et al.[23] successfully immunized mice with
a pool of four HLA-DR-restricted HIV Th cell epitopes. T-cell vaccines will not prevent
infection, but aim to allow the immune system to control infection and limit or completely
stop the development of disease caused by the infection.
A correlation between the ability to contain HIV infection and the presence of strong
HIV-specific CD8+ T-cells and Th cell responses has been observed[24]. Vaccines stim-
ulating CD4+ or CD8+ T-cell responses to HIV may therefore act to delay or prevent
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Figure 1.1: The antigen processing pathway[22]. The endogenous antigen processing and
presentation pathway: Peptides produced via cytoplasmic degradation of peptide by the protea-
some are transported in to the ER via TAP where they are available for binding to MHC class I
molecules. The chaperon molecules tapasin, calreticulin, ERp57 and β2m make up the peptide
loading complex along with TAP and facilitate the binding process. Figure reproduced from [22].
HIV progression. Such T-cell vaccines have been successful at reducing the viral load
of Simian Immunodeficiency Virus (SIV) infected macaques by 1000 fold compared to
unvaccinated SIV-infected macaques. However, a successful HIV T-cell vaccine has not
yet been achieved.
A patient’s immune system could be manipulated to focus on specific disease related
epitopes that it otherwise would have been unable to recognise. For example, Toes et
al.[25] observed strong and protective tumor-reactive CD8+ T-cell responses when vac-
cinating a murine model with immunogenic T-cell epitopes from oncogenes required for
tumor growth. Alternatively, identification of immunogenic epitopes from self-proteins
can be used for de-selection purposes when treating autoimmune diseases[26].
1.3 Modelling Complex Biological Systems
The biological processes occurring in the cells and tissues of the human body are highly
complex, with a large number of components and interactions. To be able to understand
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such complex systems it is necessary to not only identify the components of the system but
also the interactions between them. Systems biology is the study of the interactions within
complex biological systems with the aim of understanding the underlying mechanisms of
the molecules and pathways. This is important for treating complex diseases such as
cancer and Human immunodeficiency virus (HIV).
However, when dealing with complex systems it can be difficult to gain an intuitive
understanding of the behaviour of the system and what one would expect to observe if
certain aspects were to change. Therefore, the development of computational mathemat-
ical models to describe complex systems is becoming more and more common in both
biology and medicine, and is a growing area of research[27].
A mathematical model embodies the current hypothesis and knowledge of the sys-
tem being studied, and by comparing the output with experimentally collected data, any
discrepancies or inconsistencies in the dynamic behaviour of the system can be identified
and investigated. In this way mathematical models can help support or disprove current
beliefs and point to areas where further research is needed. Models which are shown
to be consistent with the current knowledge and behaviour of the system can be used as
predictions to guide future experiments.
To construct a model of a biological system at the macroscopic level, where we are
interested in the concentrations of molecules, a set of equations describing the interactions
occurring between the component molecules are required that quantitatively represents
each interaction by numerically describing each process using rate constants. Ideally,
these rate constants would be determined via experiment, however in many cases the
methods or data required are not available, and so the values of the rate constants have
to be estimated using fitting techniques or by using the literature to estimate a range
in which such a value would fall. No matter how the parameter values are obtained,
however, there will always be some magnitude of uncertainty, due to experimental error,
lack of data or poor fit of the model to the data. Therefore, there will always be an
uncertainty associated with the output of the model, where in this case the output will
be the concentrations of each species in the model, either absolute or relative to one
another. A sensitivity analysis can reveal which parameters have the biggest impact on the
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output of the model and thus determine which parameter values are the source of the most
uncertainty. Furthermore, a sensitivity analysis can reveal which are the most important
mechanistic steps in a biological system or pathway and so identify possible therapeutic
targets.
The emergence of ‘high-throughput’ approaches has allowed the automation of ex-
periments so that many observations can be carried out in parallel, thus greatly increasing
the rate of data collection[28] and providing a wealth of data with which to build compu-
tational models of cellular processes. High-throughput experimental techniques are used
in several fields, such as genomics, transcriptomics and proteomics and the data collected
can then be analysed by bioinformaticians and statistions. For example, in transcrip-
tomics, using high-throughput technology it is possible to measure the expression lev-
els of the mRNA of thousands of genes in parallel, using complementary DNA (cDNA)
microarrays[29].
Hondowicz et al. 2012[30] developed a high-throughput protocol to screen CD8+
T-cells, using amplification and in vitro transcription of minigene libraries and Enzyme-
Linked ImmunoSpot (ELISPOT) assay and identified two novel T-cell epitopes targeted
in newly diagnosed type I diabetes sufferers. This demonstrates how high-throughput
technologies can be used for T-cell antigen discovery.
Harndahl et al. 2011 [31] used a high-throughput pMHC dissociation assay, screen-
ing hundreds of peptides binding to MHC-I molecule HLA-A*02:01. Such data could
be used, for example, to help train the machine learning algorithms mentioned in Section
1.3.2 and discussed in more detail in Section 2.2.
Mathematical and computational modelling has been successfully applied to a wide
range of biological and medical problems. Extensive research has been carried out in to
heart disease by modeling blood flow and electrical activity in the heart with the aim
of aiding physicians with treatment options, such as determining the optimal bypass
construction[32]. One important area of model development is in describing different
aspects of the human immune system. For example, a simple system of two ordinary
differential equations (ODEs) can capture the primary and secondary response of the im-
mune system to a target population of pathogen e.g. virus, bacteria or tumour cells [33].
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Wodarz & Nowak 2002[34] applied a basic model of viral dynamics to HIV infection,
simulating the impact of anti-viral therapies on viral load and the dynamics of antigenic
escape using a simplified model of virus-immune interactions.
1.3.1 Modelling the TCR
Considerable effort has gone in to modelling TCR triggering, the earliest of which
was McKeithan’s 1995[35] paper in which TCR activation was modelled using ‘Kinetic
proofreading’ as had been previously applied to models of DNA replication and protein
synthesis[36, 37]. This model is based upon the fact that there is a time lag between
the pMHC-TCR binding and T-cell signalling. The model starts off with the TCR in the
inactive state, and when the pMHC binds it is required that it stay associated with the
TCR long enough for N sequential modifications in the path to signal transduction have
been completed. Therefore pMHC with a low dissociation rate are more likely to result
in a T-cell signal than those with a high dissociation rate. Those complexes with a high
dissociation rate can overcome this by being present in large quantities and so increase
the probability of a successful full signal. Dushek et al. 2009[38] modified this simple
model to investigate the impact of pMHC-TCR rebinding, whilst van den Berg 2002[39]
also modified the model to study T-cell antagonism by peptides that are variants of an im-
munogenic peptide, which suggest that in addition to dissociation rate, the pMHC-TCR
affinity and the pMHC presentation level are also important for T-cell activation. Coombs
et al. 2002[40] incorporated this model in to their study of pMHC-induced TCR down-
regulation, and the trade-off between kinetic proofreading and serial engagement (where
T-cell activation requires a single peptide serial engages multiple multiple TCRs).
Germain and colleagues introduced kinetic proofreading with positive and negative
feedback loops, where the negative feedback reduces the number of subsequent activa-
tion steps and the positive feedback enhances further signalling[41, 42, 43], leading to
bistability in the T-cell response. Predictions made by the model were also verified when
Altan-Bonnet and Germain 2004[43] measured ERK-1 (extracellular signal-regulated ki-
nase, the mediator of positive feedback) response at different pMHC densities, and found
that - as the model predicted - there is a sharp pMHC-discrimination threshold and so a
sharp drop in response time as the number of pMHC decreases.
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Wylie et al. 2007[44] adapted this feedback model in an attempt to reconcile the sen-
sitivity of T-cells discrimination between foreign antigen and ‘self’ with the inhibition of
signalling by antagonists (i.e. where certain pMHC complexes reduce T-cell signalling).
This study highlighted the importance of accounting for the stochastic nature of biochem-
ical reactions.
Whilst the TCR models which include feedback loops are an improvement on just a
simple kinetic proofreading model, there are still major issues with parametrisation, how
to model stochasticity and they fail to take in to account the impact of TCR clustering
and signal segregation (i.e. spatial effects)[44, 45, 46]. Furthermore, kinetic proofreading
models do not consider the mechanisms by which the signal from the TCR is initiated
following pMHC binding, but just assume that the signal begins as soon as binding occurs.
Current experimental evidence suggests that TCR triggering occurs following a con-
formational change in the TCR[47, 48], however the exact mechanism is still not under-
stood. Ma et al. 2008[49] postulate a TCR deformation model in which the mechanical
stress at the TCR-pMHC interface results in conformational change of TCR/CD3 complex
(where CD3 is a T-cell co-receptor) in an effort to provide a mechanistic explanation for
the sensitivity and specificity of TCR triggering, an idea which has gained experimental
support[50, 51, 52].
Molecular aggregation models are another class of TCR triggering models, due to
experimental evidence suggesting that aggregation of TCR via pMHC oligomers leads
to TCR triggering[53, 54]. However, experimental evidence that pMHC oligomerisation
actually occurs on the APC is lacking[47].
Segregation models are another class of TCR triggering model that propose TCR
triggering is the result of segregation of the TCR/CD3 complex[55]. Burroughs et al.
2006[56] model TCR segregation using a stochastic model of TCR diffusion in the pres-
ence of pMHC. Whilst this model yielded some interesting results, it was highly sensitive
to certain parameters and overly simplified the kinetic proofreading steps. For a full re-
view of this model, and those mentioned above see [57].
To date there does not exist a model of TCR signalling that can account for all aspects
of the process and fits all experimental evidence. It is likely that, since TCR signalling is
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a complex and multi-faceted process, some combination of the models discussed above
will be required to reconcile all the shortcomings on the models when used on their own.
1.3.2 Predicting peptide-MHC affinity
T-cell epitopes can be identified using high-throughput mass spectrometry methods, how-
ever, these methods can only scan a limited number of peptides and MHC-I alleles at a
time. Therefore, coupled with the expense of such procedures, it is infeasible at present
to perform full scans of all potential T-cell epitopes for complex viruses such as HIV[58].
The peptide-MHC binding step is thought to be the most restrictive in the antigen
processing pathway, leading to the development of biochemical competition assays to
measure the associated affinity[59], in which the affinity or IC50(nM) value (half the
maximal inhibitory concentration), is found by determining the concentration of test pep-
tide required to fill half of the MHC binding sites when competing against a radioactively
labelled peptide. By automating such measurements, large numbers of affinities can be
measured efficiently, and the Immune Epitope Data Base (IEDB)[60] contains a collection
of over 100,000 measured affinities.
However, the biochemical assays used to measure these affinities require large
amounts of resources and equipment which is still quite expensive, and the sheer number
of possible peptide sequences for most pathogens, makes scanning of entire genomes in-
feasible. This has lead to the development of models which predict the affinity of a peptide
sequence for a specific MHC allele. Such models use machine learning algorithms, such
as Artificial Neural Networks (see Section 2.3), applied to the large sets of experimentally
measured peptide-MHC affinity data already collected, in order to make predictions about
which peptides will be immunogenic, such as BIMAS[61] and NetMHC[62].
Such methods are used to narrow down the number of peptides screened in high-
throughput mass spectrometry experiments. For example, Farrell et al. 2016[63] used the
MHC class II binding prediction methods TEPITOPEpan[64] and NetMHCIIPan[65] to
select for 376 peptides out of more than a million possible peptides of Mycobacterium
bovis to be sequenced to screen for promiscuous immunogenic epitopes (i.e. peptides that
bind a wide range of MHC alleles and elicit at T-cell response).
However, high affinity does not always correlate with high cell surface abundance,
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or immunogenicity, as many other factors also influence the immunogenicity of a pep-
tide. The Immune Epitope Data Base (IEDB)[60] MHC class I processing tool combines
peptide-MHC affinity, TAP affinity and proteasomal cleavage probabilities, and provides
a measure of how immunogenic a peptide is. The tool combines these three measures
into a ‘Total Score’, which is designed to be proportional to cell surface abundance of the
peptide, where the higher the score, the more immunodominant the peptide.
Despite including some of the most important steps in antigen processing, these ma-
chine learning algorithms still only provide a static prediction of immunogenicity as they
are unable to account for the kinetics of the protein from which the peptide is cleaved,
which will influence the availability of peptides for MHC binding.
1.3.3 Models of antigen presentation
Chang et al. 2005[66] constructed a mathematical model of MHC-II antigen presentation
within a single macrophage, made up of a set of ODEs describing the levels of MHC-II
mRNA, the number of MHC-II both intracellular and on the surface, free self-peptide
and self-peptide-MHC-II both surface and intracellular. They also include the impact of
IFN-γ by modelling the number of free IFN-γ receptors, the number of free IFN-γ and
the number of IFN-receptor-ligand complexes.
Chang et al. use this model to investigate possible mechanisms of inhibition of anti-
gen presentation by Mycobacterium tuberculosis (Mtb) using a mathematical model of
antigen presentation in macrophages. There are several proposed mechanisms of Mtb
antigen presentation inhibition. Moreno et al. 1988[67] proposed inhibition occurs at
during antigen processing, Hmama et al. 1998[68] postulated that Mtb down-regulates
MHC-II during maturation or peptide loading, whilst Noss et al. 2000[69] suggest that
the downregulation occurs at the stage of synthesis of MHC-II mRNA.
By simulating the impact of each of the proposed mechanisms of inhibition, they
found that down-regulation of MHC-II is effective at inhibiting antigen presentation in
macrophages but there was a time lag of 10 hours between the down-regulation and ob-
serving the effects of the inhibition. On the other hand, the impact of the other mecha-
nisms were more immediate, but more easily attenuated. They therefore concluded that
the optimal strategy for Mtb antigen inhibition was to target multiple cellular processes.
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Dalchau et al. 2011[22] constructed a model of MHC-I antigen presentation, using a
set of ODEs to describe the levels of free peptide, MHC and tapasin, the levels of bound
pMHC and pMHC-tapasin, and the cell surface levels of pMHC, to investigate process of
peptide optimization, where only peptides with a low rate of dissociation will stay bound
long enough for the complex to egress to the cell surface. Tapasin has been shown to
enhance peptide optimisation[70, 71, 18], and by fitting the model to experimental data,
Dalchau et al. showed that tapasin bound to pMHC increases a peptides dissociation
rate. They quantified this effect using a filter relation, in which the abundance of surface
pMHC following the non-tapasin pathway is proportional to 1/ui, whereas for the tapasin
pathway it is proportional to 1/u2i , where ui is the pMHC dissociation rate.
1.4 Motivation and Overview
The discovery of T-cell epitopes is of paramount importance in medical science, for the
development of T-cell vaccines against certain viruses such as HIV, and for developing
therapies to treat cancer and autoimmune diseases. Due to the large number of HLA
alleles (over 13,000) and the high degree of polymorphism in MHC renders experimental
approaches to identify T-cell epitopes (even high-throughput methods) impractical both
in terms of time and expense.
Prediction models built using machine learning techniques can predict peptide spe-
cific properties of the antigen processing pathway, such as pMHC binding affinity, pro-
teasomal cleavage probability and TAP affinity. However, these predictions are static as
they do not account for protein kinetics, which in turn determines peptide abundance and
thus probability of cell surface presentation.
By combining the predictive power of these tools with a mechanistic model of anti-
gen presentation could provide dynamic quantitative predictions of pMHC surface pre-
sentation, and thus reduce the number of possible candidate peptides to be screened ex-
perimentally.
In this thesis we focus on modelling the intracellular (endogenous) antigen presenta-
tion pathway at the molecular level, simulating the dynamics of proteins involved in this
subsystem of the immune system, using the MHC-I antigen presentation model presented
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in Dalchau et al.[22]. A more rigorous description of the model can be found in Section
2.6.
In Chapter 2 we describe the theory behind mathematical modelling including deter-
ministic and stochastic differential equations, machine learning techniques and the pep-
tide filtering model of Dalchau et al. 2011[22]. In Chapter 3 we extend the peptide
filtering model by calibrating it to experimental data of competition between a target and
competitor peptide, and use the calibrated model to predict the competition between the
target peptide and a range of competitor peptides with different off-rates. In Chapter 4
we simulate the HeLa cell peptidome using experimentally measured HeLa cell protein
copy numbers and half-lives. Then, in Chapter 5 we predict the cell surface presentation
of HIV epitopes by HLA alleles associated with control and progression of the disease by
combining the peptide filtering model with existing models of HIV intracellular kinetics,
and using machine learning tools to estimate relative peptide-specific parameters. The
general conclusions of this work can be found in Chapter 6.
Chapter 2
Theory
2.1 Introduction: Chemical Reaction Networks
Chemical Reaction Network Theory was developed by Fritz Horn, Martin Feinberg and
Roy Jackson[72, 73], and is a framework for modelling how a chemical system evolves
in time. The concentrations of the species within a system change as a result of simulta-
neously occurring chemical reactions, and so in CRNT the aim is to represent the system
using a set of differential equations that describe how each species changes in time, and
solve these equations to track the concentration of each species over time. The state of
the system is then given by the concentrations of each chemical species at any given time.
Several assumptions are made in CRNT, such as the concentrations of species cannot be
negative, increasing species concentration increases the rate of the reactions it is involved
in and the temperature of the system is constant, as is the pressure.
A Chemical Reaction Network (CRN) is a set of chemical reactions R := {Ri|i ∈
{1,2, ..,nr}}, between a set of speciesS := {S j| j ∈ {1,2, ..,ns}}, where any linear com-
bination of the species forms set of complexes C := {Ck|k ∈ {1,2, ...,nc}}. We can then
define a chemical reaction network asN = (S ,R,C ). Each reaction can be denoted as:
Ri : ∑
j∈S
αi jS j→ ∑
j∈S
βi jS j (2.1)
The coefficients αi j and βi j are stoichiometry coefficients, and they describe the
amount of reactants (left-hand side of Equation 2.1) and products (right-hand side of
Equation 2.1), involved in the reaction. The stoichiometry coefficients can be arranged in
2.1. Introduction: Chemical Reaction Networks 30
to a stoichiometry matrix, defined as:
[Γ]i j = βi j−αi j (2.2)
For example, consider the following reaction:
S1+2S2→ 3S3+S4 (2.3)




















For a CRN with ns species and nr reactions, the stoichiometric matrix [Γ] has ns rows
and nr columns. For example, Equation 2.3 describes a single reaction, nr = 1 with four
chemical species, ns = 4, and which gives the 1×4 stoichiometric matrix in Equation 2.4.
If the reaction were reversible,
S1+2S2↔ 3S3+S4 (2.5)








By modelling the CRN mathematically we can determine how the concentrations of each
species,~c(t) = [c1(t),c2(t), ...,cns(t)]
T , changes over time. If we assume that each species
is in high enough concentrations and the solution is sufficiently well mixed, that stochastic
effects can be ignored, then we can model the dynamics of the system ordinary differen-
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tial equations (ODEs). If however, the concentrations of the species are too small that
stochastic effects are large, we must then use stochastic modelling.
2.1.1 Deterministic ODE modelling
A deterministic model is a system for which a given set of initial conditions will always
produce the same output. This is because deterministic modelling does not include any
random terms. When modelling a CRN, the reactions are represented by ODEs, which
consist of variables and parameters that describe how the system changes with time, and
the reaction is therefore represented as a continuous process. This is because we are as-
suming a spatially homogeneous distribution of particles, and so a constant reaction rate.
In deterministic modelling, the variables are the concentrations of the species involved in
the reactions, and the parameters are the rate constants that describe how fast or slow a
specific reactions occurs.
To model the dynamics of the system we need to consider net stoichiomet-
ric change following each reaction in the network - described by the stoichiome-
try matrix given in Equation 2.2 - and the rate function of each reaction, ~r(t,~c) =
[r1(t,~c(t))r2(t,~c(t)), ...,rnr(t,~c(t))]
T . At this point we have not made any assumptions
about the rate functions of each reaction, and so they depend on both time and the con-
centrations of each species involved in the reaction. The dynamics of the systemN can




It is common in deterministic modelling of CRNs to assume mass action kinetics, in
which the rate of a reaction is proportional to the concentration of the chemical species
involved in the reaction. As an example let us consider the following CRN:
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Reaction Rate
/0
k1→S1 r1 = k1
S1
k2→S2 r2 = k2c1
S1+S2
k3→S3 r3 = k3c1c2
2S2
k4→S4 r4 = k4c22
2S2+2S4
k5→S5 r5 = k5c22c24






cαi jj = kic
αi
i , (2.8)




j . Therefore, we define a mass action chemical reaction
network asN = (S ,R,C ,K ), whereK := {ki > 0|i = 1, ...,nr}, and the time evolu-








where Γi denotes the ith column of the stoichiometry matrix.
2.1.1.1 Solving ODEs
Once we have put together the system of ODEs that describes a CRN using mass action
kinetics, in order to visualise what happens to the species within the network and how
their concentrations change with time we must solve the system. For example, consider
the reaction:
/0 k⇀Y (2.10)
For k > 0 this reaction describes the synthesis or supply of species Y with concen-
tration y(t), and is known as the simple exponential growth model. The ODE describing




In order to simulate this simple model we need to solve for y(t). For initial conditions
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y(t) = y0ekt (2.14)
Using this solution we can now describe the behaviour of the system at any time point.
However, it is not usually possible to solve a system of ODEs analytically, and so nu-
merical methods must be used instead. An example of a simple numerical method is the
Euler Method. For an initial value problem (IVP) like the simple exponential growth with
y(0) = y0 considered above, the Euler method uses the backwards difference formula to
produce a sequence of solutions y0,y1,y2, ..., such that each past value yn can be used to
approximate yn+1.
To derive the backwards difference formula, consider the change in the quantity y,
∆y, between time t and t+∆:
∆y = y(t+∆t)− y(t) (2.15)
We can calculate the rate of change of this function with time i.e. the derivative, by








Equation 2.16 is just the definition of the derivative. However, if ∆t is finite, we can





where O(∆t) refers to the higher order terms of the Taylor series expansion. If we define
∆t as h, which will just be the size of the time step, y(t +∆t) as yn+1, and y(t) as yn, we
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can write:
yn+1 = yn+hy′n (2.18)
This is the backwards difference formula, where the current value yn+1, is calculated
using the previous value yn. The error associated with this approximation, O(h), is of the
order h, and so will get smaller as h (or ∆t) gets smaller, meaning a better approximation
is achieved for smaller time steps. Therefore, for small h, Equation 2.18 will closely
approximate the solution of y given in Equation 2.14.
In this thesis, when modelling large systems, such as the model of HIV intracellular
kinetics (Chapter 5), we solve our system of ODEs in MATLAB, using their suite of ODE
solvers. Our preferred solver is ode15s, which is well suited to stiff models, such as where
one has a system where some of the components decay much more rapidly than others.
The ode15s solver uses backwards differentiation formulas (BDF) optionally, but its de-
fault method is numerical differentiation formulas. The Euler method described above is
a one-step method, which only calculates the current function value using only one previ-
ous value. To achieve greater accuracy, linear multi-step methods can be used where the
solution to the ODE is approximated using a linear combination of the function values at
several previous time points. This is achieved by approximating y(t) with an interpolating
polynomial and differentiating with respect to time. For problems of order k, Newton’s






∇myn+1−h fn+1 = 0 (2.19)
where fn+1 = y′n+1, and ∇ is the backwards difference operator, where ∇
0yn = yn and
∇myn = h f (tn,yn).
The numerical differentiation methods used by ode15s add a term to the BDF to






∇myn+1−h fn+1−κγk∇k+1yn+1 = 0 (2.20)
where κ is a scalar parameter and γk = ∑kj=1
1
j .
To minimize the time it takes to solve the system, there is an option to provide a
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Jacobian, J= dydx , where x is the vector of parameters of the system. Otherwise, the solver
would approximate the Jacobian, and for large systems such as the HIV model, where
many proteins and individual peptides are being tracked, this can make the solver very
inefficient.
2.1.2 Stochastic modelling
In deterministic modelling, the ODE representations of the reactions, describes the popu-
lation of the set of species S (as defined in Section 2.1.1), evolving with time as a whole,
and does not take in to account that fact that such a system is actually made up of individ-




where /0 means the species is either leaving the network, or degrading, and so it is no
longer part of the network. If we wrote this reaction as a deterministic ODE, we would
be making the assumption that degradation of each molecule of Y is coordinated with
one another, so that a certain number of them will always degrade within a specified time
interval. In reality, however, each molecule of Y will have a half-life that is independently
and identically distributed (i.i.d) from within the same distribution, but their values will
be mutually exclusive of one another.
Therefore, deterministic ODEs in fact describe the average population of Y, and how
it evolves with time, and the half-lives of the molecules will be exponentially distributed
random variables. In the situation where the number of the reaction molecules is very
small, you would expect to see a very large variation in their half-lives from the mean,
due to the relatively low number of samples from the distribution. In this case, the de-
terministic approach would not capture the behaviour of the system very well. Stochastic
modelling therefore deals with the probabilities of a reaction occurring within a certain
time-frame, and the exact number of molecules present in the system at that time. Such
a system is in turn modelled using differential equations where the probabilities are the
variables.
If we consider again CRN as defined in Section 2.1 with ns species of molecules that
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can undergo nr different types of reactions involving a subset of the constituent molecular
species, with the number of each species given by the vector ~c(t). Each of these nr
possible reactions will change the number c j(t) of the species involved by an integer
amount. Therefore, as before for each reaction Ri ∈R we can determine the change in
the state vector using the stoichiometric matrix Γ, as defined in Equation 2.2.
In stochastic theory, it is assumed that transitions in the state space occur randomly
in time as the result of accidental collisions between the set of species S , i.e. the events
are continuous and independent of one another. This is known as a Poisson process, and
each reaction is assumed to occur according to the exponential probability distribution.
The rate at which a reaction occurs is a function of only the current state of the system,
in a Markov-like way. Therefore, the likelihood of reaction i ∈ {1,2, ...,nr} occurring in
time interval ∆t is defined by a propensity function, ai(~c(t)) and so the probability that
reaction i will occur in the small time interval t+∆t is ai(~c(t))∆t.
We therefore construct a system of ODEs to describe the probability of the system
being in a certain state (i.e. specific integer number of molecules of all of the ns species,
described by~c(t)) at time t. The number of possible differential equations is the number
of possible states, n, that the system can be in, and this collection of differential equations
is known as the Chemical Master Equation (CME)[74].
For each possible state we construct the ODE on the probability of the system being
in that state n with species numbers described by~c(t+∆t) at time t+∆t. We do this using
the law of total probabilities. There are only two possible ways that the system can come
to be in state n at time t +∆t, either it arrives in state n at time t +∆t, or it was in state n
at time t and has remained in that state at time t+∆t, i.e. ~c(t+∆t) =~c(t).
If the system arrives in state n at time t +∆t, then this means that the previous state
of the system was exactly~c(t+∆t)−Γi for all reactions i. Therefore, the probability that






where P(~c(t+∆t)−Γi, t) is the probability that the system was in a state where the number
of molecules was exactly~c(t+∆t)−Γi at time t.
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If the system was in state n at time t and has remained in state n at time t +∆t, then










where P(~c(t), t) is the probability that the system was in state n with number of molecules
~c(t) at time t.
Therefore, the probability that the system is in state n with number of molecules
~c(t+∆t) at time t+∆t is,































ai(~c(t)−Γi)P(~c(t)−Γi, t)−ai(~c(t))P(n, t) (2.26)
Therefore, the current state of the system, only depends upon the state directly pre-
ceding it and not any of the other historic states, meaning the CME is a Markov process.
2.1.2.1 Stochastic simulation algorithm
For very large systems, the CME is very difficult to solve, and so instead the Stochastic
Simulation Algorithm (SSA), also called Gillespie’s Algorithm, is used where realisations
of the state of the system are computed in accordance with the probability distribution
described by the CME.
We want to compute the time t+θ , when the next reaction occurs and which reaction
it will be. The first step in the SSA is to determine the probability that the ith reaction
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occurs in time interval [t + τ, t + τ + δτ), denoted P(τ, i|~c(t), t)δτ . To do this first lets
consider the probability of the system being in state n with~c(t) molecules and no reaction
occurring in interval [t, t + τ) which we will name P0(τ|~c(t), t). If we want to compute
the probability that no reaction occurs over the interval [t, t + τ + δτ), we can therefore
write this as the probability of no reaction occurring over interval [t, t + τ), P0(τ|~c(t), t),
multiplied by the probability of no reaction occurring over interval [t + τ, t + τ+δτ) (i.e
Pstay given in Equation 2.23). Therefore,

















Taking the limit where δ t→ 0 and solving for P0(τ|~c(t), t):





This shows that the time to the next reaction when in state n is exponentially dis-
tributed with mean value 1/a0, where a0 =∑nri=1 ai(~c(t)). Next we will consider the prob-
ability that the next reaction to take place over interval [t+τ, t+τ+δτ) is of type i, which
is simply dependent upon the propensity function ai(~c(t))δτ . Therefore, the probability
that the ith reaction occurs in time interval [t+τ, t+τ+δτ), P(τ, i|~c(t), t)δτ , is given by
the product of the probability that no reaction occurred in interval [t, t + τ), P0(τ|~c(t), t),
and the probability that the ith reaction occurred in interval [t+ τ, t+ τ+δτ):





To simulate the SSA we require the time to the next reaction and the index of the
next reaction. We re-write equation 2.30 as:
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We can then define the next reaction index as ai(~c(t))∑nri=1 ai(~c(t))
, where the probability of
the next reaction being the ith reaction is therefore the relative contribution of ai(~c(t))
to the total reaction rate of the system i.e. for each reaction i, the next reaction in-
dex is a random variable s1 which lies in the uniform interval [0,1]. We can also say
that∑nri=1 ai(~c(t))exp(−∑nri=1 ai(~c(t))τ) is the density function of exponentially distributed
random variable τ with parameter ∑nri=1 ai(~c(t)). It can be shown that the time to the next
reaction can be written as,τ = ln(1/s2)/a0, where s2 is a random number in the uniform
interval [0,1]. Therefore, P(τ, j|~c(t), t) is the joint probability distribution for the two
random variables i and τ .
The Gillespie algorithm is based upon these two observations. In order to compute
realisations of the state of the system, the reaction index s1 and reaction time s2 can be
independently sampled from the uniform distribution [0,1]. The steps of the algorithm
are given below in Algorithm 1.
Algorithm 1 Gillespie’s Stochastic Simulation Algorithm
1. Initial the state of the system n0 = n at t0 = t, and the total reaction propensities
in that states, a0 = ∑nri=1 ai(~c(t)).
2. Draw two independent random numbers s1 and s2 from the uniform distribution
[0,1].
3. Determine the index of the next reaction by taking the smallest value of i for
which ∑ik=1 ak(~c(t)) = s1a0.
4. Determine the time to the next reaction by calculating θ = ln(1/s2)/a0.
5. Update the state of the system: ~c(t+θ) =~c(t)+Γi.
6. Update time t→ t+θ .
7. Re-evaluate the total reaction propensities for the new state, a0 = ∑nri=1 ai(~c(t +
θ)).
8. Go to step 2.
The algorithm terminates when a threshold of time has been simulated.
2.2 Machine learning
Machine learning is the name of an area in computer science where algorithms are defined
by ‘training’ them on existing sets of data. The simplest example of this is a classifier,
where when an input vector is provided it will produce a single discrete output. For
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example, a simple model for predicting whether a peptide binds to an MHC allele, would
take the sequence of amino acids of the peptide as input and output either ‘binding’ or
‘non-binding’.
In order to create such a predictive model, the parameters of the classifier must first
be determined by training the model on a set of data. The model will ‘learn’ which sets
of inputs are most likely to produce a certain output, and produce a generalised predictive
model. The more data available with which to train the model, the better the model will be
at correctly predicting the class of input data not included in the training set. This type of
machine learning is called Supervised Learning, where the algorithm learns a set of rules
to determine the output from the input, and it can also be used to produce continuous
outputs, such as predicting the IC50 of a peptide to an MHC allele.
Other types of machine learning include Unsupervised Learning and Reinforcement
Learning. In Unsupervised Learning, the desired output is not provided, but the algorithm
must find some structure within the input data, and identify similarities or differences
between them. In Reinforcement Learning, the algorithm must optimise itself through
trial and error to produce the best decision pathway to achieve the best result. This type
of machine learning is often used in robotics and navigation.
Machine learning has been used to predict peptide binding to MHC alleles, and there
are several algorithms available online, where one can input a protein or peptide sequence
and the model will output a result pertaining to how well the peptide binds, such as the
IC50, the half-life, or a numerical score which predicts binding to occur over a certain
threshold value.
For example the BIMAS (BioInformatics and Molecular Analytics Section)
predictor[61], which can be found at http://www-bimas.cit.nih.gov/
molbio/hla_bind/, predicts the half-time of dissociation of a peptide from an HLA
allele, whereas the IEDB (Immune Epitope Data Base) predictor[75], which can be found
at http://tools.iedb.org/mhci/, produces a predicted IC50 (nM) value for the
peptide to the HLA allele.
To predict the HIV peptidome, we used the IEDB prediction tool, as it is able to
produce predictions for many more HLA alleles than the BIMAS predictor, and so enables
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us to compare between several known controlling and non-controlling alleles. The IEDB
predictor allows the user to choose between several different prediction methods. We
chose the IEDB recommended Consensus method[76], which combines Artificial Neural
Networks (ANN)[77, 78], Stabilized Matrix Methods (SMM)[79] and Scoring Matrices
derived from Combinatorial Peptide Libraries (Comblib)[80].
These three methods are combined as it is thought that combining the output of sev-
eral predictive methods may lead to a better predictive method overall[81]. The predic-
tions from each of the three predictors are converted in to percentile rank scores, and the
overall score for a peptide is taken as the median of the three percentile rank scores[60].
2.3 Artificial Neural Networks
Artificial neural networks (ANN) are computational models that are based upon biological
neurons in the human brain[82]. There are three layers in ANNs: input, hidden and output
(Figure 2.1 a) and each layer is made up of neurons, or nodes. The weighted sum of the
inputs to a node is calculated, and the output of a certain node oi is determined by the
applying an activation function to the weighted sum (Figure 2.1 b). For a given set of
input values x1,x2, ...,xn, there will be a corresponding set of output values, such as y1,y2
for a network with only two output nodes, for which there is either a known or desired
value.
When training a neural network, the connection weights ωi, j, that connects node i
to node j, are set at random, and are then modified during the training, using a method
known as ‘back-error propagation’. Each time the system is run, there will be an error
between the output of the system t1, t2 for instance, and the required output values y1,y2.
Back-error propagation aims to minimise this error, by using the gradient descent method
to calculate the gradient of the error function with respect to all the weights in the neural
network. A node with k inputs will have a corresponding k+1-dimensional error surface,
and the gradient function will find the minimum of that surface by taking the derivative
and following the direction of maximum negative gradient, and updating the weighting
parameters accordingly.
The back-error propagation method requires the activation function to be differen-
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tiable. The activation function represents the ‘firing’ of the neuron. The simplest acti-
vation functions are binary, and so the neuron is either firing or not firing. However, for
multi-layer networks, non-linear logistic classifiers work better, which output a probabil-
ity between 0 and 1 that the neuron is firing. The most commonly used activation function
of this type is the sigmoidal function, φ(z) = 1/(1+ e−z), as shown in Figure 2.1 c.
Figure 2.1: Artificial neural networks (ANN) are based upon biological neurons. a) The three
layers in ANNs: input, hidden and output. b) The output of a node is determined by applying an
activation function (c) to the weighted sum of the inputs to a node.
2.4 Stabilized Matrix Method
The Stabilizied Matrix Method (SMM), proposed by Peters et al. 2003[79], is a modifica-
tion to the assumption that each peptide in a sequence contributes independently contribu-
tions to binding (AIB) to MHC-I, by including pair-wise interactions between the amino
acids within the peptide and also considering the errors inherent in any experimental data,
to avoid over-fitting.
In the SMM method, they first construct a scoring matrix to quantify the contribution
of each amino acid residue within the peptide to the binding affinity of the peptide to
the MHC allele. This matrix assumes independent contributions to binding, and so the
contribution of amino acid A and position i within the peptide, is given by sA,i, and thus
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where s0 is a constant offset.
During training, the aim is to minimize the difference between Sk and the measured
IC50 value. However, in order to avoid over-fitting, a second term is added to the min-
imization function, which introduces a trade-off between fitting to the data, whilst also






The impact of the second term on the right hand side is to avoid over-fitting to the data, by
ensuring that the fitting process is biased towards those values of sA,i which are important
to the minimisation of the first term on the right hand side of the equation i.e., those values
of sA,i which do not significantly improve the fit to the data are forced towards zero. To
incorporate the interactions between the amino acid A at position i, and amino acid A′ at
position i′ within a peptide, pair-coefficients s′A,i,A′,i′ are introduced in to the total score
calculation. Therefore, for peptide k,













The pair-coefficient s′A,i,A′,i′ quantifies the difference in the binding affinity of a peptide
k when amino acid A is at position i AND amino acid A′ is at position i′ compared with
the independent average contribution to the binding affinity when amino acid A at posi-
tion i i.e. sA,i and amino acid A′ at position i′ i.e. sA′,i′ . Including the pair interactions
improves the predictions compared to the AIB method, and the SMM predictions outper-
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forms Gulukota et al.’s ANN method[83], Segal et al.’s classification tree method[84], and
Doytchinova et al.’s additive method[85].
2.5 Combinatorial Peptide Library
A combinatorial peptide library is a mixture of a very large number of different peptides.
Sidney et. al[80] present a positional scanning combinatorial library, in which the affinity
of a large pool of peptides, all of which share a single residue at a specific position, is
calculated to determine the average influence the shared residue has on binding affinity
overall. For a 9-mer where each position can be one of the 20 possible amino acids, there
will be 180 (9x20) different pools of peptides. The affinity of each peptide to an MHC
alleles is determined by experimentally measuring the IC50 (nM), which in this case is
approximately the dissociation constant KD.
For each position in a peptide, the contribution of each of the 20 residues is deter-
mined by calculating the average relative binding (ARB) affinity, under the assumption
that each position contributes independently. Each position is associated with a specificity
factor SF, which is the amount by which the ARB of all 20 amino acids at that position
differs from the average affinity of the entire library. Primary anchors are those positions
with a specificity factor SF > 2.4, and secondary anchor positions were identified by de-
termining the standard deviation of the ARB values for each of the 20 amino acids at each
position. A peptide is then given a score which is the product of the value for the residue
at that position for each peptide of the 9 amino acids in the peptide.
2.6 A Peptide Filtering Model
Much of the work in this thesis is based upon the dynamical systems model of peptide
filtering conceived by Dalchau et al. 2011[22], therefore a detailed description of the
model is required. Figure 2.2 shows a diagrammatic representation of the peptide filtering
model. The change in concentration of each molecular species in the system is assumed
to conform to the laws of mass-action kinetics, and so the system can be described by a
set of coupled ordinary differential equations (ODEs), as follows:
d[Pi]
dt
= gi−dP[Pi]−bP[Pi][M]− c[Pi][T M]+ui[MPi]+uiq[T MPi] (2.36)
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d[M]
dt
= gM−dM[M]−bT [M][T ]+uT [T M]−bP[Pi][M]+ui[MPi] (2.37)
d[T ]
dt
= gT −dT [T ]−bT [M][T ]+uT [T M]+uT v[T MPi] (2.38)
d[MPi]
dt
= bP[Pi][M]−ui[MPi]+uT v[T MPi]− e[MPi] (2.39)
d[T MPi]
dt







This model begins with peptide supply, gi from the cytoplasm in to the ER, where the
peptide can either degrade with rate dP, or bind to an MHC allele with rate bP or MHC-
tapasin complexes with rate c (where c > bP, Equation 2.36). MHC is supplied to the
ER at rate gM, and degrades with rate dM. Similarly, tapasin is supplied at rate gT and
degrades at rate dT . MHC and tapasin bind with rate bT and unbind with rate uT . When
a peptide binds to a tapasin-MHC complex, the presence of tapasin increases the peptide
unbinding rate by factor q so only high affinity peptides will stay bound long enough
for tapasin to unbind allowing the peptide-MHC complex to egress to the cell surface.
Furthermore, the presence of the peptide increases the unbinding rate of tapasin from the
tapasin-MHC-peptide complex by factor v. The peptide-MHC complex egresses to the
cell surface at rate e. In the peptide filtering model, it is assumed the supply rate of each
peptide gi is a constant and does not depend upon the cytoplasmic peptide concentration,
or the peptide affinity with TAP. Furthermore, the peptide-MHC binding rate bP is as-
sumed to be the same for each peptide in the system, and so differences in affinity for
MHC are determined by the peptide-MHC unbinding rate, ui. To reach the cell surface
a peptide-MHC complex must leave the ER and pass through the Golgi (see Figure 1.1),
2.6. A Peptide Filtering Model 46
however in the model, the ER and the Golgi are not considered to be two separate com-
partments, and so the rate e describes the egress out of the ER and through the Golgi.
Once at the cell surface a peptide-MHC complex can irreversibly dissociate with rate ui,
and the empty MHC will then decay with rate dMe. By considering the equilibrium so-
lution to the system of ODEs (Equations 2.36 - 2.42), Dalchau et al.[22] arrived at the
following approximations for the cell surface abundance of a peptide in the absence and












In the absence of tapasin (Equation 2.43), the concentration of peptide Pi on the surface
in equilibrium, [MePi]∗, with off-rate ui, can be approximated by the Nie/ui in the limit
e << ui, i.e. under the assumption of maximal optimization, where only the most stable
pMHC complexes egress to the cell surface. In the presence of tapasin (Equation 2.44),
[MePi]∗ can be approximated by Niex/u2i , where x = uT v/q, this time in the limit e,x <<
ui, which again assumes only the most stable complexes will egress. Therefore, in the
absence of tapasin, the number of peptide-MHC cell surface complexes at equilibrium
with unbinding rate ui is proportional to 1/ui, whereas in the presence of tapasin, this
number is proportional to 1/u2i . As mentioned in the introduction, the chaperone molecule
TAPBPR was only recently discovered to have a similar optimising effect as tapasin by
filtering out low affinity peptides The filtering model presented here was put together
before the TAPBPR filtering mechanism was fully known, therefore TAPBPR was not
included in this model.
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Figure 2.2: A peptide filtering model[22]. Peptides are supplied to the ER via TAP where the
rate for each peptide is denoted gi. Once in the ER peptides can either bind (parameter bP) and
then unbind (parameter ui) from an MHC allele (M), or the peptide-MHC complex (MPi) can
egress to the cell surface (rate parameter e). The other pathway a peptide can take is to bind to
an MHC-tapasin complex (T M) denoted by rate constant c and unbind denoted by parameter uiq.
Or, the tapasin can unbind (uT v) before the peptide and then the complex can egress to the cell
surface. The MHC allele is produced with rate coefficient gM and degrades at dM, and tapasin is
produced and degrades with rate parameters gT and dT respectively. Tapasin and MHC can bind
and unbind, denoted by the rate coefficients bT and uT respectively. Figure reproduced from [22].
Chapter 3
A Model to Predict Peptide Competition
for MHC class I Binding and
Presentation
3.1 Introduction
The first vaccine was developed over 300 years ago when an animal poxvirus was used
to vaccinate against smallpox, leading to the eventual worldwide eradication of smallpox.
Vaccines commonly use inactivated or attenuated forms of the virus, or in the case of pro-
tein vaccines, a highly immunogenic component of the virus, such as the capsid proteins.
These types of vaccines induce a humoral response, where antibodies produced by B-cells
destroy the extracellular pathogen and so offer antibody-mediated immunity. They do not,
however, offer cell-mediated immunity provided by T-cells and B-cells. Attenuated virus
and protein vaccines can contain thousands of proteins, however, the immune response
is usually only dependent on a small number of the proteins. Such a large number of
proteins can cause allergenic and reactogenic responses, are at risk of contamination from
extraneous sources, and are inflexible to escape variants[86]. Peptide vaccines, on the
other hand, are easily produced, are able to induce T-cell responses and can be easily
adapted to escape variants.
As previously mentioned, T-cell vaccines have been successfully used to immu-
nise mice against HIV[23], to vaccinate a murine model against tumour growth[25], and
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Rosario et al. used a synthetic HIV peptide vaccine to boost HIV-specific T cell responses
in a macaque model[87]. However, the selection of effective peptide sequences to include
in a peptide vaccine is complicated by the sheer sequence diversity of even short peptides
of between 8 and 11 amino acids. Furthermore, it is difficult to know whether a given
sequence will remain abundant at the cell surface for long enough to prime circulating
T-cells.
In the search for immunogenic epitopes, the development of accurate and reliable
predictive models is of paramount importance in immunoinformatics. However, the ma-
chine learning algorithms discussed in Chapter 2, which provide predictions of MHC
binding affinity, may not be sufficient on their own, as a high predicted affinity does
not always correlate with peptide cell surface abundance or CTL response. For example,
Feltkamp et al.[88] found that whilst efficient MHC binding is required for CTL response,
it does not always guarantee that a peptide with a high affinity will be immunogenic. Sim-
ilarly, Ochoa-Garray et al.[89] found a weak correlation between peptide-MHC affinity
and CTL immunogenicity. Furthermore, peptide-MHC affinity was also found to have a
weak correlation with cell surface abundance[90], a precursor to immunogenicity.
The likelihood that a peptide will be presented on the cell surface also depends on the
concentration of peptide in the ER, which in turn depends upon their affinity for TAP, and
the abundance and degradation of their source proteins. For example Bassani-Sternberg et
al. 2015[91] found that peptide-MHC abundance correlates with both protein abundance
and degradation rate. However, Milner et al. 2006[92] reported only a weak correlation
between the abundance of peptide-MHC and the abundance of their proteins of origin.
Furthermore, the cytokine interferon gamma (IFN-γ), which is primarily produced
as part of the immune systems response to pathogenic infection or cancer, increases the
expression of MHC-I proteins, the immunoproteasome, TAP and tapasin, meaning it can
profoundly influence the immunopeptidome. Aberrant expression of IFN-γ is strongly
linked with the development of systemic autoimmune diseases, such as lupus, and is also
less strongly linked to rheumatoid arthritis and multiple sclerosis[93].
Therefore, as no strong correlation has been observed between peptide-MHC abun-
dance and any one of the steps in the antigen processing pathway on its own, it is likely
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that a combination of these factors is required to obtain accurate predictions of T-cell
epitopes. However, the machine learning approaches developed thus far produce static
predictions that do not incorporate peptide abundance, and therefore will under-estimate
the potential relevance of peptides originating from highly abundant proteins. However,
the relative importance of peptide abundance and peptide-MHC stability in determining
cell surface abundance is yet to be determined. While the peptide filtering model of
MHC class I presentation[22] includes explicit terms for the supply of peptide into the
ER (which should scale with the cytosolic abundance of the parent protein), and peptide-
MHC stability, the effects of differential peptide abundance have not yet been tested ex-
perimentally.
In this chapter, we have directly addressed the question of the relative importance
of peptide abundance and peptide-MHC stability. We have augmented the peptide filter-
ing model to interpret experimental measurements that directly measure the intracellular
peptide abundance of two different peptides and simultaneous measurements of those
peptides bound to MHC class I molecules at the cell surface of individual cells.
The peptide filtering model described in Section 2.6 can be used to simulate the cell
surface presentation of a range of peptides with different MHC unbinding rates and ER
supply rates[22]. We decided to see if the model could be used to predict the cell surface
presentation of two competing peptides with different MHC unbinding rates at a range of
different abundances, and in the presence and absence of IFN-γ .
3.2 Experimentally Quantifying Peptide Competition
Our experimental collaborators in the University of Southampton Cancer Science Unit de-
veloped an assay to measure the abundance of two competing peptides in the cytoplasm
and the cell surface simultaneously, using an assay adapted from Lev et al. 2010[94].
A target peptide SSLENFRAYV (SSL) was endogenously fused with a ubiquitin tagged
fluorescent protein (mCherry) and a competitor peptide ASNENMETM (ASN) was simi-
larly tagged with the fluorescent protein (Venus)[95](see Figure 3.1 A). The target peptide
SSL had a much slower off-rate (2.8×10−5s−1) to the mouse MHC allele H2Db than the
competitor peptide ASN (5.2× 10−5s−1). In the cytoplasm, the tagged peptides were
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Figure 3.1: Simultaneous measurement of intracellular peptide abundance and cell surface
pMHC. (A) Experimental setup used by our collaborators. Fibroblasts were co-transfected with
constructs expressing fusion proteins made of a fluorescent protein, ubiquitin and a peptide. Cy-
toplasmic ubiquitin hydrolases cleave the fusion proteins, releasing an equimolar ratio of peptide
and fluorescent protein. ASNENMETM-H2Db surface complexes were be detected using E10
Fab and SSLENFRAYV-H2Db using 1C3 chimeric Mab. (B) In a single transfection assay cells
were expressing low to high levels of both fusion proteins and were separated in different gates
for the purpose of the analysis. (C) Cell surface expression SSLENFRAYV-H2Db in the pres-
ence of increasing competitor concentration. The dark blue curve corresponds to gates P(1, 1) to
P(8, 1) with no competitor and shows the maximum surface expression as the cytoplasmic level
of SSLENFRAYV peptide increases (represented on the x-axis). The other curves represent the
SSLENFRAYV-H2Db surface expression in the presence of different ASNENMETM competitor
concentration, down to the light blue bottom curve corresponding to gates P(1, 8) to P(8, 8) with
the maximum level of competitor in untreated wild-type cells (top panel) or in IFN-γ treated cells
(bottom panel). (D) Corresponding ASNENMETM-H2Db surface expression.
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cleaved by cytoplasmic ubiquitin hydrolases, the idea being that the peptides are released
at an equimolecular ratio to the fluorescent proteins, which can then be quantified us-
ing flow cytometry techniques, as described in Neijssen et al. 2005[95]. The released
peptides can then be transported in to the ER and bind to MHC Class I molecules, and
subsequently transit to the cell surface. A chimeric 1C3 monoclonal antibody was used
to detect SSL-H2Db complexes on the cell surface, and an E10 Fab antibody was used to
detect ASN-H2Db, and the abundance was then quantified using flow cytometry. The cy-
toplasmic concentration of the flourescently tagged proteins was varied from low to high
for both SSL and ASN, and the peptide-MHC cell surface abundance was measured as
these concentrations changed (Figure 3.1B). The collected data showed that the cell sur-
face presentation of the more stable peptide-MHC complex SSL-H2Db was much higher
than the ASN-H2Db complex for similar cytoplasmic protein concentrations, but that as
the concentration of ASN increased in the cytoplasm for constant levels of cytoplasmic
SSL, the cell surface abundance of SSL-H2Db decreased as ASN-H2Db increased (data
points P(.,1 to 6) Figures 3.1 C & D top). An equivalent set of experiments was carried
out but with mouse fibroblasts treated with mouse IFN-γ for 48 hours (data points P(.,1:6)
Figure 3.1 C & D bottom), to determine the impact of IFN-γ on peptide competition. In
general the presence of IFN-γ resulted in higher cell surface presentation of both SSL and
ASN and reduced the competition between the peptides, as can be seen by the reduction
in the spread of the SSL data points (Figures 3.1 C & D bottom), compared to without
IFN-γ (Figures 3.1 C & D top).
3.3 A Mechanistic Model of Peptide Competition
The peptide filtering model[22] describes the supply of peptide from the cytoplasm in
to the ER with the supply rate gi, as described by Equation 2.36. Therefore, in order to
use the model to predict peptide competition we needed to augment the peptide filtering
model with several new factors (see Figure 3.2):
1. Conversion of intracellular abundance fluorescence to rate of peptide supply
2. Conversion of simulated cell surface copy number to antibody-based detection of
cell surface pMHC abundance
3.3. A Mechanistic Model of Peptide Competition 53
3. The effect of IFN-γ on MHC-I and tapasin expression
4. Self/endogenous peptides
5. Peptide-specific on-rates
Figure 3.2: Diagrammatic representation of how we calibrated the model. The intracellular
concentration of each peptide and their measured MHC unbinding rate were used as inputs to
the model. We then fit the model to fluorescence data of the pMHC surface abundance. Square
coloured boxes indicate measured or simulation data, grey boxes indicate models and rounded
boxes represent inference algorithms. The red and blue line connectors represent peptide-specific
information, and the dashed blue lines indicate that inferred parameters are eventually substituted
back into the models for simulation/prediction.
To convert the intracellular abundance measured via Venus/mCherry fluorescence to ER
supply rates for each peptide, we used two conversion factors fSSL and fASN for SSL
and ASN respectively, accounting for conversion from fluorescence units to numbers
of molecules, intracellular degradation and peptide supply to the ER via TAP. As SSL
and ASN were tagged with different fluorescent molecules, and will likely have different
degradation rates and TAP affinities (and so different supply rates), the value of the scale
factor will be different for the two peptides. Therefore, we define the supply rate gi of
each peptide i as:
gi = fi×Fi, (3.1)
where Fi is the fluorescent measurement corresponding to the intracellular abundance of
peptide i.
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A scale factor is also required to convert the fluorescent measurements of cell sur-
face peptide-MHC Hi to number of complexes [MePi], in other words the model output,
denoted hSSL, and hASN and this scale factor will be different for each peptide as different
antibodies were used to detect them:
Hi = hi× [MePi] (3.2)
We fit the model to two repeated SSL-ASN competition experiments, and as a result
inter-experiment variations were observed in the measurement of SSLENFRAYV-H2Db
at the cell surface using the 1C3 monoclonal antibody. Therefore, to obtain a better fit,
the value of hSSL was allowed to differ between the two experiments, hSSL,1 and hSSL,2 for
experiments 1 and 2 respectively. To account for the addition of IFN-γ an up-regulation
factor was required to increase the supply of MHC and tapasin. As with hSSL we fit a
different value of the IFN-γ up-regulation parameter for each of the two experiments that
we will denote γ1 and γ2, to account for inter-experiment variations. The up-regulation
factor was applied to both the MHC-I and tapasin supply rates, i.e. gIFNM = γgM and
gIFNT = γgT .
To achieve a better fit to the data we included a single additional peptide to represent
the self-peptides present in the system, and the supply rate gsel f was to be inferred. This
single self-peptide was given an MHC unbinding rate of usel f = 10−4s−1 as this is the
average peptide-MHC unbinding rate. The dissociation of ASN and SSL with the MHC-I
molecule were measured using a Brefeldin A decay assay as described in Boulanger et
al. 2009[18], and these measurements were used to determine the ASN and SSL MHC-I
unbinding rates, uASN and uSSL respectively. To further improve the fit to the data we also
inferred the ASN binding rate to MHC-I, bASN .
We used Microsoft’s Visual Genetic Engineering of Cells (GEC) software (freely
available from http://research.microsoft.com/gec) to perform parameter
inference. We specified the reaction system using the domain-specific Language for Bio-
chemical Systems (LBS) and used an adaptive Metropolis-Hastings algorithm from the
Filzbach software (https://github.com/predictionmachines/Filzbach)
to perform the inference.
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3.3.1 Parametrising the augmented peptide filtering model using
Markov chain Monte Carlo
We wish to find the values of the set of parameters θ = { fSSL, fASN , hSSL,1, hSSL,2, hASN ,
γ1,γ2, gsel f ,bASN} that best fits the data D. Assuming the model, H, we are using is correct,
we therefore aim to approximate the posterior probability density P(θ |H,D), in other
words the probability of the set of parameter values θ , given the data D. The posterior
probability distribution is proportional to the product of a likelihood function P(D|θ ,H)
and a prior parameter probability density P(θ |H), according to Bayes’ theorem:
P(θ |H,D) = P(D|θ ,H)P(θ |H)
P(D)
(3.3)
The likelihood function P(D|θ ,H) describes the probability of the data D given the set of
parameter values θ , and the prior P(θ |D) contains our beliefs about the distribution of the
parameters beforehand. The normalising factor P(D) is the probability of the data D over
all possible values of the parameter set θ . This normalising factor cancels out during the
inference process, and so does not need to be computed.
Under the assumption that the model H correctly describes the biological system,
then any differences in the model output are due purely to experimental error, i.e. the
data point yi is normally distributed, where the mean of the distribution is the model
prediction xk at time t = tk and the variance σ2 is, in this case, proportional to the measured
fluorescence (σ =α√yk for some α), therefore yk ∼N(xk,σ2). Therefore, the probability




Therefore, given the set of parameter values θ , the total likelihood function is the product
of the probability of each data point yk. When dealing with the product of very small
numbers it is easier to compute the log-likelihood function, as follows:
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For more details on MCMC see Robert & Casella (1999)[96]. Due to the complexity
Algorithm 2 Description of the steps in the Metropolis Hasting’s Algorithm





2. Draw candidate set of parameter values θcand from proposal distribution e.g.
Gaussian distribution centered around θ 0
3. Evaluate the target distribution (here the log-likelihood) at θcand
4. Calculate log-acceptance ratio r = l(θcand)/l(θcurrent) and evaluate α = min[1,r]
5. Generate random number u≈U [0,1]
6. If u≤ r accept proposed parameter values θcurrent = θcand , else θcurrent = θ 0
7. Iterate
of the model we cannot solve for the posterior probability density analytically, and so
we must approximate it. We invoked the Filzbach software (available from https:
//github.com/predictionmachines/Filzbach) which uses a Metropolis-
Hastings (MH) Markov chain Monte Carlo (MCMC) algorithm to sample from and ap-
proximate the posterior distribution. Monte Carlo sampling produces a sequence of val-
ues that have been drawn from some probability distribution. From these n samples, the
expected value of the distribution can be computed. For very large values of n the dis-
tribution of the parameter values visited along the Markov chain converges to the true
joint posterior distribution. Markov chains are stochastic models where the probability
of an event occurring only depends upon the state of the system after the previous event.
Therefore, in this case, the new values of the parameter vector θt+1 only depends upon the
previous parameter vector θt , and the probability of transition between these two states is
described by the transition probability of the Markov chain. In the Metropolis-Hastings
algorithm, a transition is accepted depending upon the ratio of the proposed transition to
the likelihood of the current state. The system is initialised at arbitrary starting values
for the parameters, then for each iteration a candidate set of parameter values θcand are
sampled from the distribution, with a log-acceptance ratio, r = l(θcand)/l(θcurrent). If the
ratio is greater than 1, and thus the likelihood is improved by the candidate parameter
values, then they are accepted. If the ratio is less than 1, generate a random number u
from the uniform distribution U [0,1], and if u≤ r accept the candidate parameter values,









































































































Figure 3.3: Marginal posterior distributions for calibration parameters. The marginal pos-
teriors were established from 50,000 MCMC samples with a burn-in period of 20,000 runs. The
parameter inference incorporated 2 experiments, for which γ and hSSL had specific values (denoted
by the superscripts 1 and 2). Each experiment measured SSL surface presentation or ASN surface
presentation, and was either treated with IFN-γ or not (therefore, 4 scenarios per experiment).
In all simulations shown in the manuscript, the parameter set that had the highest value of the
log-likelihood function was used.
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see Algorithm 2. To apply the Metropolis-Hastings algorithm to infer the parameters of
our augmented model of peptide competition, we combined data from two separate ex-
periments. We fit the model parameters to two sets of experimental data, where in each
experiment the cytoplasmic concentration of SSL and ASN were varied and their cell sur-
face abundances measured as described in Section 3.2. The cell surface abundance was
measured in fluorescence and so each measurement will be associated with a background
fluorescence. Therefore we were also required to fit for an additional eight parameters,
o f f1, ...,o f f8, to account for the background fluorescence of SSL and ASN cell surface
abundance with and without the addition of IFN-γ .
Figure 3.4: Pairwise correlations in the parameter joint posterior distribution. For each pair
of parameters, the Pearson correlation coefficient was calculated over 50,000 MCMC samples
with a 20,000 run burn in.
The MCMC algorithm was run for 50,000 samples with a burn-in period of 20,000
runs. Figure 3.3 shows the results of the MCMC fit, with the log-likelihood in the first
panel and the marginal posteriors for the parameter values in the remaining panels. For
each parameter, the value that corresponds to the highest value of the log-likelihood was
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chosen as the best-fit parameter. From the marginal posteriors we can see that the major-
ity of the parameters are approximately Gaussian distributed, except for the background
offsets, with the exception of o f f1 and o f f8. The distribution of the offset samples are
peaked at very low values close to 0 or in some cases lower than 0. This suggests a level of
inaccuracy in the model that has resulted in lower-than-expected values of the background
fluorescence being selected in order to try to compensate for this. Indeed, of the pair-wise
correlations observed between the parameters (Figure 3.4), the largest magnitude corre-
lations are between pairs of offsets, or offset-γ pairs. There is low pair-wise correlation
between the rest of the parameters, where the colour bar ranges from 1 (full positive cor-
relation) to -1 (full negative correlation). This suggests that the data is adequate to obtain
well constrained best fit values for all parameters.
3.4 Results: Model Calibration
We fit the model to the data (Figures 3.5 and 3.6) as described in Section 3.3 and deter-
mined the goodness of fit by calculating the normalised root mean square error (NRMSE),
where a lower value, closer to 0, means a better fit. The dots (experimental data) and lines
(model simulation) are coloured to indicate the level of competitor peptide, so that the im-
pact of peptide competition on the relationship between intracellular abundance and cell
surface presentation can be compared conveniently. The highest SSL cell surface abun-
dance P(.,1) Figures 3.5 and 3.6 panels A and C corresponds to the lowest cytoplasmic
abundance of ASN. However, in the presence of IFN-γ when we reach very high SSL cy-
toplasmic abundance the SSL surface abundance is no longer ordered according to ASN
concentration. This suggests that at such high levels of cytoplasmic SSL and abundance
of free MHC-I proteins to bind to, the competition due to ASN, when the ASN abundance
is small i.e. P(.,1)−P(.,4), has very little impact on SSL cell surface abundance. The
model using the best fit parameter values fit well to the SSL surface expression without
IFN-γ for both experiments, but the fit to SSL with IFN-γ has a lower NRMSE in the
second experiment (Figure 3.6) than the first (Figure 3.5) with NRMSE of 0.0483 and
0.1284 respectively. We believe the reason for this is that for the first experiment, the
model is overestimating the competition due to ASN in the presence of IFN-γ .
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Figure 3.5: Model calibration, experiment 1 Comparison of the model (solid lines) evaluated
at the maximum likelihood parameters values against experimental measurements (dots) for a sin-
gle experiment measuring SSLENFRAYV vs ASNENMETM competition. The different colours
represent different cytoplasmic levels of ASNENMETM, with P(.,1) and S(.,1) as indicated by
the blue dots and lines respectively, representing the lowest ASNENMETM abundance, and P(.,7)
and S(.,7) with the red dots and lines, representing the highest ASNENMETM abundance. The
normalised root mean square error (NRMSE) between the data and the simulation is also indicated
for each comparison.
The model is however able to capture the increase in both SSL and ASN cell sur-
face abundance with the addition of IFN-γ (Figures 3.5 and 3.6 panels C and D), and
Figure 3.6 C shows especially that the model is able to capture the narrowing in the verti-
cal variation between the SSL cell surface levels for different constant ASN cytoplasmic
concentrations. The averaged fluorescent measurements for cells with low levels of E10
fluorescence displayed trends that were inconsistent with the trends of intermediate and
high expression levels. We attributed this to a low signal-to-noise ratio, and therefore
suggest that these data are unreliable (Figures 3.5 and 3.6 panels B and D) and are not
captured by the model as they are not a result of the competition between the peptides.
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In spite of this the model is able to capture the general trend of the ASN cell surface
abundance decreasing as the SSL cytoplasmic concentration increases (x-axis), whilst the
ASN concentration stays constant (the individual coloured lines).
Figure 3.6: Experiment 2: Comparison of the model (solid lines) evaluated at the maximum
likelihood parameters values against experimental measurements (circles) for a single experiment
measuring SSLENFRAYV vs ASNENMETM competition. The different colours represent dif-
ferent cytoplasmic levels of ASNENMETM, with P(.,1) and S(.,1) as indicated by the blue dots
and lines respectively, representing the lowest ASNENMETM abundance, and P(.,7) and S(.,7)
with the red dots and lines, representing the highest ASNENMETM abundance. The normalised
root mean square error (NRMSE) between the data and the simulation is also indicated for each
comparison.
3.5 Results: The Calibrated Model Predicts Peptide
Competition Well
In this study we wanted to know how the competition between two peptides is influenced
by changing the off-rate of the competitor peptide, when the target peptide is in com-
petition with varying competitor abundance. In turn, we wished to know how well our
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augmented peptide filtering model, adapted from [22], was able to predict these interde-
pendences. To this aim we calibrated the augmented model to flow cytometry data of
Peptide BIMAS score NetMHC4.0 (nM) t1/2 min ui s−1 E10 Score
ASNEAMETM 3.4 2208.8 43 2.7×10−4 8.2
ASNENMETA 17 94.6 52 2.2×10−4 14.2
ASNENMETV 17 13.2 132 8.8×10−5 16.8
ASNENMETL 343 9.6 191 6.1×10−5 11.8
ASNENMETI 343 6.6 212 5.4×10−5 13.1
ASNENMETM 343 7.3 223 5.2×10−5 11.5
ASNENLETM 411 10 238 4.9×10−5 4.1
SSLENFRAYV 0.5 23.4 408 2.8×10−5 3.8
ASIENMETM 1029 3 456 2.5×10−5 8.9
ASIENLETM 1235 3.6 502 2.3×10−5 1.8
Table 3.1: Peptide sequences and off-rates BIMAS Score was determined using BIMAS pre-
dictor which can be found at http://www-bimas.cit.nih.gov/molbio/hla_bind/
and the NetMHC 4.0 tool was used to predict the IC50 of H-2Db binding (nM). Peptide half-
lives (t1/2) were determined experimentally by BFA decay assays and converted into off-rates as
log(2)/half-life (sec). The E10 score represents the MFI/1000.
peptide competition between a target peptide SSL and a competitor peptide ASN. Once
calibrated, we then used the inferred parameter values in the model to predict the com-
petition between SSL and several ASN variants, where amino acid substitutions in the
sequence of ASNENMETM were chosen which change the unbinding rate of ASN with
MHC-I. We used the BIMAS[61] tool to predict the peptide-MHC half-lives, and the
MHC binding tool NetMHC4.0[62] to predict the peptide-MHC IC50 to chose the sub-
stitutions which would result in either a higher or lower off-rate than the original ASN
sequence, and compared the two methods.
The half-lives (t1/2) of the ASN variants in complex with MHC-I (H-2Db) were
determined experimentally in brefeldin A decay assays [18], and comparison to the pre-
dicted values showed that in this case BIMAS performed better than NetMHC4.0 (Table
3.1). Our experimental collaborators performed another set of experiments, as described
in Section 3.2, where the ASN variants were tagged with the fluorescent protein Venus
and used in a competition assay against SSL tagged with mCherry, whilst the surface
expression of the ASN variants was determined using an E10 Fab antibody. Only ASN
variants that were recognised well by E10 were used. From these half-lives we were able
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to compute the peptide-MHC unbinding rate as ui = log(2)/t1/2, and use these values
when performing simulations to predict the competition between SSL and the ASN vari-
ants using the calibrated model parameters. Each ASN variant had a different binding
affinity to E10. Therefore, to obtain a better fit, we scaled the predicted model ASN fluo-
rescent intensity for each ASN variant by the ratio of their E10 affinity to that of ASN (see
Table 3.1). We assumed that the point mutations have a limited impact on TAP affinity
and so each ASN variant has a similar ER supply rate. The data shows a general trend
of increased competition with SSL for H-2Db binding with increased half-life of binding
of the variants (Figure 3.7 P(.,:), see Table 3.1 for pMHC half-lives), with the maximum
competition observed in the presence of the slowest off-rate peptides ASIENMETM and
ASIENLETM (off-rates of 2.5×10−5s−1 and 2.3×10−5s−1 respectively).
With the addition of IFN-γ , competition between SSL and the ASN variants was re-
duced in all cases, as can be seen by the smaller spread of data points (Figure 3.7, dots
P(.,:)), and similarly for the slower off-rate ASN variants (Figure 3.8, dots P(.,:)). How-
ever, for the more unstable p-MHC complexes, the addition of IFN-γ was not sufficient to
increase the cell surface level to recognisable levels, and there appears to be a low signal-
to-noise ratio, as with the -IFN-γ case, as discussed earlier. As mentioned earlier we fit
for two values of the parameter hSSL to account for experimental differences between ex-
periment 1 and 2. The best for value of hSSL,1 for experiment 1 (Figure 3.5) was used in
the predictions of SSL vs METV, whilst the value of hSSL,2 for experiment 2 (Figure 3.6)
was used in the predictions of the remaining peptides.
We determined how well the model was able to predict the competition by calculating
the NRMSE between the simulation and the data. Figures 3.7 and 3.8 shows the data and
the simulated SSL and ASN cell surface abundance respectively, against the data for SSL
vs the ASN variants without and with IFN-γ , panels A and B on both figures, whilst panels
C and D show the data and the simulated cell surface of the ASN variants. The model
was able to predict the competition data very well for LETM vs SSL and METI vs SSL
as demonstrated by the low NRMSE values, whilst the model predicted the competition
between the remaining peptides reasonable well, as demonstrated by the slightly higher
NRMSE values.
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Figure 3.7: Predicting cell surface presentation of SSL when competing against ASN vari-
ants. The competition between SSL and ASN variants was predicted using the calibrated model.
Each ASN variant had a different off-rate from MHC-I, as given in table 3.1. Each panel shows
the predicted SSL presentation (coloured lines) against the fluorescent data (coloured dots) for
SSL vs A) ASIENLETM, B) ASIENMETM, C) ASNENLETM, D) ASNENMETI and E) AS-
NENMETV, both with and without IFN-γ . The normalised root mean-squared error (NRMSE)
between the data and the simulation is also shown for each panel.
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Figure 3.8: Predicting cell surface presentation of ASN variants competing against SSL.
TThe competition between SSL and ASN variants was predicted using the calibrated model. Each
ASN variant had a different off-rate from MHC-I, as given in table 3.1. Each panel shows the
predicted ASN presentation (coloured lines) against the fluorescent data (coloured dots) for SSL
vs A) ASIENLETM, B) ASIENMETM, C) ASNENLETM, D) ASNENMETI and E) ASNEN-
METV, both with and without IFN-γ . The normalised root mean-squared error (NRMSE) between
the data and the simulation is also shown for each panel.
3.5.1 A simple peptide competition metric predicts cell surface abun-
dance
We have demonstrated that by augmenting the peptide filtering model[22] as described in
Section 3.3 (see Figure 3.2) we are able to predict the competition between two peptides
of different off-rate and varying cytoplasmic concentration. However, we also wished
to test if the simple peptide filter relation[22], in which the cell surface abundance of
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a peptide is proportional to the ratio of its supply rate gi to the square of its unbinding
rate u2i , could provide a simpler and more intuitive method of predicting competition.
This filter relation was used by Dalchau et al[22] to predict the equilibrium cell surface
abundance of a pMHC complex.
Figure 3.9: Cell surface abundance without IFN-γ can be predicted by a peptide competition
metric. The peptide competition metric MePratio (Eq. 3.6) was calculated using measurements of
cytoplasmic peptide abundance for SSLENFRAYV and variants of ASNENMETM (horizontal
axis) and compared with the simulated cell surface abundance of SSLENFRAYV (vertical axis),
in the absence of IFN-γ .
The filter relation when used on its own does not provide a good estimation of the
peptide cell surface abundance when that peptide is competing against other peptides, as
it only approximates equilibrium cell surface presentation of a peptide in terms of its own
supply and off-rate from MHC-I, and does not include the impact of competing peptides.
Therefore, in order to account for the impact of the competitor peptide we normalised
the filter relation. Initially we wanted to see how well the normalised filter relation could
approximate the output of the peptide filtering model. In this case we are trying to predict
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SSL cell surface abundance when in competition with ASN and self peptides, and we
will approximate the supply rates of the two competing peptides gi with the cytoplasmic
peptide abundances. The calibration of the model included a self peptide supply rate
gsel f and unbinding rate usel f , and so we will use the best fit values of these parameters
to represent the competition of the self peptides in the normalised filter relation. The








We calculate the normalised peptide filter metric for the SSL cell surface abundance for
each competition experiment described above, with and without IFN-γ and calculated the
Pearson’s correlation coefficient between the metric and the corresponding model output.
The different coloured traces represent the different cytoplasmic concentrations of ASN
with which SSL is competing. There is a strong correlation between the normalised pep-
tide filter metric and the model output for all experiments, both with and without IFN-γ
(Figures 3.9 & 3.10 respectively), with all correlation coefficients greater than 0.7. The
highest ASN concentration (red dots S(.,7)) result in the lowest SSL cell surface abun-
dance, and correspondingly much lower values for the normalised filter metric. Similarly,
the lowest ASN concentration (blue dots S(.,1)) results in the highest SSL surface abun-
dance and also very high values of the metric.
If the metric is accounting for all important parameters that influence cell surface
abundance we would expect similar values of the metric between traces to result in sim-
ilar values of the cell surface abundance. This is indeed the case as can be seen as the
traces in general follow the same trajectory as the value of the metric increases, show-
ing a consistent relationship exists between the value of the metric and the cell surface
abundance.
Once we had confirmed the metric was able to approximate the model, we wanted to
see if it could be used alone to predict the experimental data. When applying the metric
to the data, however, we do not have any data regarding the amount of self-peptide in
the system. Using the calibrated values for gsel f and usel f from the model resulted in a
worse correlation (data not shown) than ignoring the self-peptide contribution entirely.
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Therefore, the metric used to approximate the data was just the ratio of the peptide filter







To approximate the supply of each peptide - as we did in the model - we scaled the
cytoplasmic MFI concentration of each peptide, [SSL]MFIcyt and [ASN]
MFI
cyt by the calibrated
conversion scale factors fSSL and fASN respectively.
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Figure 3.10: Cell surface abundance with IFN-γ can be predicted by a peptide competition
metric. The peptide competition metric MePratio (Eq. 3.6) was calculated using measurements
of cytoplasmic peptide abundance for SSLENFRAYV and variants of ASNENMETM (horizontal
axis) and compared with simulated cell surface abundance of SSLENFRAYV (vertical axis), in
the presence of IFN-γ .
We observed a strong correlation between the metric and the data for SSL vs ASIEN-
METM and SSL vs ASIENLETM without IFN-γ (Figure 3.11 panels B and F respec-
tively), whilst the remaining datasets had a weaker correlation with the metric with SSL
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vs ASNENMETV having the weakest correlation of 0.52.
Figure 3.11: Cell surface abundance without IFN-γ can be predicted by a peptide competi-
tion metric. The peptide competition metric MePratio (Eq. 3.7 was calculated using measurements
of cytoplasmic peptide abundance for SSLENFRAYV and variants of ASNENMETM (horizon-
tal axis) and compared with the experimentally measured surface abundance of SSLENFRAYV
(vertical axis), in the absence of IFN-γ .
However, the metric was less successful at approximating the SSL cell surface abun-
dance in the presence of IFN-γ , with all correlations less than 0.6 (Figure 3.12). As
before if the metric were accounting for all important parameters influencing cell surface
abundance, similar values of the metric should correspond to similar values of cell sur-
face abundance. However we observed quite a spread in cell surface abundance for the
same value of the metric between the traces for all experiments without IFN-γ with the
exception of SSL vs ASIENMETM and SSL vs ASIENLETM, and similarly for +IFN-γ .
This suggests the metric as applied here to the data is failing to account for an important
parameter. The poor performance of the metric for the data compared to the simulations
is most likely due to the missing contribution of the self-peptides in the data metric, and
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so the metric is over-estimating the SSL cell surface presentation, especially when ASN
cytoplasmic abundance is low e.g. P(.,1).
Figure 3.12: Cell surface abundance without IFN-γ can be predicted by a peptide compe-
tition metric. The peptide competition metric MePratio (Eq. 3.7) was calculated using measure-
ments of cytoplasmic peptide abundance for SSLENFRAYV and variants of ASNENMETM (hor-
izontal axis) and compared with the experimentally measured cell surface abundance of SSLEN-
FRAYV (vertical axis), in the presence of IFN-γ .
3.6 Discussion
The competition between peptides for binding and presentation by MHC-I in the ER is
an important step in determining the T-cell response against cells infected with foreign
pathogens, and understanding this step can aid in designing effective treatment and thera-
pies for many infections and diseases. Dalchau et al. 2011[22] developed a mathematical
model of antigen presentation by MHC-I, including only three main components: MHC,
tapasin and peptide. The model was originally developed to explain how peptide optimi-
sation by tapasin differs between MHC-I alleles. However, it was yet to be tested to see
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if this model could predict peptide competition.
We augmented the peptide filtering model, so that the model could relate intracel-
lular peptide abundance to cell surface abundance, via tapasin-assisted optimisation of
pMHC loading and presentation. Using experimental data collected by our experimental
collaborators, we calibrated the model and used it to predict the cell surface abundance
of two competing peptides binding to the same MHC allele, where the off-rate of the
competitor peptide varied. The calibrated model was able to capture the changes in cell
surface abundance of a target peptide as the abundance of competitor peptide changes for
competitor peptides with a range of unbinding rates.
The calibrated model was also able to account for the effect of the up-regulation
of MHC and tapasin production following the production of IFN-γ , and the resulting
decrease in the impact of increased abundance of the competitor pepitde on the target
peptide. This agrees with Dudek et al. (2012)[97] where it was observed that presenta-
tion of the high affinity JAK-1355363 (SYFPEITHI), and the lower affinity IGRP2062 14
peptide (VYLKTNVFK) by H-2Kb, were both increased from ∼ 2,000 to ∼ 15,000 and
from ∼ 1 to ∼ 25 copies per cell respectively after treating NIT-1 insulinoma cells with
IFN-γ . A better understanding of IFN-γ is important as it is produced following viral in-
fection and is associated with autoinflammatory and autoimmune diseases, and has been
used in immunotherapy as an immunostimulant, however the mechanisms behind how it
works are poorly understood. IFN-γ also has a role in cancer immunosurveillance[98]
and tumour cells can also evolve immune escape mechanisms to block the IFN-γ path-
way. Therefore, it would be beneficial to be able to predict CD8+ T-cell epitopes that are
likely to be presented on tumour cells and the impact the addition of IFN-γ has on their
subsequent presentation.
The increase in peptide presentation as a result of IFN-γ production may therefore
alter which set of peptides are immunodominant. In our study the surface expression
of the lower affinity peptide was enhanced in the presence of IFN-γ and Henrickson et
al. (2008)[99] showed that T-cell activation can only occur above a threshold antigen
dose. Therefore, the presence of IFN-γ could result in a CD8+ T-cell response to develop
against a broader range of peptides.
3.6. Discussion 72
We also found that a simple competition metric, Equations 3.6 & 3.7, based on the fil-
ter relation (Dalchau et al 2011[22]) correlated well with the model simulated cell surface
abundance although the metric correlated less well with the corresponding experimental
data, most likely due to the missing contribution of the self-peptides. The competition
metric demonstrates the trade-off between the supply rate of the peptide - and thus its
abundance in the ER - with the peptide-MHC unbinding rate on determining the cell sur-
face abundance of a peptide. Such a simple metric could be used in vaccine design to
quickly determine the concentration and pMHC half-life required for a peptide to be suc-
cessfully presented in sufficient numbers on the cell surface, without the need for further
experiment or simulation.
Chapter 4
A Mechanistic Model to Predict HeLa
Cell Antigen Presentation
4.1 Introduction
On February 8th 1951 cervical cancer cells were taken from Henrietta Lacks (without her
knowledge), a cervical cancer sufferer who later died from the disease. It was found that
these cells could be developed, for the first time, in to an immortal cell line, meaning the
cells would not die after a certain number of divisions, known as the Hayflick limit. These
cells, known as HeLa cells, however, are cancer cells and so can multiply more rapidly
than normal cells. As a result HeLa cells, have been used in a multitude of medical and
biological experiments all over the world for many years, such as developing the polio
vaccine and have furthered our understanding of cancer and are routinely used to test
cancer treatments. HeLa cells are also used to grow viruses and further our understanding
of infections such as HIV, and improve our understanding of the cell environment more
generally. In 1999 it was observed that HeLa cells contain human papillomavirus (HPV)
18 DNA[100] and HPV18 has been linked to very aggressive cervical cancers. The HPV
vaccine has been successful in preventing infection by specific types of HPV, including
HPV16 and HPV18 which have are both associated with a high risk of cervical cancer.
The HPV vaccine is a traditional protein vaccine, as it contains HPV L1 capsid proteins.
This demonstrates how vaccines can be used to prevent cancer by providing immunity to
the oncoviruses that cause them.
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4.1.1 Cancer vaccines
Many cancers are not caused by viruses, and even in the case of HPV where a virus does
cause cancer, low vaccination rates[101] mean that additional novel treatments are still
required. Therefore a cancer vaccine has to either target an existing tumour (a therapeutic
cancer vaccine), or prevent a tumour from developing (cancer immunoprevention). In-
deed, the HPV vaccine would have no therapeutic effect on a person who had already
developed cervical cancer as a result of HPV infection.
As an example of cancer immunoprevention, Nanni et al.[102] used an allogenic
tumour cell vaccine (i.e. cancer cells taken from one patient which are then processed and
turned in to a vaccine to prevent tumours of the same type) along side cytokines and other
immunostimulants to prevent mammary carcinomas in a murine model.
Many therapeutic cancers vaccines are ‘autologous’, meaning they are made from
tumour cell samples of a specific patient and are used to treat that patient, and so contain
antigens specific to the individuals tumour[103].
Whole allogenic or autologous tumour cell vaccines have the potential to present the
entire spectrum of tumour-associated antigens (TAAs) to the patient’s immune system.
However, one issue with autologous vaccines is that large samples of the patient’s tu-
mour are often required to make a vaccine that covers the entire spectrum of TAAs, which
may not always be easy to acquire. Furthermore, tumours are heterogeneous, meaning
that a vaccine developed to target a specific tumour may be ineffective against other tu-
mours even within the same patient, as different antigens will be presented. Allogenic
tumour cell vaccines, however, usually contain three established tumour cell lines, and
their production is standardized and on a large scale, meaning clinical results are reliable
and cost-effective[104]. However, the procedure is still complex and costly.
Peptide vaccines usually use several peptides of identified TAAs with the aim of
stimulating a T-cell response in complex with MHC-I proteins. Advantages of peptide
vaccines are that they are often more cost-effective and easier to produce than whole tu-
mour cell vaccines, however, they cover a small spectrum of possible TAAs. A melanoma
vaccine made up of six melanoma-associated peptides, demonstrated peptide vaccines to
be safe and provided evidence of T-cell response to the melanoma[105]. As mentioned
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in Section 1.2, strong protective T-cell responses have been observed against cancer epi-
topes, for example Toes et al.[25] reported such a response when vaccinating a murine
model with epitopes from oncogenes required for tumour growth. However, at this point
in time peptide vaccines are not optimized as they have a low response rate in clinical
trials[106].
Therefore, a model that can predict epitopes derived from proteins expressed by
oncogenes (mutated human genes involved in oncogenesis), may be able to help re-
searchers more easily and quickly identify possible targets for T-cell vaccines for specific
cancers.
HeLa cells have been used in an incredible number of experiments, and as a result
there exists a large amount of readily available data regarding the HeLa cell proteome.
In the previous chapter we demonstrated the augmented peptide filtering model can be
used to predict the competition between a competitor and target peptide and that a simple
metric provides a good approximation of the cell surface abundance of the target peptide
as competitor abundance varies. We wanted to see if we could use this model to predict
the presentation of an entire peptidome, and how well the filter relation correlates with
the predicted cell surface abundance of each peptide. If the filter relation provides a
good approximation to the predicted cell surface abundance of a peptide when competing
against an entire peptidome, then it could be a useful tool with which to predict T-cell
epitopes quickly and easily against a background of self peptides.
4.2 Methods
4.2.1 Obtaining quantitative measurements of the HeLa cell pro-
teome
To be able to simulate the presentation of peptides derived from the HeLa cell peptidome
we required a set of data measuring the abundance and half-life of the majority of proteins
within the proteome of a cell. Boisvert et al.[107] quantified the intracellular abundance of
a set of HeLa cell proteins using a method known as SILAC, in which an essential amino
acid is supplemented with a non-radioactive, isotopically labelled form of that amino acid,
which results in a mass-shift in the peptide compared to the control, or ‘light’ peptide.
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The abundance of the protein is then measured as the intensity ratio of ‘light’ and ‘heavy’
peptides which correlates with the relative amount of the cognate protein from which the
peptide derived. Nagaraj et al. 2011[108] measured the intracellular protein copy number
of around 8000 HeLa cell proteins, and labelled each one using their International Protein
Index (IPI) identifier.
In the first analysis we wanted to correlate the protein abundance, protein degrada-
tion, peptide-MHC off-rate and proteasomal cleavage probability with the peptide cell
surface abundance predicted by the model. Therefore, we decided to use the Nagaraj et
al. protein abundances, as they were in units of copy number, and therefore we would be
able to predict an approximate peptide cell surface abundance, as opposed to the Boisvert
et al. abundances which were quantified as an intensity ratio. We then compared the
Nagaraj dataset to a dataset from Boisvert et al.[107] where the protein half-lives for
6000 HeLa cell proteins were measured in the cytoplasm, nucleus and nucleolus. We
matched the Boisvert proteins with the Nagaraj et al.[108] proteins and found a cross-
over of 4000 proteins. Out of these 4000 proteins only approximately 2000 had mea-
sured cytoplasmic degradation rates. We then converted the IPI identifiers to Uniprot IDs,
from which we found the corresponding protein amino acid sequences from the Uniprot
database(http://www.uniprot.org/). We then ran these sequences through IEDB
MHC-I processing prediction tool[109]. This tool provides a predicted MHC-I binding
affinity for each peptide, a proteasomal cleavage probability and a TAP affinity. We chose
to run the predictions for all peptides 8-11 amino acids in length binding to HLA-A*68:02
as this MHC-I allele is known to be present in HeLa cells.
4.2.2 Calculating peptide-MHC off-rates
We calculated the unbinding rates using the approximation ui = bP.IC50i where IC50i is
the IEDB predicted affinity of peptide i and bP is the peptide-MHC association rate. The
value of bP = 103M−1s−1 was chosen such that the off-rates of the most stable peptides
were approximately 10−5s−1.
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4.2.3 Approximating proteasomal cleavage probabilities
Certain peptides will have a higher probability of being cleaved than others, because some
proteasomes have preferences to cut peptides of a certain length, but also vary in their
catalytic activity against different amino acids at the cut site. There are online machine
learning tools which provide predictions for the likelihood that a given peptide sequence
will be cleaved from the protein. The IEDB MHC-I processing tool[109] gives this value
as a cleavage score, which is proportional to the logarithm of the amount of peptide gen-
erated from the cleavage of the peptides C-terminal. This score however, does not provide
the actual probability of a peptide sequence being produced from the degradation of one
protein. Experimentally measured values of proteasomal cleavage probabilities are sadly
lacking in the literature, but it has been measured that the well known peptide SIINFEKL,
or an N-terminally extended version of it, is produced via degradation of the OVA 6−8%
of the time it degrades[110]. SIINFEKL is known to be a highly immunogenic peptide,
and so it is likely that it is produced with a high probability during proteasomal cleavage.
Therefore, we set the highest possible probability of proteasomal cleavage to be 10%, and
used this as an upper bound when predicting the proteasomal cleavage probabilities for
the peptides in the model.
4.2.4 Model
To simulate the presentation of the HeLa cell peptidome from the protein data we had
acquired, we used the peptide filtering model described in Section 2.6. To do this we had
to provide an approximate supply rate for each peptide using the protein data and protea-
somal cleavage probabilities we had acquired for each peptide. Therefore the supply rate
of peptide i derived from protein j is:
gi = Ai, j · ki, j · psi, j (4.1)
Here, Ai, j refers to the abundance of the protein j from which peptide i is derived, ki, j
refers to the degradation rate of the protein j from which peptide i is derived (= ln(2)/τ1/2
where τ1/2 is the protein half-life), and psi, j refers to the cleavage probability of peptide i
from protein j.
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We then normalised the peptide supply gi to ensure that when we summed the sup-
ply rate of each individual peptide it equalled the total supply of peptide from the original
model which is important as the bimolecular rate constants (e.g. peptide-MHC associa-
tion) were inferred at these levels.
The concentration of each peptide [Pi]∗ was assumed to be constant and at steady
state. Therefore, in this case Equation 2.36 describing the peptide dynamics is equal to
zero, and we simply write [Pi]∗ ≈ gi/dP, where dP is the rate of peptide degradation. This
approximation can be derived as follows.
Solving Equations 2.39-2.41 at steady state we get the following expressions for




























where x= uT v/q and we are assuming peptide loading takes place via the tapasin pathway
and so [T M]∗ >> [M]∗ Similarly, solving Equation 2.36 at steady state we obtain:
[Pi]∗ =
−ui[MPi]∗−gi
(c[T M]∗( uiui+x −1)−dP)
(4.5)
If we substitute [MePi]∗ = e[MPi]/ui in to Equation 4.4 and rearrange for c[T M]∗ we get:








Substituting Equation 4.6 in to Equation 4.5 we arrive at the approximation:





Finally, if we assume high peptide turnover and thus rates of supply and degradation then
gi >> e[MPi]∗, and therefore we can approximate [Pi]∗≈ gi/dP (see [22] for more details).
Therefore we assume that any peptide that egresses from the ER is rapidly replaced, en-
suring the concentration of peptide in the ER remains at steady state levels throughout the
simulation. This approximation is useful practically as it reduces the number of equations
in the system and so makes simulating the model for a very large number of peptides more
efficient.
4.2.5 Simulations
The simulations were carried out in MATLAB R2015b using the ode15s stiff solver to
approximate the solution to the system of ODEs. We provided a Jacobian matrix to im-
prove the efficiency of the solver and reduce the run time. We further reduced the number
of peptides being simulated by removing all peptides where the unbinding rate was pre-
dicted to be higher than u < 1× 10−2/s. Peptides with an off-rate higher than this limit
will be unlikely to bind to an MHC-I allele long enough to be presented, therefore their
impact on competition and the cell surface abundance of other peptides is likely to be very
small. This lead to the simulation of 440,258 peptides in total. The supply rates to the ER
were determined as described in Equation 4.1. The degradation rate of each protein was
determined from the measured half-lives reported in the Boisvert et al.[107] dataset. The
protein levels were kept constant at their measured copy number, and the peptide supply
at steady state.
We analysed the output at t = 10 days to allow those proteins with long half-lives
time to degrade sufficiently. We then chose only those peptides whose abundance at this
time was predicted to be greater than or equal to 1. This is because a large number of
peptides were predicted to have an abundance of less than 1 which does not make any
physical sense and would skew the results of any analysis. The following analysis was
therefore only applied to the 17,416 peptides with a cell surface abundance greater than
or equal to 1 at t = 10 days.
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4.2.6 Approximating cell surface abundance with the filter relation
We wanted to see how well the filter relation could approximate the simulation results in
the case where a large number of peptides are competing for binding to MHC-I alleles.
We calculated the filter relation for each peptide. The normalised filter relation, Fi, will
approximate the relative cell surface abundance of each peptide compared to all others








where gi is the supply rate of peptide i and ui is the peptide-MHC unbinding rate, and gk
and uk are the supply rates and unbinding rates of peptide k where i 6= k, and N is the total
number of peptides.
4.2.7 Neo-epitope prediction
For the second analysis we wished to predict the presentation of novel epitopes (neo-
epitopes) derived from mutated proteins present in tumours. Identifying immunogenic
T-cell neo-epitopes is critically important for the development of cancer vaccines. Identi-
fying possible neo-epitopes requires the identification of the corresponding mutated pro-
teins. The Broad-Novartis Cancer Cell Line Encyclopedia (CCLE)[111] provides genetic
mutation profiles for over 1000 cell lines, including HeLa cells.
Boegel et al. 2014[112] carried out an analysis where they predicted antigenic muta-
tions for a large number of cancer cell lines including HeLa cells. They scanned cell-line
specific mutations from both the CCLE and the COSMIC Cell Lines Project [113] and
then used the IEDB resource platform to predict high affinity peptides that would bind to
the HeLa cells endogenous HLA alleles, HLA-A*06:02 and HLA-B*15:03. However, in
this analysis they did not incorporate the protein abundance, degradation or the proteaso-
mal cleavage probabilities when predicting the mutant epitopes. Therefore, we decided
to carry out an analysis where we predicted the presentation of mutant epitopes using our
model of peptide presentation.
We chose to use the CCLE HeLa cell mutant dataset and searched for matches within
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the Boisvert et al. and Nagaraj et al. HeLa cell proteome data. For this analysis there were
a greater number of matches when using the Boisvert et al. abundances and half-lives.
The HeLa cell CCLE mutant dataset identifies each protein using the Ensembl transcript
(ENST) ID http://www.ensembl.org/index.html. Therefore we converted
each protein’s IPI from the Boisvert dataset to an ENST ID and matched the two datasets.
We then obtained the protein sequences from the Ensembl database and inserted the amino
acid mutations for each matched mutated protein from the HeLa cell dataset. We then
simulated the presentation of peptides from all of the proteins in the Boisvert dataset that
had both abundance and cytoplasmic half-life measurements, but this time including the
mutated protein sequences. We used the intensity ratios for the abundance of each protein
as we are only interested in relative levels of presentation in this analysis, as the data does
not exist with which to test the predictions of the abundances of the mutated peptides. The
half-lives, off-rates and proteasomal cleavage probabilities were determined as described
in the previous sections. Once the simulation was complete we identified the peptides
containing a mutation and normalised them by the most abundant mutated peptide on the
cell surface, so that we could compare their presentation levels.
4.3 Results and Discussion
The cell surface abundance after 10 days of all peptides from all proteins is shown in
Figure 4.1, where panels A, B, C and D show the simulated cell surface abundance plot-
ted against peptide off-rate, protein half-life, protein abundance, and peptide cleavage
probability respectively.
4.3.1 Correlation of cell surface abundance with individual parame-
ters
We chose to look at the influence of these four components on peptide abundance as
protein abundance, protein degradation, peptide off-rate and proteasomal cleavage have
been reported to influence efficient HLA-I presentation[107, 91, 114, 22, 115, 116], and
the probability of cleavage as this will determine the relative amounts of each peptide
from each protein available in the cytoplasm. However, a weak correlation was observed
between the peptide cell surface abundance and four parameters when considering each
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parameter individually (Pearson correlations: protein abundance, ρ = 0.031; protein half-
life, ρ =−0.017; peptide off-rate, ρ =−0.0088; and cleavage rate, ρ = 0.0083).
4.3.2 Correlation of cell surface abundance with normalised filter re-
lation
We then calculated the filter relation (Equation 4.8) for each peptide (Figure 4.1 E) and
found a very strong positive correlation (ρ = 0.998) with the model predicted cell surface
abundance, demonstrating that the filter relation can be used to predict the relative cell sur-
face abundance of an entire peptidome. The strong correlation between the filter relation
and the cell surface abundance, compared to the weak correlations observed when con-
sidering the parameters on their own, suggests that efficient peptide-MHC presentation
requires the optimisation of all four properties. For example, optimizing peptide-MHC
affinity so that the unbinding rate is very slow (on the order of 10−5s−1) does not guar-
antee a high cell surface abundance, as can be seen in Figure 4.1 C where we observe
peptides with much higher off-rates having similar abundances to those peptides with
much lower off-rates.
4.3.3 Correlation of cell surface abundance with raw filter relation
Whilst the correlation between the filter relation described by Equation 4.8 and the model
predicted cell surface abundance is very high, it may not be always possible to calculate
this value as it requires the characterisation of a large fraction of a cell’s proteome. In
cases where this data is not available, and a prediction of the relative abundances of pep-
tides is required, the raw (un-normalised) value of the filter relation can be used, given as
follows:
Fi = gi/u2i (4.9)
To calculate this value an estimate of the supply of the peptide to the ER and a measure
or prediction of the peptides MHC unbinding rate is required only for the peptide of in-
terest, making it much simpler to acquire the relevant data. The correlation between the
raw filter relation and the model predicted peptide cell surface abundance is high, with
a Pearson’s correlation coefficient of ρ = 0.999. Oddly, this is slightly higher than that
of the normalised filter relation (ρ = 0.998). This is most likely because not one peptide
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dominates the competition in the ER and therefore there will be very little difference be-




gk/u2k is approximately equal for
each peptide, and so the normalising factor acts simply as a constant scale factor. This
would not be true however if we were dealing with a case such as that presented in Chap-
ter 3 where two peptides were competing in increasingly high abundance, suggesting they
dominate in the cytoplasm and ER. If, however, a large number of peptides are competing
and no single peptide or group dominates, each peptide faces the same level of compe-
tition from all other peptides. Therefore, the normalising constant is less important, and
the cell surface abundance can be predicted using the raw filter relation given in Equation
4.9.
Figure 4.2: The relationship between the raw (unnormalised) filter relation and the cell sur-
face abundance A strong positive correlation was observed between the cell surface abundance
and the raw filter relation Equation 4.9, which combines the four properties of protein abundance,
degradation and peptide unbinding rate in to a single metric, but does not normalise by the sum of
this value for all other competing peptides. The correlation observed between the simulated cell
surface abundance and the raw filter relation is higher than that of the normalised filter relation
(Equation 4.8).
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4.3.4 Comparison of predicted abundance with IEDB ‘Total Score’
We wanted to see if the peptides that are predicted to have the highest affinity and highest
cleavage probability are predicted to be the most abundant by the model. The IEDB
MHC-I processing tool provides a ‘Total Score’ for each peptide, which combines the
proteasomal cleavage score, the TAP affinity and the MHC-I affinity to predict a quantity
that is proportional to the amount of peptide on the cell surface. The Total Score is the
sum of the predicted TAP score, the proteasomal score and the MHC-I binding score.
The MHC-I binding score is the -log10 of the IC50 value. In these simulations we have
only used the proteasomal cleavage scores and the IC50 values predicted by the MHC-I
processing tool. Therefore, we calculated an alternative ‘Total Score’ which is instead just
the sum of the proteasomal cleavage score and the IC50 score. Those peptides with the top
alternative ‘Total Score’ are identified as the black data points on Figure 4.1, whilst those
peptides with the highest cell surface abundance as predicted by the model are identified
as the red data points. As would be expected the peptides with the highest ‘Total Score’
all have very low unbinding rates (black data points on Figure 4.1 C), however, due to
the wide range of cleavage probabilities and protein abundances and half-lives (black
data points on Figure 4.1 D, A and B respectively) from which these peptides derive
they do not correspond to the most abundant peptides as predicted by the model. The
most abundant peptides predicted by the model all have low off-rates (though not the
lowest), middling proteasomal cleavage probabilities, and derive from proteins with high
abundances (though not the highest) and low to middling half-lives. This demonstrates
the trade-off between these parameters in determining the cell surface abundance of a
peptide, and this trade-off is captured in the filter relation. This highlights the importance
of considering protein kinetics when predicting possible T-cell epitopes for use in cancer
vaccines or immunotherapy.
4.3.5 The most abundant neo-epitopes
We predicted the relative cell surface abundance of neo-epitopes derived from HeLa cell
proteins containing point mutations to predict which mutated peptides will be the most
abundant (Figure 4.3). This simulation predicts that the peptides TVTGLTLLAV, GT-
FQNVSVQL and TVTGLTLLA, are the top three most abundant mutant peptides on the
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cell surface. The set of mutant peptides predicted here as most abundant is entirely differ-
ent from the set predict by Boegel et al. [112]. This may be because the overlap between
the Boisvert et al. [107] data set and the CCLE[111] HeLa cell mutant dataset was quite
small, meaning we may not have accounted for all of the important mutated sequences
in this simulation. However, as we demonstrated in Section 4.3.4 the peptides with the
highest affinity as predicted by IEDB do not correspond to the most abundant peptides on
the cell surface, therefore the epitopes predicted by Boisvert et al. will most likely not be
the most abundant mutant peptides on the cell surface.
Figure 4.3: The relative abundance of the highest presented neo-epitopes, normalised to the
abundance of the most abundance neo-epitope The top most abundant HeLa cell neo-epitopes
predicted by inserting amino acid point mutations in to the protein sequences where matches
between the Boisvert et al. [107] dataset and the Broad-Novartis Cancer Cell Line Encyclopedia
(CCLE) HeLa cell mutations dataset.
4.4 Discussion
This chapter provides an idea of what predictions would look like for an entire peptidome.
We have shown that the filter relation provides a better approximate to the simulated
cell surface abundance of a peptide than protein abundance, protein half-life, peptide-
MHC unbinding rate or proteasomal cleavage probability considered alone. We have also
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demonstrated that when considering an entire proteome, all that is required to predict
the cell surface presentation of a peptide is a measure of its supply - which here we
approximated as the product of protein abundance, degradation and proteasomal cleavage
probability - and the peptide-MHC unbinding rate. Unlike in Chapter 3, removing the
normalising factor and using the raw filter relation provides as good a correlation as the
normalised filter relation, likely due to the normalising factor being constant for each
peptide as not one dominates.
Unfortunately, it is not currently possible to test the predictions of cell surface abun-
dance of the HeLa peptidome, as the data are not available in the literature. Furthermore,
at this moment, high-throughput methods for determining the cell surface abundance of a
large number of peptides simultaneously do not exist. Indeed, the best attempt to date is
that of Croft et al. 2013[21] where a mass-spectrometry method was used to quantify the
presentation of eight vaccinia virus epitopes and the abundance of their source proteins
simultaneously. The abundance of the source protein however was only quantified relative
to its maximum expression, and not relative to the other proteins, therefore we could not
use these measurements to test our model.
We have demonstrated that a model such as this could be used to predict the cell sur-
face presentation of novel epitopes (neo-epitopes) derived from mutated proteins present
in tumours. To improve the neo-epitope predictions we would require abundance and
half-life measurements of the entire HeLa proteome, which can then be matched to the
HeLa cell mutation datasets of CCLE and COSMIC. We hope that the development of
new proteomics methodologies will enable such experiments to be carried out, paving the
way for improved tools for the design of novel cancer treatments.
Chapter 5
A Mechanistic Model of Antigen
Presentation Following Infection by
Human Immunodeficiency Virus Type 1
5.1 Introduction
Human immunodeficiency virus type 1 (HIV-1) infects important immune cells such as
T-cells and macrophages, resulting in low levels of CD4+ T-cells. These CD4+ T-cells
are crucial to cell-mediated immunity, and so as their numbers decline, the infected per-
son becomes more and more susceptible to opportunistic infections and tumours. HIV-1
infects a cell when the subunits gp120 and gp41 of the HIV protein Env, on the outside
of the virion particle (as labelled in Figure 5.1), bind to the CD4+ T-cell receptors on the
cell surface. The virion then fuses with the cell membrane and releases its contents in to
the cytoplasm of the host cell. Once in the cytoplasm, reverse transcriptase transforms the
single stranded RNA HIV-1 genome in to double stranded DNA, which is then imported
in to the host cell nucleus and integrated in to the host genome via viral integrase.
The HIV-1 genome encodes for nine proteins: three viral structural proteins, Env,
Gag and Pol, two regulatory genes Tat and Rev, and four accessory proteins, Vif, Vpu,
Vpr and Nef. The host’s cellular machinery then transcribes the HIV-1 genome to produce
a full-length 9 kb mRNA. This full-length transcript encodes for the proteins Gag and
GagPol, and is incorporated in to the budding virions. The full-length transcript can also
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Figure 5.1: HIV-1 virion. Diagrammatic representation of HIV virion. The virion contains
several copies of the viral proteins, as well as reverse transcriptase, integrase and the viral genome
required for integration in to the host genome
be spliced once to produce 4 kb length mRNA which encodes for Env, Vpu, Vpr and Vif,
or doubly spliced to produce 2 kb mRNA that encodes for Rev, Tat and Nef (Figure 5.2).
Only the doubly-spliced 2 kb mRNA is small enough to be independently exported
from the nucleus in to the cytoplasm[117], where it is translated in to either Rev, Tat or
Nef. Rev is then imported back in to the nucleus, where it binds with the Rev Response
Elements (RRE) of the full-length and singly-spliced transcripts (see Figure 5.2). Once a
threshold concentration of RRE-bound Rev is reached, the full-length and singly-spliced
transcripts can then be exported to the cytoplasm.
Tat is also imported back into the nucleus where it binds with the trans-activating
response element (TAR), and increases the rate of transcription up to 100-fold. Full-length
mRNA in the cytoplasm is then translated to produce Gag and Pol, and singly-spliced
mRNA is translated in to Env, Vpr, Vpu and Vif. The full-length mRNA and translated
HIV-1 proteins then assemble at the cell membrane and create a new viral particle, which
is then released from the cell.
There are three main stages of HIV infection. Primary (or acute) HIV infection,
shortly following contraction of the virus, presents in many individuals as flu-like symp-
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Figure 5.2: HIV-1 intracellular kinetics. Once the HIV genome has been integrated with the
host DNA, the host machinery can be used to transcribe the HIV proteins. Full-length (9 kb)
mRNA encodes for the structural proteins Gag and GagPol, 4 kb mRNA encodes for the Env,
Vpu, Vif and Vpr, whilst the 2 kb mRNA encodes for the regulatory proteins Nef, Tat and Rev.
The mRNA 9 kb and 4 kb mRNA requires Rev binding for export to the cytoplasm, whilst the 2
kb mRNA can export independently. Once in the cytoplasm the mRNA is translated using the host
machinery in to the HIV proteins.
toms, which last between 2-4 weeks post infection, although many patients can be asymp-
tomatic. This stage is associated with rapid viremia production and depletion of CD4+
T-cells, and an expansion in the number of CD8+ T-cells[118]. Cytotoxic T-cells, also
known as CD8+ T-cells, express a T-cell receptor (TCR), which interacts with peptide-
MHC class I complexes on the cell surface (see Section 1 for more detail). If this MHC-I
molecule is presenting an HIV-1 peptide, then the CD8+ T-cell should recognise the pres-
ence of the virus and destroy the infected cell. However, in the majority of patients, this
CD8+ T-cell response is not enough to control the spread of the virus inside the body.
Following primary infection, there is a phase of clinical latency, where the infected
individual is largely asymptomatic, a period which can last from between 3 years up to
over 20 years, depending on the individual[119]. A small subset of infected individuals
maintain high CD4+ and CD8+ T-cell counts, along with low viral loads (< 10,000 HIV-
RNA copies ml−1), without receiving any anti-viral therapy or treatment, for up to 25
years[120]. Such individuals are known as long-term non-progressors (LTNP). Less than
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1% of LTNPs, known as Elite Controllers (EC), have undetectable viral loads of < 50
HIV-RNA copies ml−1[121][120] and exhibit very slow disease progression.
5.1.1 HLA and HIV-1 rates of progression
Understanding the factors that influence HIV progression rates and lead to long term
control will aid in the design of vaccines and improved treatments. Long term non-
progression is not linked to viral defects or polymorphisms[122], but has instead been
linked to the response of the host immune system. For example, HIV can be transmit-
ted from an individual experiencing fast progression to AIDS to an individual who then
becomes an elite controller[121]. Several factors are known to influence how long this
latency period lasts for, and so how long it takes for an individual to progress to acquired
immunodeficiency syndrome (AIDS)[121]. One such factor is the expression of HLA al-
leles encoded for by the individuals genome. Several HLA alleles such as B*58, B*57,
B*27 and B*14 have been found to be over-represented among LTNPs and ECs, and
they are associated with Gag-specific CTL responses[123, 124, 125, 126], which orig-
inate from highly conserved regions of the Gag protein sequence[127]. For example,
both B*57 and B*58 are associated with CD8+ T-cell responses against Gag epitopes
TW10 (TSTLQEQIGW) and KF11 (KAFSPEVIPMF)[128]. The known T242N escape
mutation in TW10 leads to diminished viral replication capacity[129], as does the A163G
mutation of KF11[130].
Furthermore, escape mutations within these CTL epitopes are associated with the
eventual transition of LTNPs and ECs to progressors[131]. There is also evidence which
suggests that allele combinations, such as HLA-B*57:01-Cw0602 and HLA-B*27:05-
Cw0102 have an even stronger effect on disease progression, indicating that the effect of
control can be additive if an infected individual expresses several HLA alleles which are
associated with LTNP[132].
Not only are HLA-B alleles associated with control of HIV, but there are also some
alleles over-expressed among individuals who progress very quickly to AIDS, such as
HLA-B*35 and -B*18. These non-controlling alleles are associated with CTL responses
against non-Gag epitopes, such as Nef and Env epitopes[133], and mutations in these
epitopes are fitness neutral[134]. The Env and Nef proteins are both highly variable, with
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Env being the most variable sequence in the HIV genome[123] and so this may explain
the inability of Env- and Nef- specific CD8+ T-cells responses to control the progression
of HIV.
It is in fact Pol and not Gag that is the most conserved HIV protein[123], and so
the strong association between Gag and control of HIV progression may be influenced
by factors other than sequence conservation. Not only are these Gag epitopes highly
conserved, but the Gag protein itself is also the most highly abundant in both the HIV
virion and the host-cell cytoplasm during the replication cycle. There are around 4900
copies of Gag per HIV virion[135], with a Gag-Pol ratio of 20:1 per virion. Similarly, the
ratio of Gag to GagPol synthesis from full-length mRNA also estimated to be around 20:1
[136]. In a study in to the Simian Immunodeficiency Virus (SIV, a close relative of HIV
that infects Macaques), showed CD8+ T-cells against Gag-specific epitopes as early as
2 hours post infection, whilst non-Gag specific responses, such as those to Nef and Env,
were not detected until de novo synthesis of HIV proteins occurs during the replication
cycle, at around 10 hours post infection[137].
We therefore wish to determine how the large concentration of Gag in both the virion
and during replication effect Gag peptide presentation compared to peptides from other
proteins, and how this impact control of disease progression. To do this we first deter-
mined if the IEDB MHC-I processing tool could predict the dominance of Gag peptides,
then we constructed a mechanistic model of HIV-1 intracellular kinetics and antigen pre-
sentation and simulated the system deterministically to determine if including Gag protein
kinetics could shed some light on Gag epitope dominance. We also compared the HIV-1
peptide presentation between a group of controlling and non-controlling alleles to see if
there was any discernible difference in the peptides presented by the two groups. Finally
we constructed a mechanistic model of the presentation of HIV-1 virion derived peptides,
which we simulated stochastically due to low molecular copy numbers, to determine the
earliest time point at which we would expect to see antigen presentation post-infection of
the cell.
5.2. Predicting HIV-1 Peptide Presentation using Existing Machine Learning Tools 93
5.2 Predicting HIV-1 Peptide Presentation using Existing
Machine Learning Tools
We wanted to see if the Immune Epitope Database (IEDB) epitope prediction methods
used alone could explain why Gag epitopes are so immunodominant and why their ex-
pression is correlated with long term non-progression. We used the IEDB MHC-I process-
ing tool, which combines predictions of proteasomal cleavage, TAP transport and MHC
class I binding[109] and outputs a ‘Total Score’ for each peptide, which is designed to be
proportional to cell surface abundance of the peptide. Thus, a higher total score means
the peptide has a better probability of being presented on the cell surface and so the more
immunodominant the peptide.
5.2.1 Methods
We used the HIV-1 clade C consensus protein amino acid sequence from http://www.
hiv.lanl.gov as the input to the IEDB MHC-I processing tool and compared the
epitope predictions for each protein. We performed this analysis for four alleles associated
with long term control of HIV: HLA-B*58:01, -B*57:01, -B*27:05 and -B*44:03 [123,
124, 125, 126, 138], and four alleles associated with fast progression: HLA-B*18:01,
-B*35:03, -B*07:02 and -B*55:01[133, 139].
We used two different methods to determine which peptides out of the total predicted
data set for each allele to consider as binding peptides. In the first method, we used a
threshold of 500 nM for the MHC-I binding predictions[140](Figure 5.3 A & D), whereas
in the second method we took the peptides within top 1% Total Score when all possible
peptides for the HIV proteome were considered (Figure 5.4 A & D). We applied two
different methods because whilst IEDB recommends a cut-off of 500 nM when predicting
a binding epitope, the prediction scores for different HLA molecules cannot actually be
directly compared. Therefore, we wanted to see if there was a discernible difference in
the results when using the two different methods.
We also compared each HIV protein by the average Total Score of peptides from
each protein (Figure 5.3 and 5.4 B & C), and recorded the total number of peptides from
each protein that were predicted to be presented for each method. For both methods,
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due to the strong association with the presentation of Gag epitopes, we would expect that
for the alleles associated with long term non-progression, the highest Total Scores would
come from Gag peptides and on average Gag peptides would have a higher Total Score.
Borghans et al.[141] used NetMHC3.0, a peptide-MHC binding prediction tool,
available at www.cbs.dtu.dk/services/NetMHC-3.0/ to predict the affinities
of HIV peptide to different HLA alleles, and then ranked each peptide among all HIV
peptides from highest to lowest affinity, where a lower rank corresponds to a high affinity
binder. They compared the predicted ranks of peptides from different HIV-1 proteins be-
tween a group of controlling alleles (HLA-B*27:05, -B*57:01 and -B*58:01) and a group
of non-controlling alleles (HLA-B*35:03 and -B*53:01). They then looked at only the
top 3 ranking Gag epitopes and found the controlling group had a significantly higher
preference for Gag than the non-controlling group. Doing the same for the other proteins
they found the non-controlling group had a preference for Nef peptides over the control-
ling group. Significant differences in the preferences for Vpu, p17, Vif and Ref epitopes
were also observed but it was concluded that the median ranks of these peptides were
so high (i.e. the peptide affinities were so low) that the differences were most likely not
physiologically important.
However, they only considered the top 3 peptides from each protein in their analysis,
and did not include proteasomal or TAP predictions. Therefore, we carried out a similar
analysis to determine if there was any statistical significance between the predicted Total
Scores of the peptides from each HIV-1 protein in the top 1% of each allele, grouping by
control vs non-control, using a Wilcoxon rank sum test.
5.2.2 Results: method 1
We selected from the output of the IEDB MHC-I processing tool for each protein only
those peptides with a predicted IC50≤ 500 nM and plotted the Total Scores of the peptides
from each protein for each allele. The controlling alleles were predicted to bind a large
number of peptides with a range of total scores. The majority of the peptides came from
Env and Pol and the lowest number of peptides from Rev and Tat, with the exception of
HLA-B*27:05.
The non-controlling alleles HLA-B*35:03 and -B*55:01 were predicted to present
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very few peptides in total, with much lower total scores than the controlling alleles. The
non-controlling alleles HLA-B*07:02 and -B*18:01 however were predicted to bind pep-
tides with a similar range of total scores to the controlling alleles, with a similar total
number being presented.
One conclusion that can be reached when using this method is that some alleles are
associated with fast progression because they simply do not present enough epitopes to
result in a successful immune response. This explanation can be applied to HLA-B*35:03
and -B*55:01 but not HLA-B*07:02 or -B*18:01. However, the issue with the method of
using a 500 nM IC50 threshold cut-off is that we cannot necessarily compare predicted
IC50 values between alleles[142][143], as the percentage of peptides predicted to bind
with 500 nM or lower varies between alleles. Therefore, a fairer comparison would be to
take the top 1% of binding peptides, so that each allele binds the same number of peptides.
5.2.3 Results: method 2
We selected from the output of the IEDB MHC-I processing tool those peptides with a
Total Scores within the top 1% of all predicted peptides for the HIV-1 proteaome. Using
the top 1% cut-off instead of the 500 nM affinity cut-off means that the number of pep-
tides bound by each allele is the same, and results in the number of peptides predicted
to bind to the controlling alleles is actually reduced and the non-controlling alleles HLA-
B*53:01 and -B*35:03 are predicted to bind as many peptides as the non-controlling
alleles. Therefore, we can no longer claim that these alleles are associated with long-term
non-progression because they do not bind enough peptides.
However, when comparing progressors to LTNPs, we found that the average To-
tal Score for the peptides presented by the non-controlling alleles HLA-B*35:03 and -
B*55:01 was much lower for each protein than the controlling alleles (Figure 5.4 A&B),
which suggests that these alleles present fewer immunogenic epitopes than the controllers,
and so are less able to control the spread of the virus. However, the non-controlling HLA-
B*07:02 allele was predicted to bind a similar number of Pol, Env and Gag peptides.
Furthermore, HLA-B*18:01 was predicted to bind a similar number of peptides overall
as the controlling alleles, and with a similar range of Total Scores.
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Figure 5.3: IEDB Total Scores for Threshold Method The IEDB MHC-I processing tools were
used to analyse the distribution of only those HIV-1-derived peptides with predicted IC50<500
nM for A) non-controlling alleles B*07:02, B*18:01, B*55:01 and B*35:03 and C) controlling
alleles, HLA-B*58:01, B*44:03, B*57:01 and B*27:05. The IEDB Total Score for each peptide
is plotted according to which protein they originate from. The red crosses indicate the average
total score of peptides from each protein. B,D) The number of peptides with IC50<500 nM is
compared for each protein.
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Again, we would have expected Gag peptides to have the highest average Total
Scores, however, the average Gag Total Score was one of the lowest for the controlling
alleles, with the highest average scores coming from Pol, Env, Nef and Vif in general (Fig-
ure 5.4 C). Similarly, for the controlling alleles HLA-B*58:01, -B*44:03 and -B*57:01,
Pol and Env were the two proteins predicted to produce the largest number of binding
peptides to the controlling alleles (Figure 5.4 D), and not Gag.
Focussing on Gag-derived peptides alone, we found that the highest average Total
Score is associated with the controlling allele HLA-B*58:01, and the lowest average Total
Score is associated with the non-controlling allele HLA-B*35:03. However, again we
found no obvious distinction between the average Gag peptide Total Scores between the
chosen set of controlling and non-controlling alleles that could explain their observed
differences in rates of disease progression. In fact, from these predictions, we would
expect Pol peptides to control HIV progression, as Pol is a highly conserved sequence and
yields a large number of peptides with high Total Scores. In contrast, the Env sequence
is highly variable[144], so even though it also produces many peptides with high Total
Scores, the higher probability of escape mutations reduces its immunogenicity.
Borghans et al.[141] used NetMHC3.0, a peptide-MHC binding prediction tool,
available at www.cbs.dtu.dk/services/NetMHC-3.0/ to predict the affinities
of HIV peptide to different HLA alleles, and then ranked each peptide among all HIV
peptides from highest to lowest affinity, where a lower rank corresponds to a high affinity
binder. They compared the predicted ranks of peptides from different HIV-1 proteins be-
tween a group of controlling alleles (HLA-B*27:05, -B*57:01 and -B*58:01) and a group
of non-controlling alleles (HLA-B*35:03 and -B*53:01). They then looked at only the
top 3 ranking Gag epitopes and found the controlling group had a significantly higher
preference for Gag than the non-controlling group. Doing the same for the other proteins
they found the non-controlling group had a preference for Nef peptides over the control-
ling group. Significant differences in the preferences for Vpu, p17, Vif and Ref epitopes
were also observed but it was concluded that the median ranks of these peptides were
so high (i.e. the peptide affinities were so low) that the differences were most likely not
physiologically important.
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Non-controlling alleles Controlling alleles
A) B) C) D)
Figure 5.4: The IEDB prediction tool suggests that Pol and Env produce the majority of
peptides presented on HLA molecules. The IEDB MHCI processing tools were used to anal-
yse the distribution of the top 1% of HIV-1-derived peptides predicted to be presented on MHCI
molecules. The predictions were made for controlling alleles, HLA-B*58:01, B*44:03, B*57:01
and B*27:05, and non-controlling alleles B*07:02, B*18:01, B*55:01 and B*35:03. A,C) The
IEDB Total Score for each peptide is plotted according to which protein they originate from. The
red crosses indicate the average total score of peptides from each protein. B,D) The number of
peptides in the top 1% is compared for each protein.
We carried out a similar analysis to that in Borghans et al. [141] on the top 1%
of peptides. We compared the median predicted Total Score of all peptides in the top
1% of each allele, grouping by control vs non-control, using a Wilcoxon rank sum test
(equivalent to the Mann-Whitney U-test used by Borghans et al.[141]). The analysis
revealed a statistically significant difference for all HIV proteins considered, suggesting
that controlling alleles prefer HIV peptides from Nef (p = 3.6× 10−6), Gag (p = 2.4×
10−6), Pol (p = 3.1× 10−18), Env (p = 1.5× 10−24), Vif (p = 1.2× 10−5, Vpr (p =
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0.0058) and Vpu (p = 1.0× 10−4) in general compared to non-controlling alleles (Rev
and Tat were not included due to the low numbers of peptides from these proteins in the
top 1%). We could conclude from this analysis that controlling alleles prefer to present
peptides from the entire HIV genome in general and that we would expect the two proteins
with the lowest p-values, Pol and Env to be associated with control of HIV, which does
not provide any explanation for the immunodominance of Gag epitopes.
Figure 5.5: Total Scores of top 1% of HIV epitopes from different HIV proteins grouped by
controllers vs non-controllers The median Total Score of the top 1% predicted HIV peptides for
either controlling alleles or non-controlling alleles was compared using a Wilcoxon rank sum test.
A significantly higher median Total Score when binding to the controlling group was observed for
all HIV proteins included in the analysis, suggesting controlling alleles preferentially bind HIV
peptides in general compared to non-controlling alleles.
5.3 A Mechanistic Model of HIV-1 Antigen Presentation
When a cell is infected by a HIV-1 virion, its constituent proteins enter the cytoplasm,
and become available for degradation by the proteasome. Following translocation to the
endoplasmic reticulum (ER) via the transported associated with antigen processing (TAP)
these peptides are then available for loading on to MHC class I molecules and presentation
at the cell surface.
During viral infection, a cytokine known as interferon gamma (IFN-γ) is produced,
which up-regulates the cell surface expression of MHC, suggesting that the cell surface
abundance of a peptide-MHC complex is an important factor in determining the T-cell
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response[6] (discussed in more detail in Chapters 1 & 3). The abundance of a peptide-
MHC complex on the cell surface is dependent upon the peptide-MHC affinity, but also
the abundance of the peptide in the ER. The abundance of the peptide in the ER is depen-
dent upon the proteasomal cleavage and TAP transport, as accounted for by the MHC-I
processing tool, however the abundance of the protein from which the peptide is cleaved
is also very important. The IEDB MHC-I processing tool cannot account for this abun-
dance because it is just dealing with the protein sequences. Therefore, we sought to put
together a model that predicts the cell surface abundance of HIV peptides by different
HLA alleles by combining the MHC-I processing tool predictions with a model for the
HIV protein abundances in the cytoplasm.
There are two sources of HIV-1 peptides; HIV-1 virion proteins and HIV-1 proteins
synthesised by the host cell machinery during viral replication. Presentation of virion
derived peptides provides the immune system a chance to detect and destroy infected
cells before viral replication begins in earnest. Once the HIV genome has been integrated
in to the host genome, the host cellular machinery will synthesise HIV-1 proteins in the
cytoplasm which begins the replication process. These proteins will also be degraded in
to peptides and some of these peptides will be presented on the cell surface. The HIV-1
host-synthesised proteins will accumulate to much higher levels in the cytoplasm than
the virion proteins, and these high concentrations will be sustained during replication.
Presentation of these peptides will most likely be of higher abundance than the virion
peptides, and their presentation will be sustained for as long as replication occurs. This
gives the immune system a second opportunity to recognise and destroy an infected cell.
We therefore sought to construct a model that incorporates the effects of viral pro-
tein intracellular kinetics, protein sequence specificities and MHC-I binding to produce
dynamic predictions of the antigen presentation profile of infected cell. We can model
the dynamics of HIV-1 peptides deriving from host-synthesised viral proteins determinis-
tically using a set of differential equations to describe the change in copy number of each
species involved in the process. However, due to the low copy number of HIV-1 proteins
within a virion, we can not assume spatial homogeneity of molecular concentrations or
constant rates of reaction. Therefore, we must model virion peptide presentation stochas-
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tically, and as a result we constructed two models of HIV-1 antigen presentation; a virion
model and a HIV-1 replication model as shown diagrammatically in Figure 5.6.
5.3.1 Methods: constructing the HIV-1 replication model
To create an integrated model of viral infection, de novo viral protein synthesis and pep-
tide presentation on MHC class I molecules, we started by combining three existing mod-
els of HIV-1 intracellular kinetics, Kim & Yin[117], Reddy & Yin[136] and Wang &
LuHua[145] to create a more complete model. We decided to use existing models and
combine them, instead of putting together a model of our own, as the existing models
have been peer reviewed, use experimentally derived values for important parameters,
and are detailed enough on their own that once combined we are able to model the kinet-
ics of almost the entire HIV proteaome. Hwijin Kim & John Yin presented two papers
Figure 5.6: Combined model of HIV-1 infection and cell surface peptide presentation on
MHCI molecules. Diagrammatic representation of the combination of the separate models that
comprise the combined model: the HIV kinetics models[117, 136, 145], and the peptide filtering
model[22].
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in 2005[117, 146], one which simulated HIV-1 kinetics from transcription in the nucleus
to study the effects of Rev on RNA splicing, whilst the other studied the purpose of the
feedback loops of Rev and Tat on the growth of HIV-1. Reddy & Yin’s 1999[147] model
covers the process from reverse transcription, which occurs straight after viral entry in
to the host cell, all the way to the budding and maturation of new virions. Wang &
LuHua[145] modelled the kinetics of Vif and Gag synthesis and well as the budding pro-
cess. This model is the most recent and up to date of the three and so its budding kinetics
were used instead of Reddy & Yin’s in the combined model. Combining all three mod-
els we were able to account for the intracellular kinetics of Rev, Tat, Gag, GagPol, Env
and Vif. The model was extended by inserting equations for the remaining proteins Nef,
Vpr and Vpu. We found half-life data from the literature from which we calculated their
degradation rates. We estimated their translation probabilities so that they produce suffi-
cient levels of proteins to allow formation of virions with the correct levels of proteins in
them, as measured experimentally.
In order to predict the cell surface presentation, these models must be combined with
the peptide filtering model[22], however we chose to simulate the virion model stochasti-
cally and the intracellular kinetics model deterministically (see Figure 5.6). We simulated
the virion model stochastically due to the low copy number of proteins within a HIV
virion, which will mean that the rate of reactions are not constant as the distribution of
molecules of each species cannot be assumed to be homogeneous, and therefore a deter-
ministic approach would be inaccurate.
5.3.2 Modelling HIV-1 intracellular kinetics
The combined model of HIV-1 intracellular kinetics begins with the Kim & Yin
model[117]. The differential equations describing the kinetics of each species in time
are as follows.








N ]− (kFsp+ kRNAdeg,N + k1a[RN ])[FN ] (5.1)
The full-length HIV-1 mRNA is produced first via transcription from the HIV-1 genome
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at the basal rate of host transcription TCb . Once the protein Tat, TN , has been translated and
imported back in to the nucleus, it binds with the Tat responsive element (TAR), which
along with some cellular co-factors, dramatically increases the transcription rate of all
mRNAs. This increase in transcription via Tat binding is denoted TCadd . Michaelis-Menten
kinetics are used to account for the saturation of either the number of polymerases or in
the number of the host cellular co-factors. In the Michaelis-Menten expression, KTat is
the equilibrium constant of Tat with TAR. The increase in transcription due to Tat binding
is multiplied by factor pv, which is the number of proviruses that have been integrated in
to the genome.
The term k(1)d [FR
(1)
N ] describes the dissociation of a Rev protein from the complex
FR(1)N , where FRN denotes the nuclear full-length transcript with Rev bound, and the su-
perscript of (1) denotes that one Rev protein is bound to the complex. Therefore the
dissociation of a single Rev from FR(1)N creates a FN . The splicing of full-length nuclear
transcript in to singly-spliced mRNA is denoted by the rate coefficient kFsp, and the degra-
dation of the full-length mRNA in the nucleus is denoted kRNAdeg,N . The term k
(1)
a [RN ][FN ]
represents the binding of a single Rev RN to a free full-length nuclear transcript, where
k(1)a is the rate coefficient for the association rate of one Rev to the full-length mRNA,
thus producing FR(1)N .
Rev-bound full-length mRNA, FR(i)N , where i is the number of Rev proteins bound
to the transcript, behaves slightly differently from Rev-free full-length mRNA:
d[FR(i)N ]
dt







+k(i+1)a [RN ]+ k
(F,i)
exp +(1−dF,(i))kFsp+ kRNAdeg,N)[FR(i)N ]
(5.2)
for i = 1,2, ...,sn.
The first term in Equation 5.2 describes the creation of FR(i)N , via the association of a
single Rev protein RN to a full-length transcript with i−1 Rev proteins bound, with rate
constant k(i)a . Similarly, FR
(i)
N can be created via the dissociation of a single Rev protein
from FR(i+1)N , with rate constant k
(i+1)
d . On the other hand, a Rev protein can unbind to
FR(i)N with dissociation rate k
(i)
d , which creates FR
(i−1)
N . Similarly, if single Rev protein
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binds to FR(i)N , with association rate k
(i+1)





also be spliced with rate (1− dS,(i))kFsp, where dS,(i) is the delay in splicing due to the
presence of the bound Rev proteins. FR(i)N is exported to the cytoplasm with rate k
F,(i)
exp ,
and is degraded with rate constant kRNAdeg,N .
Now we will look at the kinetics of the singly-spliced mRNA in the nucleus:
d[SN ]
dt




N ]− (kSsp+ kRNAdeg,N + k(1)a [RN ])[SN ] (5.3)
Full-length mRNA is spliced in the nucleus with rate constant ksp to produce singly-
spliced mRNA, SN . A single Rev protein can dissociated from a SR
(1)
N complex, which
is singly-spliced nuclear mRNA with a single Rev protein attached, at rate kd , which
creates a free SN . Singly-spliced mRNA can also be spliced with rate constant kSsp in to
multiply-spliced mRNA, and SN is also degraded with rate kRNAdeg,N . The concentration of
SN is reduced when a nuclear Rev protein RN associates with SN with rate coefficient k
(1)
a ,
thus producing SR(1)N .
Similar to FR(i)N , the kinetics of singly-spliced mRNA with i bound Rev proteins,
SR(i)N are different to those of SN ,
d[SR(i)N ]
dt






N ]+ (1−dF,(i))kFsp[FR(i)N ]− (k(i)d
+k(i+1)a [RN]+ k
S,(i)
exp +(1−dS,(i))kSsp+ kRNAdeg,N)[SR(i)n ]
(5.4)
for i = 1,2, ...,sn.
SR(i)N is created when a Rev protein RN associates with a singly-spliced mRNA
molecule with i−1 Revs bound, with rate coefficient k(i)a . Similarly, SR(i)N is also created if
a single Rev protein dissociates with rate constant k(i+1)d from singly-spliced mRNA with
i+1 bound Rev molecules. SR(i)N can also be created following the splicing of FR
(i)
N with
rate coefficient (1−dF,(i))kFsp. A Rev protein can dissociate from SR(i)N with rate constant
k(i)d , which creates SR
(i−1)
N , and a Rev protein can also associate with SR
(i)
N with rate con-
stant k(i+1)a to produce SR
(i+1)
N . Once a threshold number of Rev proteins are bound, SR
(i)
N
can be exported to the cytoplasm with rate constant kS,(i)exp . SR
(i)
N can also be spliced with
rate constant (1−dS,(i)) to create multiply spliced mRNA, MN and i free Rev proteins.
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The differential equation for the kinetics of multiply-spliced mRNA in the nucleus,







((1−dS,(i))kSsp[SR(i)N ])− (kMexp+ kRNAdeg,N)[MN ] (5.5)
Multiply spliced mRNA is produced via the splicing of Rev-free singly-spliced mRNA
SN and also via the splicing of singly-spliced mRNA with i Rev proteins bound, SR
(i)
N ,
and the rate constant for both is kSsp. The maximum number of Rev proteins that can bind
to a single transcript is denoted sn. The second term on the right-hand side also includes
the factor (1−dS,(i)), where dS,(i) is the delay in splicing due to the presence of the bound
Rev proteins. As with the previous two equations, MN degrades with rate constant kRNAdeg,N .
The term kMexp[MN ] accounts for the fact that multiply-spliced mRNA can be exported to
the nucleus independent of Rev, with rate constant kexp.
The kinetics of cytoplasmic multiply-spliced mRNA, MC, are as follows,
d[MC]
dt
= kMexp[MN ]− kRNAdeg,C[MC] (5.6)
where MC is degraded with rate constant kRNAdeg,C in the cytoplasm.
As previously mentioned, once a threshold number of Rev molecules have associated
with either full-length or singly-spliced mRNA, they too can be exported to the cytoplasm,


















N ])− kRNAdeg,C[SC] (5.8)
SR(i)N and FR
(i)
N can only be exported to the cytoplasm once a threshold level of Rev
proteins has bound to the transcript. Therefore for i < threshold, kX ,(i)exp = 0 but for i >
threshold, kX ,(i)exp 6= 0. The threshold number of Rev proteins that are required to bind
before nuclear export can begin is given in [117] as 7, with the maximum number of Rev
proteins that can bind to a single transcript, sn, being 12.
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Once they enter the cytoplasm, the i bound Rev proteins instantaneously unbind. The
kinetics of Rev proteins in the cytoplasm, RC are as follows,
d[RC]
dt




(i · (kF,(i)exp [FR(i)N ]+ kS,(i)exp [SR(i)N ]))
−(kRimp+ kRdeg,C)[RC]
(5.9)
Rev is produced in the cytoplasm via translation, with rate constant Tr, from the fraction
of multiply-spliced mRNA, f Mrev, that encodes for the rev mRNA, where fRev is the prob-
ability for this rev mRNA to encode for the Rev protein. For Rev to be able to enable
the export of full-length and singly-spliced mRNA, it has to be imported in to the nu-
cleus, which occurs with rate coefficient kRimp. Nuclear Rev RN can also be exported back
to the cytoplasm independently of any mRNA transcript, with rate constant kRexp. Those
mRNA nuclear transcripts with a threshold level of Rev proteins bound are transported
in to the cytoplasm with rate constant kX ,(i)exp where X stands for either full-length, F , or
singly-spliced, S, and they then release their bound Rev proteins back in to the cytoplasm.
Therefore, for an exported concentration of transcript X with i bound Rev proteins, where
i > threshold, there will be (i · [XR(i)N ]) Rev proteins released. To account for the con-
tribution to the cytoplasmic Rev pool from all exported transcripts with i > threshold
bound Rev proteins we must sum up over i, where kX ,(i)exp for i < threshold is zero. The
degradation of Rev in the cytoplasm occurs with rate constant kRdeg,C.
































Rev can be imported in to the nucleus with rate constant kRimp and can be exported back
in to the cytoplasm with rate constant kRexp. When a Rev dissociates with rate constant
k(i)d from a full-length mRNA FR
(i)
N , or a singly-spliced mRNA SR
(i)
N , with i bound Rev
proteins, it increases the nuclear pool of Rev. Therefore, we must sum over all i from 1
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to the maximum number of bound Rev, sn, to account for the dissociation of Rev proteins
from all Rev-bound transcripts. When a Rev-bound transcript, XR(i)N degrades with rate
constant kRNAdeg,N , it releases the i Rev proteins it is bound to, and so we must also sum up
over all i to account for this. Similarly, we must sum over all i when considering the i
Rev proteins released during the splicing of singly-spliced mRNA, at rate constant (1−
dS,(i))kS,(i)sp . We must also sum over all association events, where a Rev protein associates
with a transcript XR(i−1)N , with rate constant k
(i)
a . Finally, Rev degrades in the nucleus with
rate constant kRdeg,N .
The cytoplasmic kinetics of the protein Tat which is required for the increase in the
transcription rate of HIV transcripts, are described in Equation 5.11. Tat is translated
from both multiply-spliced mRNA, MC and singly-spliced mRNA, SC, at rate Tr where
the fraction of tat mRNA in these transcripts is f Mtat and f
C
tat respectively. The probability
that this tat mRNA encodes for Tat is given by fTat .
d[TC]
dt
= fTat ·Tr(˙ f Stat [SC]+ f Mtat [MC])+ kTexp[TN ]− (kTimp+ kTdeg,C)[TC] (5.11)
Cytoplasmic Tat is imported in to the nucleus with rate constant kTimp where it can increase
the rate of transcription. Free Tat proteins in the nucleus, TN can also be exported back
in to the cytoplasm with rate constant kTexp. Tat is degraded in the cytoplasm with rate
constant kTdeg,C.
Once in the nucleus, the kinetics of Tat are as follows,
d[TN ]
dt
= kTimp[TC]− (kTexp+ kTdeg,N)[TN ] (5.12)
where kTexp is the rate constant of Tat export in to the cytoplasm, and k
T
deg,N is the rate
constant for degradation of nuclear Tat.
The Kim and Yin[117] model as described above provides the kinetics for the steps
of HIV-1 transcript synthesis, and the translation and kinetics of the proteins Rev and Tat.
To model the dynamics of the important structural proteins, Gag, GagPol and Env, we
use the model presented by Reddy and Yin[147]. They write the differential equations
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describing the protein dynamics as follows:
d[Gag]
dt
= fGag ·Tr[FC]− kGag[Gag]− kbud[Gag] (5.13)
d[GagPol]
dt
= fGagPol ·Tr[FC]− kGagPol[GagPol]− kbud[GagPol] (5.14)
d[Env]
dt
= fEnv ·Tr[SC]− kEnv[Env]− kbud[Env] (5.15)
Both Gag and GagPol are translated from full-length cytoplasmic mRNA, FC, with trans-
lation probability fGag and fGagPol respectively. Env is translated from singly-spliced
cytoplasmic mRNA, SC, with translation probability fEnv. The degradation of each pro-
tein is described by the second term in each of the Equations 5.13-5.15, where kProt is
the degradation rate of each protein Gag, GagPol and Env. The third term in Equations
5.13-5.15 describes the budding process, where the proteins are translocated to the cell
membrane to create new virions. This step is not included in the Reddy and Yin model, but
is taken from Wang and LuHuas[145] model where the value of kbud was chosen to ensure
the levels of full-length cytoplasmic mRNA reached a steady state at 3,900 molecules per
cell. This steady state level is the average of a set of experimental data measuring the
concentration of intracellular Gag.
The Wang & Hua[145] model also included the synthesis of the Vif protein, whose
dynamics are as follows:
d[Vi f ]
dt
= fVi f ·Tr[SC]− kVi f [Vi f ]− kbud[Vi f ] (5.16)
Vif is translated from single-spliced mRNA with probability fVi f , degrades with rate con-
stant kVi f and is translocated to the cell membrane for budding with kbud .
Unfortunately, none of the previously existing models include the kinetics of the
remaining proteins Nef, Vpr, Vpu. Nef is translated from multiply-spliced cytoplasmic
mRNA and is incorporated in to a single virion at between 60− 200 copies per virion.
To model Nef we used the average rate of degradation of eukaryotic proteins as given in
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[136] for the degradation rate, and set the budding rate to be the same as the rate given
in [145] for the previous equations. We then set the probability of translation fNe f so
that the trade-off between it and the two other rates kNe f and kbud resulted in there being
between 60− 200 copies of Nef in a single budding virion[148]. The Vpr protein is rel-
atively stable, with a measured half-life of around 20h[149], which we used to calculate
the degradation rate of Vpr, kV pr. Vpr is found in the HIV-1 virion at a ratio of 1 : 7 to
the number of copies of Gag[135], and so we set the probability of translation fV pr from
singly-spliced mRNA to ensure that the ratio of Gag:Vpr is as stated, using the value
calculated from the half-life for the degradation rate, and the same budding rate as the
other proteins. Finally, for the Vpu protein, we could not located any measurements of
Vpu half-life in the literature, nor could we find any information regarding the number of
copies of Vpu in a HIV-1 virion. The mRNA and protein dynamics from the combined


















Figure 5.7: Simulated HIV mRNA. The combined model was used to simulate full-length (FC),
singly-spliced (SC) and multiply-spliced (MC) mRNA copies in the cytoplasm. The full-length
cytoplasmic mRNA (FC) reaches a steady state level of 3,900 copies, which agrees with the ex-
perimentally measured average[150].
and more complete model of HIV intracellular kinetics are shown in Figures 5.7 & 5.9 A
respectively. Following viral entry to a cell, there will be a delay before the viral genome
is integrated in the cell genome in the nucleus, experimentally measured to be around 8.5
hours post infection[151], during which time the model will only simulate the degradation
of the virion proteins and their peptide production. Gag is the most abundant protein for
the majority of the replication process, with the exception of the short time required for
the translation of Rev from multiply-spliced mRNA and its subsequent binding to full-
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length and singly-spliced mRNA in the nucleus. During this time, the concentration of
Rev and Tat available for cytoplasmic degradation will be very low due to the shuttling
back and forth from the cytoplasm to the nucleus, and the binding to the other HIV tran-
scripts. The Nef protein however, which is also transcribed from multiply-spliced mRNA
accumulates in the cytoplasm, as indicated by the yellow curve in Figure 5.9 A. Gag be-
gins to accumulate to very high numbers at around 15 hours post infection. Pol, Env and
Vpr also accumulate to considerable numbers during this time.
Table 5.1: HIV-1 intracellular kinetics model parameters.
Parameter Value References
Basal transcription rate, TCb 4.1667×10−3 transcripts/s [117, 136]
Increase in Transcription by Tat
Transactivation, TCadd
0.4125 transcripts/s [152, 153, 154]
Equilibrium dissociation con-
stant of Tat with TAR, KTat
5.2453×10−5/molecule 28.57/µM[145]
Splicing rate constants, kFsp = k
S
sp 6.95×10−4molecules−1s−1 [155, 117, 136]
Rate of export from the nu-
cleus kF,(i)exp = k
S,(i)





Rate of Translation kTrans 0.075s−1 [157, 117, 136]
Fraction of Full-Length mRNA
that encodes for Gag fGag
0.95 [136]
Fraction of Full-Length mRNA
that encodes for Gag-Pol fGagPol
0.05 [136]
Fraction of Singly-spliced




mRNA that encodes for Rev
f MRev
0.19 [117]
Continued on next page
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Table 5.1 – continued from previous page
Parameter Value References
Probability that Rev mRNA will
encode for Rev fRev
0.5 [117]
Fraction of Multiply-spliced




mRNA that encodes for Tat
mRNA f STat
0.05 [117]
Probability that Tat mRNA will
encode for Tat fTat
1.0 [117]
Splicing Delay Factor Due to
Rev dF,(i) = dS,(i)
0.8 [117]





Degradation rate for Rev in the
cytoplasm, kRevdeg,C
4.833×10−6s−1 [117]
Degradation rate for Rev in the




Degradation rate for Tat in the
cytoplasm and nucleus kTatdeg,C =
kTatdeg,N
4.278×105s−1 [117]
Degradation rate for gp120 (Env
Precursor) in cytoplasm kgp120deg,C
5.55×10−6s−1 [136]
Association constant for Rev




k(i)a = 0.0233 molecules1s1
[117]
Dissociation constant for Rev
with RRE, k(1)d and k
(i)
d
k(1)d = 3.0×105 molecules1s1,
k(i)d = 3.8×102molecules1s1
[117]
Continued on next page
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Table 5.1 – continued from previous page
Parameter Value References
Rate of export of proteins
through budding kbud
0.08 h−1 [145]




mRNA that encodes for Vif fVi f
0.1 NA
Fraction of Singly-spliced








mRNA that encodes for Nef
fNe f
0.5 NA
Degradation rate of Gag, kGag 0.1054 h−1 [136]
Degradation rate of GagPol, kPol 0.1159 h−1 NA
Degradation rate of Vpr, kV pr 0.0346 h−1 [149]
Degradation rate of Env, kEnv 0.02 h−1 [136]
Degradation rate Vpu, kV pu 0.086 h−1 NA
5.3.3 Estimating the peptide-MHC-I unbinding rates
The IEDB MHC-I binding predictor tool[76] predicts the affinity of the binding between a
peptide sequence and a chosen MHC-I allele. We used consensus HIV clade C proteome
http://www.hiv.lanl.gov as inputs to the IEDB predictor. The output of the tool
is a large table of peptide sequences derived from the input protein sequence, and the
predicted affinity between the peptide and the HLA allele.
The affinity is given as an IC50 (nM) value, or half the maximal inhibitory concentra-
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tion. This value is found by determining the concentration of test peptide required to fill
half of the MHC binding sites when competing against a labelled peptide. The machine
learning algorithm is then built upon a data set of these values and their corresponding
peptide sequences.
In Section 5.2.1 we used two different thresholds for assigning a peptide to be either
binding or non-binding. In the first method, we use the raw affinity threshold of 500 nM,
where strongly binding peptide will have an IC50 of less than 50 nM, whilst a weakly
binding peptide will be between 50 and 500 nM. Peptides with an IC50 of greater than
500 nM will be assumed not to bind to the MHC allele. In the second method we clas-
sified all those peptides in the top 1% of all HIV peptides to be binders, meaning every
allele binds the same number of peptides. We therefore carried out two sets of simulations
in MATLAB. In the first set of simulations we simulated only those peptides with an IC50
less than or equal to the threshold of 500 nM. For the second set of simulations, in order
to be able to compare the cell surface abundance of the peptides presented by each allele
we required that the IC50 values between the alleles also be comparable, therefore we
had to rescale the IC50 values according to the method in Ref. [159] and used in simi-
lar studies to this[143]. We acquired the predicted IC50 values for the peptides from the
Mycobacterium Tuberculosis proteome to obtain a dataset of over 500,000 partially over-
lapping natural peptides. For each allele studied here we obtained three separate datasets
for the 9mers, 10mers and 11mers. We then combined the three datasets and took the top
1% of binders as the IC50 threshold for binding peptides for each allele. The rescaling
method described in Ref. [159] normalises each IC50 by dividing by the threshold IC50
value. However, for our purposes we require a rescaled IC50 value that is still in units of
nM. Therefore, we arbitrarily chose one allele as the reference allele and then rescaled
the predicted IC50 values relative to that allele. The reference allele was chosen to be
HLA-B*58:01, and its threshold affinity as determined using the method described above
is denoted IB58. When rescaling the predicted IC50 values for say HLA-B*57:01, we
would multiply the IC50 value by the ratio of the threshold of B*58:01 to the threshold
of B*57:01. Therefore, for allele a, the rescaled IC50 values are calculated as follows:
IC50Ra = IC50a ∗ (IB58/Ia), where IC50Ra is the rescaled IC50 of allele a, IC50a is the
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original IC50 and Ia is the rescale threshold of allele a. The results of the simulations for
method 1 are shown in Figures 5.10 and 5.11 and the results for the simulations for method
2 are shown in Figures 5.12 and 5.13. It can be assumed that the IC50 is approximately
equal to the peptides dissociation constant from the MHC allele[160, 161, 162, 163], Kd ,
where Kd = ui/bP where bP is the peptide MHC binding rate. The binding rate was kept
constant for each peptide, as experimental evidence shows that there is much less varia-
tion in HIV peptide binding rates than in the peptide off-rates[164] and the binding rate
was set to 219M−1s−1[165]. The peptide off-rate can then be determined for each HIV-1
peptide when binding to either a controlling or non-controlling allele.
5.3.4 Protein degradation and peptide cleavage in the cytoplasm
To be able to combine the HIV-1 intracellular kinetics model with the peptide filtering
model[166] a few extra steps are required, which are not included in either of these other
models, namely the kinetics of production of peptides from the HIV-1 proteins and the
transport of these peptides to the ER. These steps are described in the following equation:
d[Pi]
dt
= pi, j · kProt jdeg [Prot j]−gi[Pi]cyt−dPi,C [Pi]cyt , (5.17)
where Pi is the peptide of sequence i, cleaved from protein Prot j. The production rate of
peptide Pi is written as the product of the probability the peptide will be cleaved from the
protein, pi, j and the degradation rate of the protein, k
Prot j
deg . Peptide Pi can be degraded in
the cytoplasm with rate constant dPi,C and can also be transported to the ER with rate con-
stant gi. This is how the virion model and HIV intracellular kinetics model are connected
to the peptide filtering model; the term gi[Pi]cyt acts as the supply rate of peptide Pi to the
ER.
We approximated values for the proteasomal cleavage probability for each peptide
in the same way as in Chapter 4 Section 4.2.2. Briefly, the IEDB MHC-I processing
tool[109] predicts a cleavage score for each peptide, which is proportional to the loga-
rithm of the amount of peptide generated from the cleavage of the peptides C-terminal.
To convert this in to a probability we scaled these values down by a factor of 1000, to
get them to be within the expected range, as it has been measured that the well known
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peptide SIINFEKL, or an N-terminally extended version of it, is produced via degrada-
tion of the OVA 6−8% of the time it degrades[110]. SIINFEKL is known to be a highly
immunogenic peptide, and so it is likely that it is produced with a high probability during
proteasomal cleavage. Therefore, we set the highest potential probability of proteasomal
cleavage to be 10%, and used this as an upper bound when predicting the proteasomal
cleavage probabilities for the peptides in the model.
With this upper bound in mind, we took the amino acid sequences of HIV-1 con-
sensus clade C proteins and used the IEDB MHC-I processing tool[109] to predict the
cleavage scores for each peptide. As previously mentioned, the score is proportional to
the logarithm (base 10) of the amount of peptide generated, therefore we converted these
scores in to relative abundances of each peptide. These relative abundances ranged from
between 1≤ x≤ 80, and so to obtain relative proteasomal cleavage probabilities for each
peptide that lay within the above mentioned upper bound of 10% we divided the scores
by 1000. These scores are therefore not supposed to represent a prediction of the actual
proteasomal cleavage probabilities of each peptide, but rather the relative probability of
cleavage.
Lazaro et al[167] investigated the variability of the cytosolic degradation rates of
HIV peptides, and how this influences T-cell response. They found that their half-lives are
highly variable and sequence specific, and this variability does in fact have a significant
affect upon the efficiency of T-cell recognition. They then constructed an algorithm to
predict the probability that a certain peptide sequence will have a half-life of either, 5 s,
less than 30 s or longer than 2 mins. To do this they identified motifs which increase
stability and those which decrease it, and so the prediction algorithm outputs a stability
score for a specific peptide sequence. We therefore used their peptide stability tool to
predict the half-lives and thus the degradation rate, dPi,C . of the HIV peptides used in the
simulations.
The IEDB MHC-I processing tool predicts how well a specific peptide will be trans-
ported in to the ER by predicting an IC50 value for the peptide binding to TAP. Converting
this value in to a supply rate for each peptide is more difficult than for the cleavage prob-
abilities. The degradation of peptides in the cytoplasm is a much more efficient process
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than the transport of peptides to the ER[168], and so this helps us put an upper bound on
the possible range of the supply rate. A half-life of 5 s is the average peptide half-life
in the cytoplasm[169], and is the lower-bound of the peptide stability predictions[167].
Therefore, we decided to set the supply rate of each peptide to be 0.08 peptides/s as this
is less than the lower-bound of the peptide degradation rate i.e. gi ≤ dPi,C,min , where dPi,C,min
is calculated from the half-live of 5 s.
5.3.5 Self-peptides
Viral peptides compete not only with each other but also with peptides derived from the
host’s self-proteins or self-peptides for MHC class I binding and presentation. As self-
peptides originate from native host proteins, they should not initiate a T-cell response
due to negative selection of self-reactive T-cells. Just like the viral peptides, these self-
peptides will have a range of proteasomal cleavage probabilities, ER supply rates and
MHC class I binding rates. However, there are too many self-peptides to represent explic-
itly in the model. Therefore, to model the impact of the competition of these self-peptides
we represented the self-peptides by four additional peptides in the simulation. These four
peptides were given a range of unbinding and supply rates (see Table 5.2 for parame-
ters). Each different MHC allele will only bind a small subsection of the ER peptidome
with high affinity, and so the self-peptides with a medium unbinding rate (1×10−3 s−1)
were assumed to make up the majority of the peptides being transported in to the ER
and were allocated a large fraction of the total supply rate. TAP binds between 2− 5
peptides per second, and there are approximately 10,000 copies of TAP per cell[169].
We assigned the total rate of TAP transport of self-peptides to be the lower end of this
range (20,000 peptides per second) to maximise viral peptide presentation. The kinetics
Parameter Unbinding rate (s−1) Fraction of total supply
Self-peptide-MHC unbinding very high 1×10−2 0.05
Self-peptide-MHC unbinding high 1×10−3 98.5
Self-peptide-MHC unbinding medium 1×10−4 0.05
Self-peptide-MHC unbinding low 1×10−5 0.05
Table 5.2: Self-peptide parameters. The values of the four representative self-peptide parameters
used in the model.
of the self-peptides are given by are identical to those described for peptides in Equations
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2.36 and 2.39-2.42 and 5.17. In total for each peptide in the system there are 5 equa-
tions describing them alone or in complex in both the cytoplasm and ER, so for n viral
peptides and nsel f self-peptides there are 5(n+nsel f ) equations in the system. Therefore
when simulating peptides derived from HIV proteins produced via host synthesis, there
are 5(n+ nsel f ) equations in addition to the equations describing the HIV intracellular
kinetics as described in Equations 5.1-5.16.
5.4 Results of the Mechanistic Model of HIV-1 Intracel-
lular Kinetics and Antigen Presentation
5.4.1 A sensitivity analysis reveals the importance of different pa-
rameters changes in time
We performed a sensitivity analysis on a small subset of the model parameters which
are peptide specific and influence cell surface abundance, using the SUNDIALS
CVODES[170] forward sensitivity analysis (FSA) in MATLAB. The sensitivity of a
system of nonlinear first order ODEs x˙ = f (t,x,θ) with respect to the kth parameter θk is




















The CVODES FSA approximates s˙i by a centred difference quotient. Both the sensitivi-
ties and ODE systems are solved simultaneously, to provide the time dependent parameter
sensitivity. The sensitivity of the cell surface abundance of a single peptide, denoted here
as MeP - competing against a group of self-peptides - was determined for the following
set of parameters for each HIV protein: the peptide-MHC unbinding rate, u, the peptide-
MHC binding rate, bP, peptide-MHC-tapasin binding rate cP, the peptide supply rate
from cytoplasm to ER, g, the proteasomal cleavage probability of that peptide, ps, and
the synthesis and degradation rates of the protein, f j and k j, respectively. The sensitivity
coefficients si are normalised by the ratio of the baseline parameter value to the base-
line system output i.e. θk0/xi0(t) to remove the effects of units. Therefore, a normalised
sensitivity coefficient of 1 indicates a positive linear dependency of the peptide cell sur-
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face abundance upon that parameter, whilst a value of -2 indicates an inverse quadratic
dependency.
For most proteins there was in general a linear dependency upon protein synthesis
f j over time (Figure 5.8A). However, the dependence of MeP on protein degradation (k j)
for each protein was sub-linear over time (Figure 5.8B), meaning cell surface abundance
is in general less sensitive to changes in the protein degradation rate than the synthesis
rate. A transiently non-linear dependency on protein synthesis rates were observed for the
presentation of Tat and Rev peptides which may be due to the effects of nuclear shuttling.
The presentation of the Gag peptides however, showed a sub-linear dependency on protein
synthesis fi, possibly due to the rapid accumulation of Gag epitopes in the cytoplasm
resulting in the abundance instead being limited by ER translocation (Figure 5.8A).
For each protein there was a positive linear dependency of cell surface abundance
on the probability of proteasomal cleavage ps, which remained constant over time, and
a positive sublinear dependency on ER supply rate g which also remained constant over
time. Comparing the sensitivity coefficients of the peptide-MHC binding rate bP and
the peptide-MHC-tapasin binding rate cP reveals that the cell surface abundance has an
almost linear dependency on cP but the dependency on bP is highly sublinear. Therefore,
the peptide cell surface abundance is more highly influenced by the peptide binding rate
to MHC-tapasin complexes than to empty MHC.
The sensitivity coefficient of peptide unbinding rate u becomes steadily more nega-
tive as time progresses, approaching an inverse quadratic dependency over time. Indeed,
by 72 hours post infection the magnitude of the sensitivity coefficient for the unbinding
rate is the highest out of all the parameters considered, suggesting that prolonged cell
surface presentation depends highly upon the value of the unbinding rate, where lower
values are more likely to be presented for longer. The sensitivity analysis highlights the
trade-off occurring between the different parameters and their influence upon cell surface
abundance changes with time.
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Figure 5.8: Sensitivity analysis of the combined model. We calculated the sensitivity of the
cell surface presentation of optimal epitopes to seven of the model parameters: probability of
protein translation f j ( j denotes the protein), cytoplasmic degradation k j, proteasomal cleavage
probability pc, supply rate to the ER g, peptide-MHCI unbinding rate u, peptide-MHCI binding
rate b, and the peptide-MHC-tapasin binding rate cP. The sensitivities were calculated using the
CVODES module of the SUNDIALs package [171], then normalised.
5.4.2 An efficient Gag peptides dominate at the cell surface
We modelled the HIV-1 replication kinetics with deterministic ODEs, as HIV proteins are
synthesised to high abundance in the cytoplasm following reverse transcription. The Gag
protein had the highest cytoplasmic abundance in our simulations of HIV protein kinetics
using the combined model described above, in keeping with the existing models of HIV
kinetics. Experimental evidence suggests that the Gag:Pol ratio in the virion of 20 : 1
is maintained in the cytoplasm[172]. We then considered the presentation of an efficient
peptide for each HIV protein, to determine which will produce the most abundant peptides
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Figure 5.9: Example simulation of the combined model of HIV infection and peptide-MHC-
I presentation. A) Simulated levels of HIV-1 proteins produced during replication (calculated
deterministically). The complete model that produces all HIV-1 proteins is a combination of
three existing models Kim & Yin[117, 173], Reddy & Yin[136], and Wang & LuHua[145]. B)
Simulated cell surface abundance of efficient peptides derived from each protein, considered to
have ui = 10−5 s−1, a proteasomal cleavage pci, j = 0.1, and a fast supply rate gi = 0.08 peptides
s−1 to the ER.
on the cell surface if the peptide specific parameters are highly favourable and the same
for each peptide so that only protein dynamics influence the cell surface abundance. We
defined this efficient peptide as having a high affinity for MHC-I and so a low unbinding
rate (u = 1×10−5 s−1), a high proteasome cleavage probability (pci, j = 0.1), and a high
supply rate to the ER (gi = 0.08 peptides s−1). The regulatory proteins Rev, Tat and
Nef are the earliest proteins synthesised and are the first to appear in the cell cytoplasm
at around 9 hours post infection. Peptides derived from these regulatory proteins are
frequently targets of CTL response, and so may be good targets for a HIV-1 vaccines[174],
before the down-regulation of MHC-I by Nef. Rev and Tat are continuously shuttling
between the cytoplasm and the nucleus to regulate HIV mRNA nuclear export, and viral
genome translation respectively[117]. The model predicts that this rapid shuttling results
in slower cytoplasmic accumulation of Rev and Tat proteins than Nef, and even at late
times when they have reached steady state the cytoplasmic abundance of these proteins
is much lower than that of all other HIV-1 proteins (Figure 5.9 A). Therefore, out of
the three early HIV proteins, the model predicts that only the Nef optimal epitope will
be presented significantly early, around 12 hours post-infection. The optimal epitopes
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from Rev and Tat however do not appear on the cell surface in substantial abundance
until after the optimal epitopes from the later proteins, which appear at around 15-16
hours post infection (Figure 5.9 B). This suggests that any benefit that would be gained
by targeting epitopes from the early HIV proteins before MHC-I down-regulation would
only be applicable in the case of Nef epitopes and not Rev or Tat.
The Gag peptide dominates cell surface abundance, due to its very high abundance
in the cytoplasm, with a Gag:Pol ratio of 18 : 1, which is similar to the ratio in the presen-
tation of two HLA-A2 restricted peptides, gag 77-85 (SLYNTVATL) and pol RT 476-484
(ILKEPVHGV) of around 30:1[175]. The model predicts a Gag:Vpr ratio of 23 : 1 and
a Gag:Env ratio of 64 : 1. The authors further suggest that this is consistent with the ra-
tios of Gag and Pol in the virion and cytoplasm, around 20:1. However, unlike Gag, the
ranking of the cell surface abundance for the optimal epitopes deriving from the other pro-
teins does always follow the ranking of their cytoplasmic abundances. The second most
abundant in the cytoplasm is Vpr, but the Pol peptide is the second most abundant on the
cell surface, whilst Env is the third most abundant protein in the cytoplasm, however, its
epitope has only the sixth highest cell surface abundance. This highlights the important
trade-off between the rates of protein synthesis and degradation in determining peptide
cell surface presentation: Vpr has a long half-life and so is very stable[149], therefore
although it has a high cytoplasmic abundance, it degrades slowly, producing few peptides
per unit time than faster degrading proteins such as Pol. A similar argument can be ap-
plied when considering the discrepancies in the ranking of the Env protein and its optimal
epitope. Therefore, when trying to predict the cell surface abundance of an epitope the
abundance and half-life of the protein from which it derives must also be considered.
5.4.3 HIV-1 intracellular kinetics and viral peptidome: LTNP vs fast
progressors
Using the IEDB MHC-I binding tool to predict the unbinding rates and cleavage param-
eters for each peptide, we simulated deterministically the presentation of HIV-1 peptides
by a set of HLA alleles associated with LTNP and a set associated with fast progression.
The purpose behind this was to see if the simulations could explain why the presentation
of Gag epitopes is correlated with control of HIV and to see if there are any obvious
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differences in the presentation of HIV peptides by controlling alleles compared to fast
progressors.
We simulated the cell surface presentation for four alleles associated with fast pro-
gression: HLA-B*18:01, -B*55:01, -B*07:02 and -B*35:03, and four alleles associated
with long term non-progression: HLA-B*58:01, -B*57:01, -B*27:05 and -B*44:03. As
described earlier we carried out two sets of simulations using different methods to define
the threshold values for whether or not a peptide is binding or non-binding, and so will
discuss the results separately.
Method 1: results We simulated the presentation of peptides of length 8−15 amino acids
long up to 72 hrs post infection and analysed the top 12 presented peptides at 16,24 and 72
hours. These simulations were carried out deterministically in MATLAB due to the large
copy number of HIV proteins produced during HIV replication. At 16 hrs post infection
HLA-B*58:01 and -B*57:01 presented majority Gag peptides on the cell surface with
HLA-B*58:01 also presenting two Nef peptides, whilst HLA-B*57:01 only presented
one Nef peptide. At 24 and 72 hours post infection both these alleles only presented
Gag peptides in the top 12. The other two controlling alleles HLA-B*27:05 and -B*44:03
presented fewer Gag peptides at 16 hours post infection than HLA-B*57:01 and -B*58:01,
and also presented Nef and Vif peptides. By 24 and 72 hours post infection the number of
Gag peptides presented by these alleles increases with HLA-B*27:05 presenting majority
Gag and HLA-B*44:03 presenting a mixture of Gag Pol and Vif peptides. In general
using this method the controlling alleles are predicted to present largely Gag peptides in
high abundance at all time points post infection.
At 16 hours post infection the non-controlling alleles HLA-B*07:02 and -B*18:01
present a mixture of Gag and Nef peptides in the top 12, just as the controlling alleles
did. HLA-B*55:01 and -B*35:03, however, only presented one peptide at 16 hours post
infection, from Gag and Nef respectively at very low abundance. At 24 hours post in-
fection HLA-B*07:02 presents all Gag in the top 12, whilst HLA-B*18:01 presents a
mixture of Gag and Pol peptides. HLA-B*18:01 continues to present a mixture of Gag
and Pol peptides in the top 12 at 72 hours post infection, whilst three of the Gag peptides
presented by HLA-B*07:02 at 24 hours post infection are replaced by Vpr, Pol and Nef.
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The top 2 most abundant peptides presented by HLA-B*55:01 at 24 hours post infection
are Gag peptides, however the rest of the top 12 is made up of a mixture of Vpr, Pol and
Nef peptides, with a similar distribution at 72 hours post infection. HLA-B*35:03 does
not present any Gag peptides in the top 12 at 24 or 72 hours post infection, but presents a
mixture of Nef, Pol and Vpr peptides.
The simulations predicted that controlling alleles present a wide range of Gag epi-
topes at high abundance, many of which are known epitopes (Figure 5.10). For exam-
ple, the simulations predict the well known B57/B58 p24 Gag epitopes KF11 (KAFSPE-
VIPMF) and TW10 (TSTLQEQIAW) are presented in the top 12 by HLA-B*58:01 and
-B*57:01 as early as 16 hours post infection. Similarly, Gag epitope KK10 (KRWIIL-
GLNK) is associated with control when presented by HLA-B*27:05, and is predicted
to be presented in high abundance on the cell surface by 24 hours post infection. Fur-
thermore, Gag AW11 (AEQATQDVKNW) is a well known and well defined epitope of
HLA-B*44:03, and appears in the top 12 of this allele at 16 hours post infection. For the
non-controlling allele HLA-B*35:03, the simulations predict that the peptides from Nef
and Pol dominate the cell surface abundance, whilst for HLA-B*55:01, only one high
abundance Gag peptide is presented, followed by peptides deriving from Pol. Both HLA-
B*35:03 and -B*55:01 are predicted to present peptides at an overall lower abundance
than the controlling alleles. The non-controlling allele HLA-B*18:01, however, presents
a wide range of Gag peptides at a similar abundance to the controlling alleles, and with
similar peptide sequences as HLA-B*44:03 dominating at the cell surface. However,
HLA-B*18:01 does not present the HLA-B*44:03 epitope AW11, which as mentioned
earlier is associated with control of HIV progression.
The results suggest that a wide distribution of high abundance HIV-1 Gag peptides
(specifically Gag p24) presented on the cell surface may correlate with long term non-
progression. Gag p24 is a highly conserved sequence in the HIV-1 genome, and mutations
in this region negatively impact viral fitness.
Whilst HLA-B*58:01 and -B*57:01 presents HIV peptides in high abundance, their
epitopes also experience high rates of mutation, the rate of which correlate with the CTL
epitope-targeting frequencies. The epitope TW10 is the most rapidly escaping and most
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16 hrs 24 hrs 72 hrs
A) B) C)
Controlling Alleles
Figure 5.10: Method 1: Controlling alleles sustain Gag peptide presentation in high abun-
dance throughout replication.The combined model was used to predict the cell surface abun-
dance of HIV-1 peptides controlling alleles (HLA-B*58:01, -B*57:01, -B*44:03 and -B*27:05)
over time. The top 12 most abundant peptides at A) 16, B) 24 and C) 72 hours post-infection are
shown, with bar colours indicating the originating protein.
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highly targeted B*57/B*58 restricted epitope[176]. Therefore whilst B*57 and B*58
are able to present in high abundance, their epitopes are also frequently subjected to es-
cape mutations which may undermine its protective effect. However, it is known that the
T242N mutation in TW10 leads to diminished viral replication capacity[129] suggesting
that despite the high mutation rate, if some of these mutations are disadvantageous for the
virus this may still result in control of viral progression. For HLA-B*27:05, the KK10
epitope (Figure 5.10) is the most frequently targeted epitope early in infection (out of
all the HIV-1 epitopes studied in [176]), however its escape mutation rate is relatively
low compared to other highly targeted epitopes. Furthermore, its mutations are linked to
reduced capsid assembly[125], which may be the reason for its low mutation rate. As
HLA-B*44:03 and -B*18:01 both present a similar range of Gag peptides at high abun-
dance, but only HLA-B*44:03 is associated with control, we suggest control may rely on
small differences in the sequences of presented peptides. An investigation in to mutations
in the Gag-B44-AW11 epitope during acute infection found no evidence of escape mu-
tations within this sequence[177]. This may because mutations in this particular region
of p24 where AW11 is found impact viral fitness so negatively that mutated sequences
quickly disappear from the population.
The conservation of the Gag sequence alone, however, cannot explain the associa-
tion of Gag with control of HIV, as Env is also a highly conserved sequence of the HIV
genome[178]. Overall these simulations suggest that Gag epitopes are associated with
control of HIV because they dominate cell surface presentation, due to high turnover of
Gag in the cytoplasm, i.e. its large synthesis rate and relatively high degradation rate
compared to other highly abundant proteins such as Vpr and Env.
However, as mentioned earlier, the threshold of 500 nM affinity to separate binders
from non-binders, is unreliable because the predicted IC50 values for peptides binding
to different alleles are not comparable with one another. Therefore, whilst the results
from method 1 produce some interesting findings, the method used to produce them is
flawed and so the conclusions drawn above about the differences between controllers and
non-controllers as predicted by the model cannot be substantiated. We therefore carried
out a second round of simulations using method 2 as described above for more reliable
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Figure 5.11: Method 1: Non-controlling alleles HLA-B*35:03 and -B*53:01 present only
one peptide at 16 hours post infection and are unable to sustain high levels of Gag peptide
presentation at later time points. The combined model was used to predict the cell surface
abundance of HIV-1 peptides non-controlling alleles (HLA-B*07:02, -B*18:01, -B*55:01 and
-B*35:03) over time. The top 12 most abundant peptides at A) 16, B) 24 and C) 72 hours post-
infection are shown, with bar colours indicating the originating protein.
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predictions.
Method2: results Using the IC50 rescaling method described in Section 5.3.3, we sim-
ulated the presentation of HIV peptides up to 72 hours post infection, and compared
four controlling alleles HLA-B*58:01, -B*57:01, -B*27:05 and -B*44:03[123, 124, 125,
126, 138] and four non-controlling alleles, HLA-B*18:01, -B*35:03, -B*07:02 and -
B*55:01[133, 139]. We analysed the top twelve most abundant peptides on the cell sur-
face at three time points 16, 24 and 72 hours post infection, and determined which protein
they originated from.
The results of the simulations using this method are very different than those using
method 1. The cell surface abundance of the top 12 most abundant peptides at 16 hours
post infection for the controlling and non-controlling alleles are shown in Figures 5.12 A
and 5.13 A respectively. At this time point all alleles present a mixture of Gag peptides
(purple bars) and Nef peptides (yellow bars) at highest abundance. At this time point
there is very little difference between the controlling and non-controlling alleles, with
the exception of HLA-B*27:05, which presents all Gag peptides in the top 12, with the
exception of one Nef and one Vif peptide. The top 12 most abundant peptides at 24 hours
post infection for controlling and non-controlling alleles are shown in Figures 5.12B and
5.13B respectively. At this time point all controlling alleles present majority Gag peptides
in the top 12. Both HLA-B*57:01 and HLA-B*27:05 present exclusively Gag, whilst
HLA-B*58:01 presents all Gag except the 12th most abundant peptide which originates
from Pol. Similarly HLA-B*44:03 presents all Gag peptides except two Pol and one
Vif peptide. At 24 hours post infection not one non-controlling allele presents all Gag
peptides. HLA-B*55:01 presents the most Gag peptides, with 11 Gag and 1 Vpr, whilst
HLA-B*07:02 presents 10 Gag and 2 Vpr. HLA-B*35:03 presents 9 Gag, one Vpr, one
Nef and one Pol. However, the allele whose top 12 is most strikingly different from the
controllers is HLA-B*18:01. The top two presented peptides by this allele at 24 hours
post infection originate from Pol and Nef, with 8 Gag and 2 more Nef making up the
remaining 10. The top 12 most abundant peptides at 72 hours post infection are shown
in Figure 5.12 C for the controlling alleles and Figure 5.13 C for the non-controlling
alleles. The controlling allele HLA-B*27:05 presents all Gag in the top 12, whilst the
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other controlling alleles present fewer Gag peptides in the top 12 than they did at 24
hours. In the case of HLA-B*58:01 and -B*57:01, these Gag peptides have exclusively
been replaced by Pol peptides. These Pol peptides have a very high affinity with the
HLA alleles in question and so a low unbinding rate, and so this is an example of how
as time progresses, the unbinding rate becomes more important than the abundance of
the protein. The top three most abundant peptides presented by HLA-B*44:03 at 72
hours post infection are from Gag. However, the majority of the peptides presented by
this allele in the top 12 are from Pol, with a single Env and Nef peptide also presented.
The non-controlling allele HLA-B*18:01 presents majority Pol peptides at 72 hours post
infection, with the Gag peptides that were in high abundance at earlier time points being
replaced by high affinity Pol peptides. In fact this allele only presents two Gag peptides,
both in the lower half of the top 12, whilst the top three peptides presented by this allele
are Pol peptides. This suggests that this allele is unable to control the progression of HIV
as it is unable to sustain high abundance presentation of Gag peptides. This also suggests
that even if Pol peptides are presented in high abundance they will not induce a strong
enough immune response to control HIV progression.
By 72 hours post infection, HLA-B*07:02 presents three Vpr peptides in the top 12,
with the two Vpr peptides presented in the bottom two of the top 12 having increased in
abundance and replaced Gag peptides at higher ranks. Both non-controlling alleles HLA-
B*55:01 and -B*35:03 present fewer Gag peptides at 72 hours post infection than at 24
hours post infection, and both present one Gag and one Vpr peptide in the top 2 out of 12.
Therefore, one noticeable difference in general between the controlling and non-
controlling alleles is that by 72 hours post infection, the controlling alleles seem to have
a preference for presenting a mixture of Gag and Pol peptides in high abundance, whilst
the non-controlling alleles have preference for presenting Gag and Vpr peptides in high
abundance. This suggests that sustained Gag peptide presentation along with presentation
of high affinity Pol peptides will be more effective at controlling HIV progression than a
mixture of Gag and Vpr peptide presentation. We could also conclude that presentation
of Gag peptides in high abundance alone is not sufficient to ensure control.
As with method 1, the simulations using method 2 also predicted the presentation
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Figure 5.12: Method 2: Controlling alleles all demonstrate sustained Gag peptide presen-
tation, and/or combined Gag and Pol peptide presentation at later times post infection The
combined model was used to predict the cell surface abundance of HIV-1 peptides in controlling
alleles (HLA-B*58:01, -B*57:01, -B*44:03 and -B*27:05) over time. The top 12 most abundant
peptides at A) 16, B) 24 and C) 72 hours post-infection are shown, with bar colours indicating the
originating protein. All controlling alleles presented several Gag peptides by 16 hours, with the
number of Gag peptides increasing by 24 hours post-infection. The presentation of Gag peptides
at high abundance is sustained up to 72 hours post-infection.
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of known HIV-1 epitopes in the top 12 most abundant peptides. When comparing the
outputs of the combined dynamic model (Figure 5.12 D) with those resulting from the
static predictions of the IEDB processing tool (Figure 5.4), we found that the known
epitopes rank higher in our combined model.
The model predicts that TW10 is the second most abundant peptide presented by
HLA-B*58:01, and alternates between the second and third most abundant peptide pre-
sented by HLA-B*57:01 (Figure 5.12). However, the IEDB processing tool predicts
TW10 to have only the 28th highest Total Score for peptides binding to HLA-B*58:01
and only the 34th highest score for HLA-B*57:01.
The known Gag p24 KF11 (KAFSPEVIPMF) epitope of HLA-B*58:01 and -
B*57:01 is predicted to be the 11th most abundant HLA-B*58:01 peptide at 16 hours
post-infection, then increases to the 5th most abundant peptide, before slipping down to
11th place by 72 hours post-infection (Figure 5.12). Similarly, KF11 increases its rank
among the peptides presented on HLA-B*57:01, reaching 6th position by 72 hours post-
infection. However, KF11 is only ranked 23rd and 16th by the IEDB Total Scores for
HLA-B*58:01 and HLA-B*57:01 respectively.
Furthermore, the known B*58 and B*57 restricted Gag epitope ISPRTLNAW
(IW9)[141] is the 11th most abundant HLA-B*58:01 peptide at 24 hours post-infection,
but then displaced by Pol peptides at 72 hours post-infection. IW9 is consistently pre-
sented by HLA-B*57:01 at all three time points, being the 10th most abundant at 16 hours
post infection, before increasing to 5th place and remaining there by 72 hours. IW9 has
the 88th highest IEDB Total score for HLA-B*58:01 and the 54th highest total score for
HLA-B*57:01.
Finally, the known HLA-B*27:05 restricted Gag epitope KK10 (KRWIILGLNK)[?]
is the 6th most abundant peptide at 16 hours post-infection and the most abundant by
72 hours post-infection (Figure 5.12, bottom row), however it is only ranked 29th by
the IEDB Total Score. Also, known HLA-B*44:03 restricted epitope Gag AW11 (AE-
QATQDVKNW) is the third most abundant peptide by 16 hours post-infection, but then
reaches and remains the most abundant peptide from 24 hours onwards, however it has
only the 13th highest predicted IEDB Total Score.
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Figure 5.13: Method 2: Non controlling alleles are either unable to sustain high levels of Gag
peptide presentation, or present a combination of Gag and Vpr peptides at later times post
infection The combined model was used to predict the cell surface abundance of HIV-1 peptides
non-controlling alleles (HLA-B*07:02, -B*18:01, -B*55:01 and -B*35:03) over time. The top 12
most abundant peptides at A) 16, B) 24 and C) 72 hours post-infection are shown, with bar colours
indicating the originating protein.
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The mixture of Gag and Pol peptides presented by controlling alleles may be due to
the need for conservation of the Pol sequence compared to the need for conservation of
the Vpr sequence. If escape mutations are able to reduce the impact of the T-cell response
induced by Gag epitopes, further mutations in the HIV-1 genome, especially in the Pol
region, may be disastrous for viral fitness, whereas mutations in the Vpr region may have
a less adverse effect.
To investigate this further we carried out a similar analysis to that shown in Figure
5.5, but this time we analyse the top 1% most abundant peptides from each allele, grouped
the data by controlling vs non-controlling, at both 24 (Figure 5.14 a) and 72 (Figure 5.14
b) hours post infection. We did not include 16 hours post infection due to the low number
of peptides actually presented.
The median abundance of HIV peptides presented by controlling vs non-controlling
alleles was analysed using a Wilcoxon rank sum test, which revealed controlling alleles
peptides from from Gag (24hrs: p = 0.0432, 72hrs: p = 3.67× 10−7) and Pol (24hrs:
p = 0.0435, 72hrs: p = 0.0135) with statistically significant higher abundance than non-
controlling alleles. Non-controlling alleles, on the other hand, were shown to present
Vpr (24hrs: p = 0.0023, 72hrs: p = 0.0288) peptides with statistically significant higher
abundance than controlling alleles. Interestingly, at 24 hours post infection the most sig-
nificant difference between the controlling and non-controlling alleles is in the abundance
of Vpr peptides, whilst at 72 hours post infection Vpr has the lowest significance, with the
highest being associated with the abundance of Gag epitopes. The results of this analysis
support our conclusions from considering the top 12 most abundant peptides from each
allele, that non-controlling alleles have a preference for presenting Vpr peptides in high
abundance, whereas controlling alleles preferentially present Pol and Gag. Furthermore,
this also supports our position that whilst machine learning algorithms such as IEDB can
predict differences in MHC binding affinities and proteasomal cleavage probabilities, us-
ing these tools alone it is not possible to predict differences in presentation as the protein
dynamics are not taken in to account.
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(a) 24 hours post infection (b) 72 hours post infection
Figure 5.14: Controlling alleles prefer to present Gag and Pol peptides. The predicted abun-
dance of the top 1% of HIV epitopes from different HIV proteins were grouped by controlling and
non-controlling alleles. The median abundance of the top 1% predicted HIV peptides at A) 24
hours and B) 72 hours post infection was then compared using a Wilcoxon rank-sum test. At both
time points, a significantly higher median abundance was observed for Gag and Pol peptides in the
controller group, while a significantly higher median abundance was observed for Vpr peptides in
the non-controlling group.
5.5 Predicting HIV-1 Virion Antigen Presentation
The earlier viral antigen is presented on the cell surface, the sooner T-cells can detect it
and destroy the infected cell, therefore early presentation is very important to successful
immune control of a virus. The HIV-1 virion proteins provide the earliest source of viral
peptides following virion entry to the cell. Identifying virion-derived epitopes that are
presented before the down-regulation of MHC-I synthesis following the translation of the
HIV-1 protein Nef may therefore be important in developing a successful HIV vaccine.
The HIV-1 intracellular kinetics antigen presentation model presented in the previous
section predicts that peptides deriving from host-synthesised HIV-1 proteins are not pre-
sented until at the earliest 10 hours post-infection. However, Kloverpris et al. 2013[179]
detected the two protective Gag epitopes KF11 and KK10, restricted by HLA-B*57:01
and -B*27:05 respectively, and the Pol KY9 HLA-B*27:05 restricted peptide on the sur-
face of HIV-infected cells within 3 hours post-infection which could not have originated
from de novo protein synthesis. These peptides were still observed when protein synthesis
was blocked meaning they likely originated from the proteins that comprise the infecting
virion(s).
We therefore sought to construct a mechanical model of the presentation of HIV
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virion derived peptides. However, the number of copies of each HIV-1 protein within a
virion is very low, therefore many of the assumptions of deterministic modelling break
down, and so we had to simulate the virion model stochastically.
5.5.1 Methods
To model the virion protein dynamics we simply simulated the following reaction stochas-




where Prot j is the HIV protein j, and kdeg,Prot j is its degradation rate. At the beginning
of the simulation, t = 0, the number of copies of each protein is set to the experimentally
measured values found in a single virion. The proteins then degrade according to their
degradation rate.
The most abundant protein in the virion is Gag, at 4900 copies per virion[135], and
Vpr is found at a ratio of 7 : 1 to Gag, at around 700 copies per virion[135]. The Pol
protein is found at a ratio 20 : 1 to Gag[172], with around 245 copies per virion. The
copy numbers for the rest of the proteins in the virion are as follows: Vif: 101[145]; Env:
282[136]; Nef: 150[148]; Vpu: unknown; Tat: none; Rev: none.The degradation rates for
each virion protein are the same as those given in Table 5.1.
Stochastic simulations are more computationally expensive than deterministic simu-
lations, therefore we decided to simulate just one efficient peptide for each virion protein,
similar to what was done in Figure 5.9 B.This efficient peptide has the same values of
peptide specific parameters as before, a low unbinding rate (u = 10−5s−1), a high proba-
bility of proteasome cleavage (pi, j = 0.1), and a fast rate of supply into the ER (gi = 0.08
peptides s−1). Whilst we cannot determine the presentation of specific individual peptide
sequences in this way, we can determine how fast peptides can arrive at the surface in
a near-optimal scenario, and thus establish an approximate upper bound. Equation 5.17
describes the kinetics of each efficient virion peptide.
Calculating the total probability of peptide presentation from each HIV-1 protein We
simulate the presentation of an efficient HIV-1 epitope for each HIV-1 virion protein for
the case where N virions enter a cell at one time, up to 9 hours post infection. We wished
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to calculate the probability for each protein that the abundance of the efficient peptide
is greater than or equal to 1. To do this we denote by S j(t) the surface presentation of
the efficient peptide from protein j at time t. P(S j(t) ≥ 1|N = i) denotes the conditional
probability that the cell surface abundance S j(t) of peptide from protein j is greater than
or equal to 1 when the number of virions N entering the cell is equal to i. The probability
P(N = i) denotes the probability that N = i virions will enter the cell at one time.
We estimated P(N = i) using the well-known multiplicity of infection principle
[180], in which the number of infecting virions can be described by a Poisson distri-
bution with mean 1, i.e. N ∼ Poisson(1). We chose to simulate the range N = 1,2, ...,5,
which covers 99.9% of the probability mass for a Poisson with mean 1.
We estimate P(S(t)≥ 1|N = i) by simulating the presentation of the efficient epitope
from each HIV-1 protein for the range N = 1,2, ...,5 for 300 runs and determined the
fraction of times the efficient peptide abundance is greater than or equal to 1 for each
value of N. The total probability of presentation for each efficient epitope from each
virion protein is found by summing over the probability of presentation greater than or
equal to 1 for all values of N. Accordingly,




P(S(t)≥ 1|N = i).P(N = i) (5.20)
By assuming that N is Poisson distributed with mean 1, we can easily combine simulations
of the combined model for different numbers of virions.
5.5.2 Results: Gag-derived peptides are presented early following in-
fection
We simulated stochastically the peptide presentation arising from degradation of HIV-1
virion proteins using Microsoft’s Visual Genetic Engineering of living Cells (GEC)[181]
software (freely available from http://research.microsoft.com/gec), which
uses the domain-specific Language for Biochemical Systems (LBS) for specifying the
reaction system. Due to the low protein copy number we simulated the model stochasti-
cally and averaged over 300 runs. The copy number of proteins contained in one virion,
and their degradation over 9 hours is shown in Figure 5.15 A. Instead of simulating the
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presentation of many peptides predicted by the IEDB prediction tools, we decided to sim-
ulate an optimal peptide for each virion protein. This optimal peptide has a very high
affinity (and thus low unbinding rate) to MHC, a high probability of proteasome cleavage
pi, j (in this case a 10% probability of being produced each time a protein is degraded),
and a fast supply rate gi. We did this to represent the best possible peptide that could be
produced, and thus simulate the maximum possible presentation from virion proteins. We
simulated this for a maximum of 5 HIV-1 virions entering a cell at one time. If we model
the probability of a virion entering a cell using a Poisson distribution with mean µ = 1
then N = 5 is at the tail end of that distribution and so represents the optimal possible
situation which we could expect. The kinetics of the proteins contained in one virion over
9 hours post infection is shown in Figure 5.15 A. Each protein declines in abundance as it
is degraded and converted into peptides. As N increases, the concentration of the proteins
entering the cytoplasm increases, and so we would expect more peptides to be produced,
thus increasing the probability of peptide cell surface abundance of greater than or equal
to 1. For all values of N, the efficient Gag peptide is the most abundant on the cell surface
and the total probability of Gag peptide presentation converges towards 0.63, equal to the
probability that at least one virion infects the cell, i.e. P(N > 0).
By calculating the total probability of presentation we predict that an efficient Gag
peptide has a greater than 50% chance of being presented by 3 hours post-infection, rec-
onciling the observations of Kloverpris et al. 2013[179]. Our model also predicted that an
efficient Vpr peptide has a higher probability of presentation than an equivalently efficient
Pol peptide. This may be because the Pol degradation rate we are using in this simulation
is the same as the Gag-Pol polyprotein degradation rate. However, the Gag-Pol polypro-
tein is cleaved in to the enzymes integrase, reverse transcriptase and protease. The degra-
dation of these smaller constituent proteins could be faster than that of the polyprotein,
which will affect the timing and probability of presentation of the peptides cleaved from
the Pol enzymes.
Therefore, the model predicts the probability that an efficient non-Gag peptide is
presented following the entry of a single virion is low, however, if multiple virions enter
this probability could increase and become immunologically relevant.
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Figure 5.15: The virion model was simulated stochastically and averaged over M = 300 runs
and the average HIV virion protein kinetics are shown in A). We simulated the presentation of a
single, optimal peptide from each of the 7 HIV proteins contained within a virion, and calculated
the conditional probability of presentation by multiplying n(≥ 1)/M by the Poisson probability
P(N) = λNe−λ/N!, where the mean, λ = 1 and N = 1,2,3,4,5. Example simulations for N = 1
and N = 5, where N is the number of virions entering the cell are shown in B) and C) respectively.
D) We calculated the total probability of presentation for each peptide by summing the conditional
probability of presentation over N
5.6 Discussion
We sought to construct a model comprised of existing sub-component models that incor-
porates viral intracellular kinetics, protein sequence specificities and MHC-I affinity to
produce dynamic predictions of resulting viral peptidome. We chose to study HIV-1 here,
but the general model can be applied to any virus, provided its intracellular kinetics are
known. These predictions may shed some light on the characteristics of HIV-1 peptide
presentation by HLA alleles which control the spread of infection. We hoped to find some
explanation for the association of Gag peptides and a strong T-cell response against HIV
infection.
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Initially we used the IEDB MHC-I processing tool to obtain predictions of a ‘Total
Score’ for each peptide from each HIV-1 protein when binding to a set of controlling
(HLA-B*58:01, -B*57:01, -B*27:05 and -B*44:03) and non-controlling (HLA-B*07:02,
-B*18:01, -B*55:01 and -B*35:03) alleles. We used two different methods to select which
set of peptides we expected to bind to the MHC-I allele in question. The first method used
a IC50 cut-off of 500 nM, and the second method looked at the peptides whose Total Score
was within the top 1% for all HIV-1 peptides. We will only discuss the results from the
second method here as any conclusions drawn from the first method will be unreliable as
it is not actually possible to compare IC50 scores between alleles.
From the IEDB predictions of the peptides Total Scores we would expect Pol or Env
peptides to be associated with a strong T-cell response, as a large fraction of all predicted
peptides from the entire HIV genome originate from these two proteins, and in general,
the peptides from these two proteins are associated with higher Total Scores than those
from Gag. Furthermore the most significant difference in median Total Score between
the group of controlling alleles vs the group of non-controlling alleles was observed for
Pol (p = 4.8×10−18) and Env (p = 2.9×10−24), whereas the Gag was associated with a
lower significance (p= 3.4×10−6), where significance was determined using a Wilcoxon
rank sum test. In fact, this analysis revealed that there was a significant difference in
the Total Score distributions of all HIV-1 proteins when comparing controllers vs non-
controllers. Therefore, the IEDB predictions alone cannot explain why Gag peptides are
so often associated with HIV-1 control.
Gag is a highly conserved sequence in the HIV-1 genome, and mutations in this re-
gion negatively impact viral fitness, however, other highly conserved sequences such as
Pol are not associated with a similar degree of immune response. By combining existing
models of HIV-1 intracellular kinetics, with a model of peptide-MHC binding and pre-
sentation along with the IEDB prediction results, we were able to predict the cell surface
abundance of HIV-1 peptides on a single cell following infection.
The IEDB Total Score predictions show that on average peptides from Pol and Env
are the most immunogenic. However, in the simulations, Gag peptides dominate the cell
surface peptidome for both the set of controlling and non-controlling alleles. This is due to
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the large turnover of Gag in the cytoplasm during the replication cycle. If Env or Pol had
similar kinetics to Gag it is likely that their peptides would out-compete Gag for binding
to the controlling HLA alleles because they are predicted to have on average higher Total
Scores.
By simulating peptide presentation by the groups of controlling and non-controlling
alleles we were able to analyse the temporal distribution and cell surface abundance of
HIV-1 peptides up to 72 hours post-infection. The peptidome at 16 hours post infection is
much different than at later time points, with mainly Gag and Nef peptides being presented
in low abundance. At 24 and 72 hours post-infection the top 12 presented peptides of
the controlling alleles were in general a mixture of Gag and Pol peptides, whilst non-
controlling alleles presented a mixture of Gag and Vpr. Upon conducting a Wilcoxon
rank sum test at 24 and 72 hours post-infection we found that controlling alleles presented
significantly more Gag and Pol peptides, whereas the non-controlling alleles presented
significantly more Vpr peptides. We therefore conclude that a combination of Gag and
Pol peptides in high abundance on the cell surface will result in greater control of HIV-1
infection that a combination of Gag and Vpr peptides.
By analysing the specific sequences of the top 12 most abundant peptides, we ob-
served that many known Gag along with some known Pol eptiopes were presented by the
controlling alleles. It is interesting to note that these known epitopes dominate at the cell
surface in the combined model predictions, whereas using the IEDB predictions alone
their Total Scores were not among the most immunogenic of all HIV-1 peptides.
We carried out similar simulations for peptide presentation from virion entry, using
experimentally measured levels of HIV protein copy numbers within a virion. The model
predicts the presence of at least one Gag peptide by 2 hours post infection. All peptides in
the virion model had the same proteasomal cleavage, peptide supply, and MHC binding
and unbinding rates, therefore the dominance of the Gag peptide can only be a result of
the protein’s high abundance within the HIV-1 virion.
These simulations highlight the importance of protein kinetics to MHC-peptide cell
surface presentation. Peptides in the cytoplasm have very short half-lives (≈ 5s[169]) and
so only 1% of them even survive to encounter TAP. Therefore, in order to enter the ER,
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a peptide must be in very high abundance in the cytoplasm, requiring very high protein
abundance. The simulations show that even if peptides are being produced from low
abundance proteins (such as Env and Vif for example) with a very high probability of
being cleaved from the protein and high affinities to the MHC allele, they will still be out-
competed for cell surface presentation by high concentration peptides of lower affinities.
For example, the peptides with the highest Total Scores when binding to HLA-B*57:01
come from Env (Figure 5.4), however, there is not a single Env peptide present in the top
twelve most abundant peptides presented by this allele at any time point (Figure 5.12).
Indeed, at 24 hour post infection the top 12 peptides presented by HLA-B*57:01 are
entirely derived from Gag, with three Pol peptides appearing at 72 hours post infection.
However in the model, Pol degrades much faster meaning it will produce more peptides
within a certain time frame than Env will. (Note: the degradation rate of Pol in the model
was set to equal that of 1.1∗kGag because this value, along with the probability of GagPol
mRNA translation fGagPol = 0.05, and the budding rate kbud results in a ratio of Gag:Pol
in a single virion of 20 : 1. The synthesis and degradation of Env are the values presented
in [147]).
These simulations indicate the importance of considering protein kinetics when pre-
dicting epitope candidates. Being able to detect infection in the early stages before repli-
cation may be key to creating an effective HIV-1 vaccine, and this model suggests that the
only way to do that is to target Gag epitopes, as the presentation of peptides from other
HIV-1 proteins cannot be guaranteed. Therefore, tools for predicting potential T-cell epi-
topes from protein sequences alone, such as IEDB should not be taken at face value, but





The T-cell response to the presentation of foreign or mutated peptides is key to the im-
mune system’s ability to control infection from viruses and bacteria, as well as controlling
the spread of cancer. In the case of HIV, there is a strong association between disease pro-
gression and T-cell responses against certain epitopes presented by certain HLA alleles.
In the case of cancer, many patients develop endogenous anti-tumour T-cell responses, but
these responses are non-protective[182, 183]. Furthermore, immunotherapy will work in
some patients but not others.
Understanding why some T-cell responses are non-protective whilst others are pro-
tective is vital for understanding the immune system and designing effective therapies.
Therefore, it is important to develop robust methods to identify T-cell epitopes, especially
those which result in protective T-cell responses.
T-cell epitopes can be discovered using high-throughput experimental methods, such
as enzyme linked immunospot (ELISPOT), and cytokine flow cytometry (CFC), however
there are over 12,000 HLA alleles and each is highly promiscuous, therefore to scan the T-
cell response to all possible pathogenic peptides for even one HLA allele would be highly
time consuming and expensive. As a result, it is infeasible at present to perform full scans
of all potential T-cell epitopes for complex viruses such as HIV[58].
Therefore, mathetmatical models which can predict the immunogenicity of a peptide
can be very useful. As discussed in Section 2.2, machine learning tools which predict
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immune parameters such as the IC50 of the peptide-MHC binding[61, 62] can be used to
quickly screen the pathogenic sequences that might be possible T-cell epitopes and reduce
the number of possible targets to consider experimentally. However, the correlation be-
tween the predicted affinity and cell surface abundance is in general quite low[90] (where
a lower IC50 means a higher affinity and a better binder, which should result in higher cell
surface abundance). High peptide cell surface abundance has been found to correlate with
immunogencity[59, 99], therefore the development of a model which is able to predict
peptide cell surface abundance is of high importance, as it could help narrow down the
candidate epitopes for T-cell related therapies.
Dalchau et al. 2011[22] constructed a model of peptide binding and presentation by
MHC-I alleles, as described in Section 2.6. The model quantifies the key peptide-specific
properties of intracellular peptide processing, including peptide supply into the ER and
peptide MHC-I unbinding. In this thesis we extend the model to include the impact of
varying cytoplasmic abundance on peptide ER concentration, and we tested the model’s
ability to predict peptide cell surface abundance.
Firstly, we calibrated the model on an experimental data set of a target and competitor
peptide with varying cytoplasmic concentrations, with and without the addition of IFN-γ
(Figures 3.5 and 3.6). The model was in general able to capture the impact of changing
competitor abundance upon the cell surface presentation of the target peptide and visa
vesa, with the lowest NRMSE was associated with SSL surface data without the addition
of IFN-γ . The model was also able to account for the decrease in competition between
the two peptides when IFN-γ was added (Figures 3.5 and 3.6 panels B and D).
Next, we tested the calibrated model on competitor peptides with varying MHC-I
unbinding rates. The model was able to largely predict the cell surface presentation of the
target peptide SSL and the varying competitor peptides with different MHC-I unbinding
rates (Figure 3.7). We measured how well the model predicted the data by calculating the
normalised root mean square error (NRMSE) between the data and the model, where a
low value indicates a good fit.
Whilst the model predicted the competition data well, we also calculated a simple
competition metric, based upon the filter relation presented in [22], to determine if the
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metric could approximate the output of the model for the cell surface abundance of SSL
(Section 3.5.1, Equation 3.6). We calculated the Pearson’s correlation coefficient between
the competition metric and the cell surface abundance of SSL predicted by the model,
with and without IFN-γ , for each variant of the competitor peptide ASN (Figures 3.9
and 3.10). We observed a high correlation between the metric and the model output for
each simulated experiment, with correlation coefficients ranging between 0.74 and 0.86,
meaning the competition metric approximates the steady state behaviour of the model
well.
We also calculated a similar peptide competition metric using the peptide cytoplas-
mic data (Section 3.5.1, Equation 3.7), and compared the results with the SSL cell surface
data calculating the Pearson’s correlation coefficient as before for with and without IFN-γ
(Figures 3.11 and 3.12). We observed that the correlation coefficient was much higher for
the dataset without IFN-γ , with values ranging between 0.52-0.80, compared to a range
of 0.36-0.57 for with IFN-γ . We concluded this was most likely due to the missing con-
tribution of self-peptides which we were unable to quantify for the data metric (Equation
3.7), whereas this value was included in the simulation metric (Equation 3.6) using the
calibrated self-peptide parameter values.
Having tested the peptide competition metric against experimental data of two pep-
tides (three including the one representative self-peptide) competing, we then wanted to
test how well the normalised filter relation (Equation 4.8) could approximate simulations
of an entire peptidome of competing peptides (Chapter 4). To do this we used experi-
mentally measured protein abundance and half-life and predicted the unbinding rates of
each peptide from each protein using the IEDB MHC-I binding prediction tool. The nor-
malised filter relation for peptide i is the ratio of the supply rate gi to the square of the
peptide off-rate u2i , divided by the sum of the ratio gk/u
2
k for each of the peptides k that
peptide i is competing against. Here we approximate gi as the product of the protein
abundance, protein degradation and the probability of cleavage, as predicted by the IEDB
MHC-I processing tool. We therefore considered the four parameters off-rate, protein
abundance, protein degradation and proteasomal cleavage separately and found a weak
correlation between these parameter values and the cell surface abundance of the peptide
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(Figure 4.1 A,B,C and D). However, when combining these parameters in to the filter re-
lation we observed a very strong correlation of 0.998, demonstrating that the filter relation
applied to each peptide can be used to predict the relative cell surface abundance of an
entire peptidome competing for the same MHC allele.
We then compared the performance of the normalised filter relation (Equation 4.8)
and the raw filter relation (Equation 4.9), in predicting peptide cell surface abundance.
We found that the raw filter relation performed just as well as the normalised filer rela-
tion. This is likely because for a very large number of peptides competing in the ER, the
normalisation factor in Equation 4.8 will be the same for each peptide, as no one peptide
will dominate. This suggests that if one wished to predict the cell surface abundance of
a peptide when in competition with an entire peptidome, all one would require would be
data quantifying the peptide supply rate to the ER and the peptide-MHC unbinding rate
of only the peptide in question.
We also demonstrated that our model could be used to predict which neo-epitopes
derived from mutated tumour proteins would be presented in highest abundance on the
cell surface, and compared our results to those of Boegel et al. 2014 [112] who predicted
the IEDB affinities of peptides deriving from mutated proteins and chose those peptides
with the highest affinity to be the most immunogenic. Unsurprisingly, our set of abun-
dant neo-epitopes was different from Boegel et al.’s, however we observed only a small
overlap between the dataset we used to quantify the abundance and degradation of the
HeLa cell proteins (Nagaraj et al. 2011[108]), and the Broad-Novartis Cancer Cell Line
Encyclopaedia (CCLE)[111] dataset of HeLa cell mutations. Therefore, a larger set of
HeLa cell protein abundance and degradation measurements is required to improve these
predictions.
Next we wished to simulate a viral peptidome, however the temporal appearance
of viral proteins is very important in determining the timing and abundance of viral epi-
topes. In this case the competition metric would be of no use unless it was calculated
at many different time points. We chose to model HIV-1 peptide presentation and so we
combined already existing mechanistic models of HIV-1 intracellular kinetics with the
peptide filtering model, and used the IEDB p-MHC binding prediction tools to estimate
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peptide-specific parameters.
When simulating a highly efficient peptide originating from each of the 9 HIV-1
proteins the model predicted that the Gag peptide would dominate at the cell surface
(Figure 5.9 B). As discussed in Section 5.2 varying rates of progression for HIV-1 to
AIDS are observed depending upon the HLA alleles expressed by the infected individual.
Certain MHC-I alleles associated with long term control of HIV-1 are associated with a
strong T-cell response against the epitopes they present, with the majority of the known
T-cell HIV-1 epitopes originating from the Gag protein.
The results of the machine learning algorithms alone cannot explain why Gag is
so immunogenic (Figures 5.4 and 5.5), as the Gag peptides do not have the best To-
tal Scores and when comparing between the controlling (HLA-B*58:01, -B*57:01, -
B*27:05, -B*44:03) and non-controlling group (HLA-B*07:02, -B*18:01, -B*53:01, -
B*35:03) there is a significant difference in Total Scores for all HIV-1 proteins.
We simulated the presentation of HIV-1 peptides by the controlling and non-
controlling alleles and found that at both 24 and 72 hours post infection the abundance of
Gag and Pol peptides presented by the controlling group was significantly greater than the
non-controlling group, whilst the abundance of Vpr peptides was significantly greater in
the non-controlling group (Figures 5.12, 5.13, 5.14). We therefore conclude that control
of HIV-1 requires high abundance of both Gag and Pol peptides, whilst a high abundance
of Gag and Vpr is associated with fast progression.
Furthermore, the model predicts that the controlling alleles will present several
known HIV-1 epitopes in the top 12 most abundant peptides (Figure 5.12), whereas the
rank of these epitopes among the predicted IEDB Total Scores are much lower. This
demonstrates that only predicting peptide specific parameters such as MHC affinity and
proteasomal cleavage is insufficient and highlights the importance of considering protein
kinetics when predicting possible T-cell epitopes.
We also simulated the presentation of HIV-1 peptides following virion entry in to
the cytoplasm. The copy number of HIV-1 proteins in a single virion is very low and
so the concentration of peptides resulting from the degradation of these proteins will be
even lower. When dealing with such low concentrations the assumptions of deterministic
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modelling no longer hold and so we simulated the presentation of an efficient peptide
from each protein stochastically. The model predicts a 50% chance of an efficient Gag
peptide being presented at 3 hours post infection, agreeing with experimental observations
of Kloverpris et al 2013[179].
6.2 Further Work
This work has shown that the prediction of cell surface abundance of pMHC requires
embedding peptide sequence based algorithms in models that also incorporate chemical
rate equations describing protein kinetics and the known mechanisms of the antigen pro-
cessing and presentation pathway, as machine learning predictions are static and so their
power when used alone will always be limited. The aim of such a model is to provide re-
liable predictions of cell surface abundance and possible T-cell epitopes to narrow down
the number of peptides experimentalists have to consider.
In this work we have focussed on putting together such a model for HIV-1 however
this approach can be applied to any virus, provided the relevant data is available. In order
to be able to construct such a model, the important parameters in the viral intracellular
life-cycle are required, such as mRNA transcription and protein translation or, more sim-
ply, quantitation of viral protein abundance and degradation over time in the cytoplasm
following virion entry and de novo synthesis. Once such data is acquired it can be com-
bined with predictive machine learning algorithms and already existing models of the
antigen processing and presentation pathway, such as was here done for HIV-1.
HIV has been extensively studied and so models of HIV-1 viral intracellular kinetics
and additional parameters such as protein half-life already existed in the literature. How-
ever, this is not the case for the majority of viruses. Therefore, in order to progress in this
field of research the acquisition of such data is required, and so biologists must begin to
design experiments with the aim of furnishing such quantitative, predictive models. As
has been demonstrated here, such models can be genome specific by considering only
the immune molecules (such as MHC-I) expressed by a certain individual. Such models
therefore have broad applications in the field of personalised medicine, where rapid simu-
lations could be used to help decide upon treatment dependent upon the patients genome.
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6.2.1 The impact of DRiPs
Up to this point we have not considered the contribution of Defective Ribosomal Prod-
ucts (DRiPs). As mentioned in Chapter 1, DRiPs are defined as “prematurely terminated
polypeptides and misfolded polypeptides produced from translation of bona fide mRNAs
in the proper reading frame”[15]. In other words DRiPs are generated by the degradation
of proteins synthesised during the pioneer round of translation, proteins whose translation
has been prematurely terminated, and proteins which misfold or fail to assemble into their
multisubunit protein complexes. Yewdell[15] first proposed that peptides might derive
from DRiPs in 1996 to explain the rapid presentation of viral T-cell epitopes. However,
our simulations along with experimental evidence such as Kloverpris et al. 2013[179],
demonstrate that early T-cell responses can result from the processing and presentation of
proteins comprising the infecting virion(s).
However, it has been proposed that DRiPs make up a significant source of self and
viral peptides[15, 16], and rapid degradation of these newly synthesised proteins may
allow T-cell recognition of foreign or mutated peptides much earlier than if peptides de-
rived from the degradation of native proteins alone. However, there is some disagreement
over just how significant DRiPs as a source of peptide. Several studies have provided
evidence that DRiPs contribute upwards of 30% of all degraded proteins[184, 185]. How-
ever, this would mean that a large amount of energy is essentially wasted on producing
non-functional proteins[186].
To incorporate DRiPs in to, for example, the model of HIV-1 antigen presentation
the rate of translation of DRiPs from the HIV-1 mRNA, and the degradation rate of the
corresponding DRiPs would need to be experimentally determined or estimated. The
production of peptides via proteasomal cleavage of these DRiPs could be modelled in
the same way as was done in this thesis, and the resulting peptide pool could then be
connected to the antigen processing model as described in Equation 5.17.
Even without experimental data characterising the synthesis and degradation of HIV-
1 DRiPs, some simple predictive simulations could be carried out to determine what val-
ues of the synthesis and degradation would result in either some percentage increase in
cell surface abundance, or an earlier presentation time.
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6.2.2 Including the T-cell response
The T-cell response to a presented epitope is known to depend upon both the dose and the
affinity between the TCR and the pMHC complex. The model we have presented in this
work does not yet account for the affinity between the pMHC complex and the TCR and
how this determines the T-cell response. Therefore, the next step in this area of research
would be to combine the model of peptide cell surface presentation with existing models
of T-cell signaling such as Lever etal.[187]. To make this peptide specific, the affinity
between the pMHC and the TCR would need to be predicted. One way of doing this is to
use molecular dynamics simulations. For a more detailed description of how this would
work see Eccleston et al[188].
Appendix A
Abundance Project: LBS Code
1 / / S i m u l a t e f o r some t ime i n t h e p a s t , add i n p u t s a t
2 / / t ime 0 . 0 , t h e n f o l l o w f o r a d d i t i o n a l t ime
3 d i r e c t i v e sample −2*24*3600 , 1*24*3600 .0 1000
4 d i r e c t i v e s i m u l a t i o n d e t e r m i n i s t i c s t i f f
5 d i r e c t i v e p l o t Me−P1 ; Me−P2 / / s p e c i f y o u t p u t d a t a w r i t t e n t o f i l e
6 / / D e c l a r e a l l o f t h e p a r a m e t e r s t h a t a r e t o be i n f e r r e d
7 d i r e c t i v e p a r a m e t e r s [ i n 1 = 0 . 0
8 ; i n 2 = 0 . 0 ; upreg1 = 0 . 0 ; upreg2 = 0 . 0
9 ; u p f a c t o r 1 , ( 1 . 0 , 1 0 0 0 0 . 0 ) , 1 . 0 , log , random
10 ; u p f a c t o r 2 , ( 1 . 0 , 1 0 0 0 0 . 0 ) , 1 . 0 , log , random
11 ; o f f s e t 1 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
12 ; o f f s e t 2 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
13 ; o f f s e t 3 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
14 ; o f f s e t 4 , ( 0 . 0 , 1 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
15 ; o f f s e t 5 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
16 ; o f f s e t 6 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
17 ; o f f s e t 7 , ( 0 . 0 , 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
18 ; o f f s e t 8 , ( 0 . 0 , 1 5 0 0 0 . 0 ) , 1 . 0 , r e a l , random
19 ; s1 , ( 1 e−3 ,10000 .0) , 1 . 0 , log , random
20 ; s2 , ( 1 e−3 ,10000 .0) , 1 . 0 , log , random
21 ; s f1 , ( 1 e−4 ,10000 .0) , 1 . 0 , log , random
22 ; s f2 , ( 1 e−4 ,10000 .0) , 1 . 0 , log , random
23 ; s f3 , ( 1 e−4 ,10000 .0) , 1 . 0 , log , random
24 ; b2 , (1 e−12 ,1e−6) , 2 . 7 5 5 e−10 , log , random
25 ; g0 , ( 0 . 0 , 1 0 0 0 0 0 . 0 ) , 2 5 0 0 0 . 0 , log , random
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26 ]
27 / / Auto−g e n e r a t e d sweep 151209
28 d i r e c t i v e sweep mysweep1 = { upreg1 = [ 0 . 0 ] , upreg2 = [ 0 . 0 ] ,
29 ( in1 , i n 2 ) = [ ( 7 8 . 0 0 , 8 8 . 0 0 ) , ( 1 7 1 . 0 0 , 1 3 4 . 0 0 ) , ( 5 1 9 . 0 0 , 1 5 3 . 0 0 ) ,
30 ( 1 8 0 9 . 0 0 , 1 4 1 . 0 0 ) , ( 5 6 4 1 . 0 0 , 1 3 8 . 0 0 ) , ( 1 7 9 3 4 . 0 0 , 1 3 5 . 0 0 ) ,
31 ( 5 8 0 8 5 . 0 0 , 1 3 7 . 0 0 ) , ( 1 3 9 6 5 7 . 0 0 , 1 4 2 . 0 0 ) , ( 7 8 . 0 0 , 6 0 9 . 0 0 ) ,
32 ( 1 8 1 . 0 0 , 5 8 8 . 0 0 ) , ( 5 7 8 . 0 0 , 5 7 0 . 0 0 ) , ( 1 8 0 8 . 0 0 , 6 1 2 . 0 0 ) ,
33 ( 5 4 7 5 . 0 0 , 6 2 5 . 0 0 ) , ( 1 7 4 5 2 . 0 0 , 6 3 2 . 0 0 ) , ( 5 5 9 1 6 . 0 0 , 6 1 0 . 0 0 ) ,
34 ( 1 3 9 0 7 7 . 0 0 , 6 1 5 . 0 0 ) , ( 7 9 . 0 0 , 1 8 4 2 . 0 0 ) , ( 1 7 8 . 0 0 , 1 8 4 1 . 0 0 ) ,
35 ( 5 8 8 . 0 0 , 1 8 0 0 . 0 0 ) , ( 1 8 6 1 . 0 0 , 1 8 5 5 . 0 0 ) , ( 5 6 1 9 . 0 0 , 1 9 5 7 . 0 0 ) ,
36 ( 1 7 2 8 4 . 0 0 , 1 9 9 1 . 0 0 ) , ( 5 5 4 8 7 . 0 0 , 1 9 6 1 . 0 0 ) , ( 1 3 7 1 3 2 . 0 0 , 1 9 8 6 . 0 0 ) ,
37 ( 8 1 . 0 0 , 5 6 6 5 . 0 0 ) , ( 1 7 7 . 0 0 , 5 6 9 7 . 0 0 ) , ( 5 8 0 . 0 0 , 5 4 7 9 . 0 0 ) ,
38 ( 1 9 3 5 . 0 0 , 5 5 6 7 . 0 0 ) , ( 5 9 2 9 . 0 0 , 5 8 6 3 . 0 0 ) , ( 1 7 8 6 8 . 0 0 , 6 2 9 4 . 0 0 ) ,
39 ( 5 5 7 3 9 . 0 0 , 6 5 8 3 . 0 0 ) , ( 1 4 0 0 3 6 . 0 0 , 6 5 0 9 . 0 0 ) , ( 7 9 . 0 0 , 1 8 0 4 5 . 0 0 ) ,
40 ( 1 7 5 . 0 0 , 1 7 5 2 7 . 0 0 ) , ( 5 7 0 . 0 0 , 1 7 4 8 6 . 0 0 ) , ( 1 9 6 6 . 0 0 , 1 7 2 1 9 . 0 0 ) ,
41 ( 6 3 5 3 . 0 0 , 1 7 3 3 8 . 0 0 ) , ( 1 9 0 5 6 . 0 0 , 1 8 1 4 6 . 0 0 ) , ( 5 6 1 7 3 . 0 0 , 1 8 9 5 5 . 0 0 ) ,
42 ( 1 4 1 4 6 8 . 0 0 , 1 9 8 2 0 . 0 0 ) , ( 7 4 . 0 0 , 5 7 9 7 7 . 0 0 ) , ( 1 7 3 . 0 0 , 5 4 9 3 7 . 0 0 ) ,
43 ( 5 4 2 . 0 0 , 5 4 7 5 8 . 0 0 ) , ( 1 9 6 5 . 0 0 , 5 2 8 1 9 . 0 0 ) , ( 6 4 3 1 . 0 0 , 5 1 0 4 7 . 0 0 ) ,
44 ( 1 9 2 1 5 . 0 0 , 5 2 6 2 8 . 0 0 ) , ( 5 8 6 8 4 . 0 0 , 5 4 1 8 5 . 0 0 ) , ( 1 4 2 7 5 6 . 0 0 , 5 5 6 6 8 . 0 0 ) ,
45 ( 6 5 . 0 0 , 1 4 1 8 7 1 . 0 0 ) , ( 1 7 4 . 0 0 , 1 3 7 5 7 6 . 0 0 ) , ( 5 7 3 . 0 0 , 1 3 5 6 0 4 . 0 0 ) ,
46 ( 1 7 4 0 . 0 0 , 1 4 1 7 3 5 . 0 0 ) , ( 6 4 2 4 . 0 0 , 1 3 4 6 3 5 . 0 0 ) , ( 1 9 4 4 6 . 0 0 , 1 3 4 0 6 5 . 0 0 ) ,
47 ( 6 0 5 3 3 . 0 0 , 1 3 4 4 6 8 . 0 0 ) , ( 1 4 7 2 1 1 . 0 0 , 1 3 6 2 7 8 . 0 0 ) ] }
48 / / Auto−g e n e r a t e d sweep 151209
49 d i r e c t i v e sweep mysweep2 = { upreg1 = [ 1 . 0 ] , upreg2 = [ 0 . 0 ] ,
50 ( in1 , i n 2 ) = [ ( 8 1 . 0 0 , 1 0 4 . 0 0 ) , ( 1 6 7 . 0 0 , 1 5 3 . 0 0 ) , ( 5 2 5 . 0 0 , 1 7 1 . 0 0 ) ,
51 ( 1 7 6 0 . 0 0 , 1 5 6 . 0 0 ) , ( 5 4 6 5 . 0 0 , 1 4 7 . 0 0 ) , ( 1 7 5 3 8 . 0 0 , 1 4 2 . 0 0 ) ,
52 ( 5 2 4 8 3 . 0 0 , 1 4 1 . 0 0 ) , ( 1 3 7 1 1 5 . 0 0 , 1 5 4 . 0 0 ) , ( 8 0 . 0 0 , 5 6 1 . 0 0 ) ,
53 ( 1 7 9 . 0 0 , 5 4 1 . 0 0 ) , ( 5 7 3 . 0 0 , 5 5 1 . 0 0 ) , ( 1 7 6 3 . 0 0 , 6 2 8 . 0 0 ) ,
54 ( 5 0 7 2 . 0 0 , 6 5 0 . 0 0 ) , ( 1 5 5 0 4 . 0 0 , 6 1 1 . 0 0 ) , ( 5 6 0 5 0 . 0 0 , 6 2 1 . 0 0 ) ,
55 ( 1 2 2 7 9 5 . 0 0 , 6 7 2 . 0 0 ) , ( 7 9 . 0 0 , 1 8 1 3 . 0 0 ) , ( 1 7 2 . 0 0 , 1 7 3 8 . 0 0 ) ,
56 ( 6 3 9 . 0 0 , 1 7 2 7 . 0 0 ) , ( 1 8 5 1 . 0 0 , 1 7 7 0 . 0 0 ) , ( 5 4 2 9 . 0 0 , 1 9 3 4 . 0 0 ) ,
57 ( 1 6 9 1 1 . 0 0 , 1 9 9 2 . 0 0 ) , ( 4 8 8 0 0 . 0 0 , 2 0 1 3 . 0 0 ) , ( 1 3 6 0 6 5 . 0 0 , 2 1 0 6 . 0 0 ) ,
58 ( 8 1 . 0 0 , 5 5 2 1 . 0 0 ) , ( 1 6 9 . 0 0 , 5 4 6 5 . 0 0 ) , ( 6 4 9 . 0 0 , 5 0 8 2 . 0 0 ) ,
59 ( 1 9 6 6 . 0 0 , 5 1 6 2 . 0 0 ) , ( 5 9 6 0 . 0 0 , 5 6 0 0 . 0 0 ) , ( 1 7 1 2 5 . 0 0 , 6 1 7 6 . 0 0 ) ,
60 ( 4 9 7 3 6 . 0 0 , 6 5 7 9 . 0 0 ) , ( 1 3 5 8 5 3 . 0 0 , 6 0 2 8 . 0 0 ) , ( 7 8 . 0 0 , 1 6 6 4 9 . 0 0 ) ,
61 ( 1 6 5 . 0 0 , 1 6 2 2 6 . 0 0 ) , ( 6 3 4 . 0 0 , 1 6 7 8 8 . 0 0 ) , ( 2 0 7 4 . 0 0 , 1 5 7 5 2 . 0 0 ) ,
151
62 ( 6 2 9 1 . 0 0 , 1 6 0 2 4 . 0 0 ) , ( 1 8 3 3 2 . 0 0 , 1 7 1 3 9 . 0 0 ) , ( 5 2 7 8 4 . 0 0 , 1 8 4 3 7 . 0 0 ) ,
63 ( 1 2 9 2 7 4 . 0 0 , 1 9 5 5 7 . 0 0 ) , ( 7 2 . 0 0 , 5 4 0 5 6 . 0 0 ) , ( 1 6 0 . 0 0 , 5 1 8 0 5 . 0 0 ) ,
64 ( 5 5 3 . 0 0 , 4 7 5 1 0 . 0 0 ) , ( 1 8 9 0 . 0 0 , 4 8 0 6 3 . 0 0 ) , ( 6 4 3 3 . 0 0 , 4 7 6 8 6 . 0 0 ) ,
65 ( 2 0 2 3 1 . 0 0 , 4 8 4 1 2 . 0 0 ) , ( 5 5 7 2 1 . 0 0 , 4 9 7 3 9 . 0 0 ) , ( 1 3 3 0 1 0 . 0 0 , 5 4 4 5 7 . 0 0 ) ,
66 ( 6 7 . 0 0 , 1 3 8 5 8 0 . 0 0 ) , ( 1 4 7 . 0 0 , 1 3 2 3 0 3 . 0 0 ) , ( 5 1 2 . 0 0 , 1 4 7 0 0 5 . 0 0 ) ,
67 ( 1 9 2 1 . 0 0 , 1 4 9 3 5 3 . 0 0 ) , ( 5 9 6 5 . 0 0 , 1 2 7 4 2 1 . 0 0 ) , ( 2 0 1 6 5 . 0 0 , 1 2 4 0 4 7 . 0 0 ) ,
68 ( 6 1 5 2 7 . 0 0 , 1 3 1 7 6 7 . 0 0 ) , ( 1 4 0 3 1 5 . 0 0 , 1 3 9 0 5 2 . 0 0 ) ] }
69 / / Auto−g e n e r a t e d sweep 151209
70 d i r e c t i v e sweep mysweep3 = { upreg1 = [ 0 . 0 ] , upreg2 = [ 0 . 0 ] ,
71 ( in1 , i n 2 ) = [ ( 7 8 . 0 0 , 8 8 . 0 0 ) , ( 1 7 2 . 0 0 , 1 3 3 . 0 0 ) , ( 5 1 8 . 0 0 , 1 5 5 . 0 0 ) ,
72 ( 1 8 0 2 . 0 0 , 1 4 3 . 0 0 ) , ( 5 6 2 4 . 0 0 , 1 3 9 . 0 0 ) , ( 1 8 0 5 6 . 0 0 , 1 3 6 . 0 0 ) ,
73 ( 5 7 9 2 5 . 0 0 , 1 4 0 . 0 0 ) , ( 1 4 1 1 6 3 . 0 0 , 1 4 3 . 0 0 ) , ( 7 8 . 0 0 , 6 1 5 . 0 0 ) ,
74 ( 1 8 3 . 0 0 , 5 9 4 . 0 0 ) , ( 5 6 8 . 0 0 , 5 7 0 . 0 0 ) , ( 1 8 0 0 . 0 0 , 6 1 7 . 0 0 ) ,
75 ( 5 4 3 8 . 0 0 , 6 0 5 . 0 0 ) , ( 1 6 9 2 9 . 0 0 , 6 0 8 . 0 0 ) , ( 5 7 0 5 8 . 0 0 , 5 9 6 . 0 0 ) ,
76 ( 1 3 7 5 1 0 . 0 0 , 5 7 9 . 0 0 ) , ( 7 8 . 0 0 , 1 8 5 2 . 0 0 ) , ( 1 7 9 . 0 0 , 1 8 2 6 . 0 0 ) ,
77 ( 5 9 0 . 0 0 , 1 8 1 4 . 0 0 ) , ( 1 8 8 4 . 0 0 , 1 8 5 9 . 0 0 ) , ( 5 6 2 3 . 0 0 , 1 9 4 4 . 0 0 ) ,
78 ( 1 7 3 1 2 . 0 0 , 2 0 0 1 . 0 0 ) , ( 5 3 1 7 9 . 0 0 , 1 9 9 6 . 0 0 ) , ( 1 3 9 4 4 0 . 0 0 , 1 9 4 1 . 0 0 ) ,
79 ( 8 1 . 0 0 , 5 7 4 2 . 0 0 ) , ( 1 7 9 . 0 0 , 5 7 3 1 . 0 0 ) , ( 5 7 0 . 0 0 , 5 6 4 3 . 0 0 ) ,
80 ( 1 9 2 5 . 0 0 , 5 5 1 7 . 0 0 ) , ( 5 9 7 9 . 0 0 , 5 8 1 9 . 0 0 ) , ( 1 7 6 9 2 . 0 0 , 6 2 2 2 . 0 0 ) ,
81 ( 5 5 2 3 6 . 0 0 , 6 6 1 0 . 0 0 ) , ( 1 4 0 7 4 5 . 0 0 , 6 5 2 7 . 0 0 ) , ( 8 0 . 0 0 , 1 7 8 7 0 . 0 0 ) ,
82 ( 1 7 5 . 0 0 , 1 7 6 1 7 . 0 0 ) , ( 5 5 3 . 0 0 , 1 7 4 9 2 . 0 0 ) , ( 1 9 8 1 . 0 0 , 1 6 8 9 0 . 0 0 ) ,
83 ( 6 3 7 1 . 0 0 , 1 7 6 2 4 . 0 0 ) , ( 1 8 8 9 8 . 0 0 , 1 8 5 7 7 . 0 0 ) , ( 5 7 0 0 1 . 0 0 , 1 8 9 9 1 . 0 0 ) ,
84 ( 1 4 1 6 2 7 . 0 0 , 1 9 3 9 0 . 0 0 ) , ( 7 6 . 0 0 , 5 8 3 6 7 . 0 0 ) , ( 1 7 2 . 0 0 , 5 5 5 4 9 . 0 0 ) ,
85 ( 5 5 2 . 0 0 , 5 4 8 7 5 . 0 0 ) , ( 1 9 9 9 . 0 0 , 5 3 6 3 2 . 0 0 ) , ( 6 3 9 1 . 0 0 , 5 1 4 2 0 . 0 0 ) ,
86 ( 1 9 5 4 7 . 0 0 , 5 1 9 3 9 . 0 0 ) , ( 5 9 1 4 6 . 0 0 , 5 3 3 1 1 . 0 0 ) , ( 1 4 1 0 1 5 . 0 0 , 5 6 0 7 4 . 0 0 ) ,
87 ( 6 9 . 0 0 , 1 3 9 9 9 4 . 0 0 ) , ( 1 7 0 . 0 0 , 1 3 6 6 9 7 . 0 0 ) , ( 5 3 9 . 0 0 , 1 4 0 7 2 7 . 0 0 ) ,
88 ( 1 7 8 2 . 0 0 , 1 3 3 7 1 6 . 0 0 ) , ( 6 0 0 0 . 0 0 , 1 3 4 7 7 0 . 0 0 ) , ( 2 0 1 0 5 . 0 0 , 1 3 2 8 3 0 . 0 0 ) ,
89 ( 5 9 1 9 4 . 0 0 , 1 3 3 9 1 4 . 0 0 ) , ( 1 4 4 1 0 2 . 0 0 , 1 3 9 3 5 9 . 0 0 ) ] }
90 / / Auto−g e n e r a t e d sweep 151209
91 d i r e c t i v e sweep mysweep4 = { upreg1 = [ 1 . 0 ] , upreg2 = [ 0 . 0 ] ,
92 ( in1 , i n 2 ) = [ ( 8 1 . 0 0 , 1 0 1 . 0 0 ) , ( 1 6 7 . 0 0 , 1 4 8 . 0 0 ) , ( 5 2 6 . 0 0 , 1 7 0 . 0 0 ) ,
93 ( 1 7 6 6 . 0 0 , 1 5 3 . 0 0 ) , ( 5 5 1 8 . 0 0 , 1 4 2 . 0 0 ) , ( 1 7 5 0 6 . 0 0 , 1 3 3 . 0 0 ) ,
94 ( 5 4 7 9 7 . 0 0 , 1 3 3 . 0 0 ) , ( 1 2 8 1 5 9 . 0 0 , 1 4 4 . 0 0 ) , ( 7 9 . 0 0 , 5 6 9 . 0 0 ) ,
95 ( 1 8 0 . 0 0 , 5 4 2 . 0 0 ) , ( 5 8 9 . 0 0 , 5 5 4 . 0 0 ) , ( 1 7 4 3 . 0 0 , 6 2 3 . 0 0 ) ,
96 ( 5 0 1 9 . 0 0 , 6 4 9 . 0 0 ) , ( 1 6 0 5 6 . 0 0 , 6 7 1 . 0 0 ) , ( 5 3 4 0 6 . 0 0 , 5 7 6 . 0 0 ) ,
97 ( 1 1 1 9 8 2 . 0 0 , 5 7 6 . 0 0 ) , ( 7 8 . 0 0 , 1 8 0 1 . 0 0 ) , ( 1 7 3 . 0 0 , 1 7 3 6 . 0 0 ) ,
152
98 ( 6 4 1 . 0 0 , 1 6 8 8 . 0 0 ) , ( 1 8 6 7 . 0 0 , 1 7 8 8 . 0 0 ) , ( 5 3 2 7 . 0 0 , 1 8 9 2 . 0 0 ) ,
99 ( 1 6 3 3 0 . 0 0 , 2 0 4 8 . 0 0 ) , ( 4 6 6 3 0 . 0 0 , 2 0 8 5 . 0 0 ) , ( 1 3 6 8 5 9 . 0 0 , 1 7 5 2 . 0 0 ) ,
100 ( 8 3 . 0 0 , 5 4 3 7 . 0 0 ) , ( 1 6 8 . 0 0 , 5 4 5 3 . 0 0 ) , ( 6 2 3 . 0 0 , 5 1 0 0 . 0 0 ) ,
101 ( 1 9 6 1 . 0 0 , 5 1 9 2 . 0 0 ) , ( 5 8 6 0 . 0 0 , 5 5 1 0 . 0 0 ) , ( 1 6 9 1 4 . 0 0 , 5 8 1 5 . 0 0 ) ,
102 ( 5 0 4 9 0 . 0 0 , 6 3 7 8 . 0 0 ) , ( 1 3 6 7 3 2 . 0 0 , 6 1 5 0 . 0 0 ) , ( 8 0 . 0 0 , 1 6 6 9 4 . 0 0 ) ,
103 ( 1 6 3 . 0 0 , 1 6 6 3 4 . 0 0 ) , ( 5 9 4 . 0 0 , 1 7 4 1 2 . 0 0 ) , ( 2 0 1 8 . 0 0 , 1 5 6 9 8 . 0 0 ) ,
104 ( 6 3 4 2 . 0 0 , 1 6 0 2 2 . 0 0 ) , ( 1 7 9 2 2 . 0 0 , 1 6 7 2 1 . 0 0 ) , ( 5 3 2 1 0 . 0 0 , 1 8 5 3 7 . 0 0 ) ,
105 ( 1 2 3 7 7 0 . 0 0 , 2 0 4 0 2 . 0 0 ) , ( 7 5 . 0 0 , 5 4 0 4 2 . 0 0 ) , ( 1 7 1 . 0 0 , 5 1 1 7 4 . 0 0 ) ,
106 ( 5 7 8 . 0 0 , 5 3 9 7 7 . 0 0 ) , ( 1 9 4 8 . 0 0 , 4 5 5 8 5 . 0 0 ) , ( 6 6 3 3 . 0 0 , 4 3 0 2 2 . 0 0 ) ,
107 ( 1 8 7 1 1 . 0 0 , 4 9 3 7 9 . 0 0 ) , ( 5 3 5 3 2 . 0 0 , 4 9 9 5 6 . 0 0 ) , ( 1 3 1 1 3 3 . 0 0 , 5 4 8 0 6 . 0 0 ) ,
108 ( 7 1 . 0 0 , 1 3 2 0 7 0 . 0 0 ) , ( 1 7 7 . 0 0 , 1 3 5 8 3 1 . 0 0 ) , ( 5 3 9 . 0 0 , 1 3 3 8 6 5 . 0 0 ) ,
109 ( 1 8 2 6 . 0 0 , 1 3 5 7 8 8 . 0 0 ) , ( 7 9 0 7 . 0 0 , 1 7 2 2 5 4 . 0 0 ) , ( 1 9 6 4 3 . 0 0 , 1 3 1 2 0 0 . 0 0 ) ,
110 ( 5 5 2 8 0 . 0 0 , 1 4 3 9 5 3 . 0 0 ) , ( 1 4 5 7 9 1 . 0 0 , 1 4 2 9 9 1 . 0 0 ) ] }
111 / / Auto−g e n e r a t e d sweep 161102
112 d i r e c t i v e sweep mysweep5 = { upreg2 = [ 0 . 0 ] , upreg1 = [ 0 . 0 ] ,
113 ( in1 , i n 2 ) = [ ( 7 5 . 0 0 , 8 1 . 0 0 ) , ( 1 5 6 . 0 0 , 1 2 1 . 0 0 ) , ( 5 3 4 . 0 0 , 1 3 7 . 0 0 ) ,
114 ( 1 7 8 4 . 0 0 , 1 2 5 . 0 0 ) , ( 5 6 2 5 . 0 0 , 1 1 9 . 0 0 ) , ( 1 8 0 1 4 . 0 0 , 1 1 2 . 0 0 ) ,
115 ( 5 7 5 7 6 . 0 0 , 1 1 2 . 0 0 ) , ( 1 4 0 5 4 9 . 0 0 , 1 1 3 . 0 0 ) , ( 7 6 . 0 0 , 5 9 3 . 0 0 ) ,
116 ( 1 7 1 . 0 0 , 5 8 5 . 0 0 ) , ( 5 8 2 . 0 0 , 5 8 7 . 0 0 ) , ( 1 7 4 4 . 0 0 , 6 4 5 . 0 0 ) ,
117 ( 5 2 8 3 . 0 0 , 6 3 7 . 0 0 ) , ( 1 7 8 0 5 . 0 0 , 6 2 9 . 0 0 ) , ( 5 4 3 8 6 . 0 0 , 5 9 2 . 0 0 ) ,
118 ( 1 4 0 8 2 2 . 0 0 , 6 0 7 . 0 0 ) , ( 7 6 . 0 0 , 1 8 4 1 . 0 0 ) , ( 1 6 2 . 0 0 , 1 8 3 2 . 0 0 ) ,
119 ( 6 3 4 . 0 0 , 1 7 4 2 . 0 0 ) , ( 1 8 4 6 . 0 0 , 1 8 7 0 . 0 0 ) , ( 5 5 3 4 . 0 0 , 1 9 6 2 . 0 0 ) ,
120 ( 1 7 4 3 4 . 0 0 , 2 0 3 0 . 0 0 ) , ( 5 4 6 0 0 . 0 0 , 1 9 9 9 . 0 0 ) , ( 1 4 5 1 7 0 . 0 0 , 1 9 4 2 . 0 0 ) ,
121 ( 7 6 . 0 0 , 5 6 7 0 . 0 0 ) , ( 1 6 2 . 0 0 , 5 6 2 7 . 0 0 ) , ( 6 3 2 . 0 0 , 5 4 1 4 . 0 0 ) ,
122 ( 1 9 5 4 . 0 0 , 5 4 5 2 . 0 0 ) , ( 5 9 9 0 . 0 0 , 5 9 0 3 . 0 0 ) , ( 1 7 7 0 1 . 0 0 , 6 2 3 8 . 0 0 ) ,
123 ( 5 4 4 3 9 . 0 0 , 6 4 1 5 . 0 0 ) , ( 1 4 0 8 0 7 . 0 0 , 6 6 6 5 . 0 0 ) , ( 7 8 . 0 0 , 1 7 7 5 3 . 0 0 ) ,
124 ( 1 6 5 . 0 0 , 1 7 5 7 4 . 0 0 ) , ( 5 8 6 . 0 0 , 1 7 3 7 4 . 0 0 ) , ( 1 9 3 5 . 0 0 , 1 7 2 8 8 . 0 0 ) ,
125 ( 6 4 0 5 . 0 0 , 1 7 3 2 0 . 0 0 ) , ( 1 8 4 9 4 . 0 0 , 1 8 1 6 6 . 0 0 ) , ( 5 5 5 3 0 . 0 0 , 1 8 9 3 6 . 0 0 ) ,
126 ( 1 4 0 3 1 9 . 0 0 , 1 9 2 1 9 . 0 0 ) , ( 7 6 . 0 0 , 5 7 8 2 4 . 0 0 ) , ( 1 6 4 . 0 0 , 5 5 9 7 5 . 0 0 ) ,
127 ( 5 7 2 . 0 0 , 5 4 3 6 8 . 0 0 ) , ( 1 9 4 6 . 0 0 , 5 4 5 1 1 . 0 0 ) , ( 6 4 9 0 . 0 0 , 5 0 8 3 6 . 0 0 ) ,
128 ( 1 9 4 3 1 . 0 0 , 5 2 4 9 4 . 0 0 ) , ( 5 7 4 4 1 . 0 0 , 5 3 1 4 8 . 0 0 ) , ( 1 4 2 7 4 5 . 0 0 , 5 5 3 5 6 . 0 0 ) ,
129 ( 7 7 . 0 0 , 1 3 7 3 9 6 . 0 0 ) , ( 1 6 8 . 0 0 , 1 4 2 0 7 4 . 0 0 ) , ( 5 6 6 . 0 0 , 1 4 8 4 5 9 . 0 0 ) ,
130 ( 1 8 3 8 . 0 0 , 1 3 9 5 7 9 . 0 0 ) , ( 6 0 8 0 . 0 0 , 1 4 2 8 2 2 . 0 0 ) , ( 1 9 3 9 9 . 0 0 , 1 3 6 1 2 7 . 0 0 ) ,
131 ( 6 0 7 6 2 . 0 0 , 1 3 7 3 3 9 . 0 0 ) , ( 1 4 7 5 3 9 . 0 0 , 1 4 0 1 7 2 . 0 0 ) ] }
132 / / Auto−g e n e r a t e d sweep 161102
133 d i r e c t i v e sweep mysweep6 = { upreg2 = [ 1 . 0 ] , upreg1 = [ 0 . 0 ] ,
153
134 ( in1 , i n 2 ) = [ ( 7 3 . 0 0 , 8 5 . 0 0 ) , ( 1 4 6 . 0 0 , 1 2 2 . 0 0 ) , ( 5 5 0 . 0 0 , 1 3 0 . 0 0 ) ,
135 ( 1 7 5 0 . 0 0 , 1 1 1 . 0 0 ) , ( 5 4 5 3 . 0 0 , 9 2 . 0 0 ) , ( 1 8 0 2 5 . 0 0 , 6 6 . 0 0 ) ,
136 ( 5 2 3 1 3 . 0 0 , 5 5 . 0 0 ) , ( 1 2 8 7 3 2 . 0 0 , 4 1 . 0 0 ) , ( 7 4 . 0 0 , 5 7 9 . 0 0 ) ,
137 ( 1 6 5 . 0 0 , 5 6 1 . 0 0 ) , ( 5 9 9 . 0 0 , 5 8 4 . 0 0 ) , ( 1 7 0 9 . 0 0 , 6 4 1 . 0 0 ) ,
138 ( 5 0 2 3 . 0 0 , 6 7 6 . 0 0 ) , ( 1 6 2 5 1 . 0 0 , 6 6 4 . 0 0 ) , ( 5 1 2 7 2 . 0 0 , 5 6 8 . 0 0 ) ,
139 ( 1 2 5 0 1 3 . 0 0 , 6 4 4 . 0 0 ) , ( 7 3 . 0 0 , 1 8 0 3 . 0 0 ) , ( 1 5 6 . 0 0 , 1 7 6 6 . 0 0 ) ,
140 ( 6 4 2 . 0 0 , 1 7 3 4 . 0 0 ) , ( 1 8 6 3 . 0 0 , 1 8 2 7 . 0 0 ) , ( 5 3 1 7 . 0 0 , 1 9 3 3 . 0 0 ) ,
141 ( 1 6 6 1 2 . 0 0 , 2 0 4 1 . 0 0 ) , ( 4 8 8 0 4 . 0 0 , 2 0 6 6 . 0 0 ) , ( 1 3 1 6 9 3 . 0 0 , 1 8 9 4 . 0 0 ) ,
142 ( 7 2 . 0 0 , 5 5 7 3 . 0 0 ) , ( 1 5 1 . 0 0 , 5 4 3 3 . 0 0 ) , ( 6 5 4 . 0 0 , 5 1 8 0 . 0 0 ) ,
143 ( 1 9 5 9 . 0 0 , 5 4 0 5 . 0 0 ) , ( 5 7 6 2 . 0 0 , 5 7 3 0 . 0 0 ) , ( 1 7 0 1 0 . 0 0 , 6 2 2 9 . 0 0 ) ,
144 ( 4 8 9 3 2 . 0 0 , 6 7 4 5 . 0 0 ) , ( 1 3 8 1 8 9 . 0 0 , 6 3 7 2 . 0 0 ) , ( 7 5 . 0 0 , 1 7 5 8 5 . 0 0 ) ,
145 ( 1 4 8 . 0 0 , 1 7 2 7 6 . 0 0 ) , ( 6 6 7 . 0 0 , 1 6 7 5 4 . 0 0 ) , ( 1 9 5 4 . 0 0 , 1 6 0 2 7 . 0 0 ) ,
146 ( 6 1 7 5 . 0 0 , 1 6 2 8 2 . 0 0 ) , ( 1 8 1 3 4 . 0 0 , 1 7 3 4 1 . 0 0 ) , ( 4 9 9 0 5 . 0 0 , 1 8 8 9 8 . 0 0 ) ,
147 ( 1 2 8 4 0 4 . 0 0 , 1 7 0 8 3 . 0 0 ) , ( 7 0 . 0 0 , 5 2 4 6 0 . 0 0 ) , ( 1 4 5 . 0 0 , 4 9 2 5 2 . 0 0 ) ,
148 ( 6 3 2 . 0 0 , 4 6 0 9 0 . 0 0 ) , ( 1 9 9 7 . 0 0 , 4 5 5 2 5 . 0 0 ) , ( 6 6 2 5 . 0 0 , 4 7 4 7 6 . 0 0 ) ,
149 ( 1 8 7 6 2 . 0 0 , 4 7 1 3 7 . 0 0 ) , ( 5 3 6 8 5 . 0 0 , 4 9 1 1 5 . 0 0 ) , ( 1 2 7 3 5 3 . 0 0 , 5 2 6 3 7 . 0 0 ) ,
150 ( 8 0 . 0 0 , 1 3 5 9 5 3 . 0 0 ) , ( 1 3 7 . 0 0 , 1 3 6 5 0 4 . 0 0 ) , ( 5 2 4 . 0 0 , 1 3 0 6 7 0 . 0 0 ) ,
151 ( 2 0 8 4 . 0 0 , 1 3 3 4 4 3 . 0 0 ) , ( 6 2 9 0 . 0 0 , 1 2 1 1 3 4 . 0 0 ) , ( 1 5 7 3 7 . 0 0 , 1 3 8 6 7 4 . 0 0 ) ,
152 ( 5 3 0 9 1 . 0 0 , 1 2 0 3 6 5 . 0 0 ) , ( 1 3 3 5 8 1 . 0 0 , 1 2 7 4 3 9 . 0 0 ) ] }
153 / / Auto−g e n e r a t e d sweep 161102
154 d i r e c t i v e sweep mysweep7 = { upreg2 = [ 0 . 0 ] , upreg1 = [ 0 . 0 ] ,
155 ( in1 , i n 2 ) = [ ( 7 4 . 0 0 , 8 1 . 0 0 ) , ( 1 5 5 . 0 0 , 1 2 0 . 0 0 ) , ( 5 3 6 . 0 0 , 1 3 7 . 0 0 ) ,
156 ( 1 7 8 3 . 0 0 , 1 2 4 . 0 0 ) , ( 5 6 7 2 . 0 0 , 1 2 0 . 0 0 ) , ( 1 8 1 2 8 . 0 0 , 1 1 7 . 0 0 ) ,
157 ( 5 7 6 9 1 . 0 0 , 1 1 9 . 0 0 ) , ( 1 4 0 6 0 4 . 0 0 , 1 2 3 . 0 0 ) , ( 7 5 . 0 0 , 5 9 1 . 0 0 ) ,
158 ( 1 7 1 . 0 0 , 5 8 6 . 0 0 ) , ( 5 8 6 . 0 0 , 5 8 3 . 0 0 ) , ( 1 7 5 8 . 0 0 , 6 4 0 . 0 0 ) ,
159 ( 5 3 6 3 . 0 0 , 6 3 8 . 0 0 ) , ( 1 7 4 3 7 . 0 0 , 6 1 9 . 0 0 ) , ( 5 8 5 6 1 . 0 0 , 6 2 7 . 0 0 ) ,
160 ( 1 4 1 8 9 0 . 0 0 , 5 7 5 . 0 0 ) , ( 7 5 . 0 0 , 1 8 5 5 . 0 0 ) , ( 1 6 4 . 0 0 , 1 8 1 3 . 0 0 ) ,
161 ( 6 3 0 . 0 0 , 1 7 5 6 . 0 0 ) , ( 1 8 6 5 . 0 0 , 1 8 7 1 . 0 0 ) , ( 5 5 4 2 . 0 0 , 1 9 7 8 . 0 0 ) ,
162 ( 1 7 6 9 5 . 0 0 , 1 9 8 8 . 0 0 ) , ( 5 4 4 6 2 . 0 0 , 1 9 9 6 . 0 0 ) , ( 1 3 6 6 0 6 . 0 0 , 1 9 3 1 . 0 0 ) ,
163 ( 7 3 . 0 0 , 5 6 9 6 . 0 0 ) , ( 1 6 1 . 0 0 , 5 5 8 1 . 0 0 ) , ( 6 2 7 . 0 0 , 5 4 3 1 . 0 0 ) ,
164 ( 1 9 4 3 . 0 0 , 5 4 1 5 . 0 0 ) , ( 5 8 9 3 . 0 0 , 5 8 8 3 . 0 0 ) , ( 1 7 5 8 2 . 0 0 , 6 2 6 5 . 0 0 ) ,
165 ( 5 4 6 9 3 . 0 0 , 6 4 6 8 . 0 0 ) , ( 1 4 4 2 4 0 . 0 0 , 6 5 8 3 . 0 0 ) , ( 7 6 . 0 0 , 1 8 0 1 8 . 0 0 ) ,
166 ( 1 6 1 . 0 0 , 1 7 6 5 4 . 0 0 ) , ( 6 0 0 . 0 0 , 1 7 6 1 7 . 0 0 ) , ( 2 0 2 6 . 0 0 , 1 7 1 9 6 . 0 0 ) ,
167 ( 6 2 6 4 . 0 0 , 1 7 3 0 2 . 0 0 ) , ( 1 8 7 0 9 . 0 0 , 1 8 0 7 6 . 0 0 ) , ( 5 5 5 2 1 . 0 0 , 1 8 9 0 4 . 0 0 ) ,
168 ( 1 4 2 3 8 6 . 0 0 , 1 9 2 7 8 . 0 0 ) , ( 7 2 . 0 0 , 5 6 9 2 1 . 0 0 ) , ( 1 6 5 . 0 0 , 5 5 8 3 4 . 0 0 ) ,
169 ( 5 6 5 . 0 0 , 5 6 0 7 6 . 0 0 ) , ( 1 9 4 2 . 0 0 , 5 1 1 3 0 . 0 0 ) , ( 6 5 6 8 . 0 0 , 5 1 9 2 1 . 0 0 ) ,
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170 ( 1 9 6 5 7 . 0 0 , 5 3 4 1 9 . 0 0 ) , ( 5 8 1 3 0 . 0 0 , 5 4 1 2 0 . 0 0 ) , ( 1 4 2 6 9 8 . 0 0 , 5 6 2 8 0 . 0 0 ) ,
171 ( 7 4 . 0 0 , 1 3 7 1 8 9 . 0 0 ) , ( 1 6 2 . 0 0 , 1 3 9 0 8 4 . 0 0 ) , ( 5 3 3 . 0 0 , 1 4 1 1 1 8 . 0 0 ) ,
172 ( 1 9 6 1 . 0 0 , 1 4 0 3 0 2 . 0 0 ) , ( 6 5 0 3 . 0 0 , 1 3 8 6 1 1 . 0 0 ) , ( 1 9 8 9 4 . 0 0 , 1 3 4 5 0 1 . 0 0 ) ,
173 ( 6 2 0 5 1 . 0 0 , 1 3 6 9 1 1 . 0 0 ) , ( 1 4 5 9 3 8 . 0 0 , 1 3 9 1 2 5 . 0 0 ) ] }
174 / / Auto−g e n e r a t e d sweep 161102
175 d i r e c t i v e sweep mysweep8 = { upreg2 = [ 1 . 0 ] , upreg1 = [ 0 . 0 ] ,
176 ( in1 , i n 2 ) = [ ( 7 1 . 0 0 , 8 3 . 0 0 ) , ( 1 4 4 . 0 0 , 1 1 8 . 0 0 ) , ( 5 6 0 . 0 0 , 1 2 8 . 0 0 ) ,
177 ( 1 7 4 6 . 0 0 , 1 1 7 . 0 0 ) , ( 5 4 4 5 . 0 0 , 1 0 5 . 0 0 ) , ( 1 7 8 4 8 . 0 0 , 9 6 . 0 0 ) ,
178 ( 5 1 2 8 3 . 0 0 , 9 0 . 0 0 ) , ( 1 3 4 6 2 3 . 0 0 , 9 5 . 0 0 ) , ( 7 0 . 0 0 , 5 7 7 . 0 0 ) ,
179 ( 1 6 6 . 0 0 , 5 5 5 . 0 0 ) , ( 6 0 2 . 0 0 , 5 7 0 . 0 0 ) , ( 1 7 4 7 . 0 0 , 6 3 0 . 0 0 ) ,
180 ( 5 1 3 5 . 0 0 , 6 6 7 . 0 0 ) , ( 1 7 0 4 0 . 0 0 , 6 6 6 . 0 0 ) , ( 4 9 6 3 7 . 0 0 , 6 8 3 . 0 0 ) ,
181 ( 1 0 9 2 4 7 . 0 0 , 3 7 1 . 0 0 ) , ( 6 5 . 0 0 , 1 7 9 6 . 0 0 ) , ( 1 6 0 . 0 0 , 1 7 2 1 . 0 0 ) ,
182 ( 6 3 9 . 0 0 , 1 7 7 0 . 0 0 ) , ( 1 8 8 1 . 0 0 , 1 8 0 3 . 0 0 ) , ( 5 3 4 9 . 0 0 , 1 9 4 4 . 0 0 ) ,
183 ( 1 6 3 0 2 . 0 0 , 2 0 3 3 . 0 0 ) , ( 4 8 9 7 7 . 0 0 , 1 9 7 5 . 0 0 ) , ( 1 4 4 8 6 8 . 0 0 , 2 1 1 2 . 0 0 ) ,
184 ( 5 8 . 0 0 , 5 6 7 3 . 0 0 ) , ( 1 5 7 . 0 0 , 5 3 4 8 . 0 0 ) , ( 6 5 1 . 0 0 , 5 2 7 5 . 0 0 ) ,
185 ( 1 9 4 7 . 0 0 , 5 3 6 0 . 0 0 ) , ( 5 8 5 8 . 0 0 , 5 6 5 1 . 0 0 ) , ( 1 7 0 4 8 . 0 0 , 6 0 5 7 . 0 0 ) ,
186 ( 4 8 2 4 8 . 0 0 , 6 3 8 8 . 0 0 ) , ( 1 3 8 1 9 2 . 0 0 , 6 0 9 9 . 0 0 ) , ( 5 0 . 0 0 , 1 7 2 1 5 . 0 0 ) ,
187 ( 1 5 6 . 0 0 , 1 6 4 2 0 . 0 0 ) , ( 6 5 8 . 0 0 , 1 6 0 3 2 . 0 0 ) , ( 2 0 0 5 . 0 0 , 1 6 1 8 4 . 0 0 ) ,
188 ( 6 2 4 2 . 0 0 , 1 6 5 1 7 . 0 0 ) , ( 1 8 6 4 4 . 0 0 , 1 7 8 7 6 . 0 0 ) , ( 4 9 7 8 5 . 0 0 , 1 8 2 9 3 . 0 0 ) ,
189 ( 1 2 8 8 7 6 . 0 0 , 1 8 7 9 4 . 0 0 ) , ( 4 5 . 0 0 , 4 9 7 9 1 . 0 0 ) , ( 1 4 0 . 0 0 , 5 0 9 8 1 . 0 0 ) ,
190 ( 6 7 3 . 0 0 , 4 9 8 2 1 . 0 0 ) , ( 1 9 4 8 . 0 0 , 4 8 8 2 4 . 0 0 ) , ( 6 3 4 0 . 0 0 , 4 7 0 1 2 . 0 0 ) ,
191 ( 1 8 9 5 5 . 0 0 , 5 0 5 2 7 . 0 0 ) , ( 5 4 0 2 6 . 0 0 , 5 0 1 4 5 . 0 0 ) , ( 1 2 7 9 7 9 . 0 0 , 5 2 6 8 8 . 0 0 ) ,
192 ( 4 0 . 0 0 , 1 3 0 9 0 8 . 0 0 ) , ( 1 5 5 . 0 0 , 1 2 6 5 0 1 . 0 0 ) , ( 7 4 2 . 0 0 , 1 4 8 2 8 6 . 0 0 ) ,
193 ( 1 8 0 5 . 0 0 , 1 4 5 2 8 4 . 0 0 ) , ( 6 9 1 8 . 0 0 , 1 3 9 2 1 3 . 0 0 ) , ( 2 0 5 9 9 . 0 0 , 1 2 2 1 2 6 . 0 0 ) ,
194 ( 5 1 8 0 5 . 0 0 , 1 4 1 1 8 2 . 0 0 ) , ( 1 4 8 2 4 5 . 0 0 , 1 3 6 7 7 9 . 0 0 ) ] }
195 / / We add a s c a l e d q u a n t i t y o f each i n p u t . The s c a l e f a c t o r s a r e s1
and s2 f o r 151209 and 161102 r e s p e c t i v e l y . Event o c c u r s a t t =0
196 d i r e c t i v e e v e n t I1 s1 * i n 1 @ 0 . 0
197 d i r e c t i v e e v e n t I2 s2 * i n 2 @ 0 . 0
198 / / S p e c i f y t h e r e l a t i o n s h i p between model s i m u l a t i o n and da ta , and
MCMC s e t t i n g s
199 d i r e c t i v e f i t { mysweep1 ; SSL ASN 151209 merged ; [Me−P1*SF3+OFF1 ] }
200 d i r e c t i v e f i t { mysweep2 ; SSL ASN 151209 IFN merged ; [Me−P1*SF3+OFF2 ] }
201 d i r e c t i v e f i t { mysweep3 ; ASN 151209 merged new2 ; [Me−P2*SF2+OFF3 ] }
202 d i r e c t i v e f i t { mysweep4 ; ASN 151209 IFN merged new2 ; [Me−P2*SF2+OFF4 ]
}
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203 d i r e c t i v e f i t { mysweep5 ; SSL ASN 161102 merged ; [Me−P1*SF1+OFF5 ] }
204 d i r e c t i v e f i t { mysweep6 ; SSL ASN 161102 IFN merged ; [Me−P1*SF1+OFF6 ] }
205 d i r e c t i v e f i t { mysweep7 ; ASN 161102 merged new ; [Me−P2*SF2+OFF7 ] }
206 d i r e c t i v e f i t { mysweep8 ; ASN 161102 IFN merged2 ; [Me−P2*SF2+OFF8 ] }
207 d i r e c t i v e f i t r u n { b u r n i n = 20000 ; sample s = 50000 ; t h i n = 1 0 ;
n o i s e m o d e l = 1 }
208 / / S t a n d a r d p a r a m e t e r v a l u e s
209 r a t e dMe = 5 .193 e−5;
210 r a t e b0 = 2 .755 e−10; / / b i n d i n g r a t e o f s e l f p e p t i d e
211 r a t e b1 = 2 .755 e−10; / / b i n d i n g r a t e o f SSL
212 r a t e c = 8 .302928 e−8;
213 r a t e dP = 0 . 1 3 ;
214 r a t e uT = 1 .184643 e−6;
215 r a t e vT = 0 .0011091974705091 ;
216 r a t e bT = 1 .662768 e−9;
217 r a t e gT = 1505 ;
218 r a t e dT = 0 . 0 0 1 7 2 5 9 6 8 ;
219 r a t e e = 7 .071 e−4; / / 0 . 1 1 4 1 8 0 4 ;
220 r a t e gM = 1 5 0 . 5 ;
221 r a t e dM = 7 .9892 e−5;
222 r a t e q = 21035 ;
223 / / S p e c i a l i s i n g p e p t i d e s u p p l y and o f f−r a t e s
224 r a t e u1 = 2 . 8 E−05; / / SSL o f f−r a t e
225 r a t e u2 = 5 . 2 e−05; / / ASN o f f−r a t e
226 r a t e u0 = 1e−4; / / s e l f o f f−r a t e
227
228 spec P1 ; spec I1 ;
229 spec P2 ; spec I2 ;
230 spec P0 ; spec I0 ;
231
232 / / You have t o use a s p e c i e s i n t h e f i t d i r e c t i v e , so j u s t i n i t i a l i s e
a c o n s t a n t s p e c i e s wi th a p a r a m e t e r i z e d v a l u e .
233 / / SF1 = s c a l e f a c t o r number o f c o p i e s o f SSL t o MFI f o r 161102 ,
234 / / SF3 = s c a l e f a c t o r number o f c o p i e s o f SSL t o MFI f o r 151209
235 / / SF2 = s c a l e f a c t o r number o f c o p i e s o f ASN t o MFI f o r bo th 161102
and 151209
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236 i n i t SF1 s f 1 |
237 i n i t SF2 s f 2 |
238 i n i t SF3 s f 3 |
239 i n i t OFF1 o f f s e t 1 |
240 i n i t OFF2 o f f s e t 2 |
241 i n i t OFF3 o f f s e t 3 |
242 i n i t OFF4 o f f s e t 4 |
243 i n i t OFF5 o f f s e t 5 |
244 i n i t OFF6 o f f s e t 6 |
245 i n i t OFF7 o f f s e t 7 |
246 i n i t OFF8 o f f s e t 8 |
247 / / S t a n d a r d modular d e f i n i t i o n o f t h e MHC model module Pep ( spec Pi , I i ;
r a t e gi , u i , b i ) {
248 I i ˜−>{g i } Pi | Pi −>{dP} |
249 M + Pi <−>{b i }{ u i } M−Pi |
250 T−M + Pi <−>{c}{ u i *q} T−M−Pi |
251 T−M−Pi −>{vT} T + M−Pi |
252 M−Pi −>{e} Me−Pi |
253 Me−Pi −>{u i } Me
254 } ;
255 <−>[gM + upreg1 * u p f a c t o r 1 + upreg2 * u p f a c t o r 2 ]{dM} M |
256 <−>[10*(gM + upreg1 * u p f a c t o r 1 + upreg2 * u p f a c t o r 2 ) ]{ dT} T |
257 T + M <−>{bT}{uT} T−M |
258 Me −>{dMe} |
259
260 / / I n s t a n t i a t e t h e t h r e e p e p t i d e s ( t a r g e t , c o m p e t i t o r , background )
wi th BG s u p p l i e d a t r a t e g0
261 Pep ( P1 , I1 , 1 . 0 , u1 , b1 ) |
262 Pep ( P2 , I2 , 1 . 0 , u2 , b2 ) |
263 i n i t I0 1 | Pep ( P0 , I0 , g0 , u0 , b0 )
Appendix B
HeLa Cell Project: Matlab Code
1 %% S c r i p t t o l o a d i n p e p t i d e f i l e s and s i m u l a t e d e t e r m i n i s t i c a l l y
2
3 c l e a r
4 c l o s e a l l
5 a l l e l e S t r = { ’ A6802 ’ , ’ B4403 ’ , ’ B2705 ’ , ’ B5801 ’ } ; %L i s t o f a l l e l e s t o
choose from
6 a l l e l e = 1 ; % i f = 1 t h e n a l l e l e = B4402 , i f = 2 t h e n a l l e l e = B2705 ,
i f = 3 t h e n a l l e l =B4405
7 d i s p ( ’ Loading s e q u e n c e s and copy numbers ’ )
8 t i c
9 l o a d ( ’ T o t a l m u t . mat ’ )
10 %r e s = T mut . r e s ;
11 %l o a d ( ’ T o t a l . mat ’ ) ;
12 %u p i = T . UPI new ;
13 i p i = t o t a l d a t a . IPIA ;
14 p r o t e i n s = t o t a l d a t a . a l l d a t a s e q ;
15 h a l f l i v e s = t o t a l d a t a . h lMatch ;
16 c o p i e s = t o t a l d a t a . I n t e n s i t y ;
17 r e s = t o t a l d a t a . r e s i d u e s ;
18 f i l e p a t h = ’ p a t h \ t o \HUMAN 9606 idmapping selected . t a b \ ’ ;
19 d e l i m i t e r = ’ , ’ ; s t a r t R o w = 3 ; f o r m a t S p e c =
’%s%f%f%f%f%s%f%f%f%f%f%f %[ˆ\n\ r ] ’ ;
20 N= l e n g t h ( i p i ) ;
21 peps = s t r u c t ;
22 f o r i = f i n d ( ma tch index ( : , 1 ) >0)
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23 f i l e n a m e = [ f i l e p a t h i p i { i } ’ mut new . d a t ’ ] ;
24 f i l e I D = fopen ( f i l e n a m e , ’ r ’ ) ;
25 d a t a A r r a y = t e x t s c a n ( f i l e I D , fo rmatSpec , ’ D e l i m i t e r ’ , d e l i m i t e r ,
’ Heade rL ines ’ , s t a r tRow −1, ’ Re tu rnOnEr ro r ’ , f a l s e ) ;
26 f c l o s e ( f i l e I D ) ;
27 p s t a r t = d a t a A r r a y { : , 3} ;
28 pend = d a t a A r r a y { : , 4} ;
29 p e p t i d e = d a t a A r r a y { : , 6} ;
30 p r o t c l e a v e = d a t a A r r a y { : , 7} ;
31 i c 5 0 = d a t a A r r a y { : , 12} ;
32 peps ( i ) . p e p t i d e = p e p t i d e ;
33 peps ( i ) . p r o t c l e a v e = p r o t c l e a v e ;
34 peps ( i ) . i c 5 0 = i c 5 0 ;
35 peps ( i ) . p s t a r t = p s t a r t ;
36 peps ( i ) . pend = pend ;
37 end
38 t o c
39 %% Remove low a f f i n i t y p e p t i d e s
40 d i s p ( ’ P r e p a r i n g o f f−r a t e s and s u p p l y r a t e s ’ )
41 % Count t h e number o f p e p t i d e s
42 np =0;
43 f o r i = 1 : numel ( peps )
44 %f o r j = 1 : l e n g t h ( r e s { i } )
45 np = np + l e n g t h ( peps ( i ) . p e p t i d e ) ;
46 %end
47 end
48 n = l e n g t h ( c o p i e s ) ;
49 bP = 1 0 ˆ 3 ;
50 % Ass ign o f f−r a t e s and p e p t i d e s e q u e n c e s
51 p = 0 ;
52 seq = c e l l ( np , 1 ) ;
53 d a t a = z e r o s ( np , 6 ) ;
54 p r o t I D = c e l l ( np , 1 ) ;
55 r e s i d u e = z e r o s ( np , 4 ) ;
56 f o r i = 1 : numel ( peps )
57 nu = l e n g t h ( peps ( i ) . i c 5 0 ) ;
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58 d a t a ( p +1: p+nu , 1 ) = peps ( i ) . i c 5 0 *bP / 1 0 ˆ 9 ;
59 d a t a ( p +1: p+nu , 2 ) = c o p i e s ( i ) ;
60 d a t a ( p +1: p+nu , 3 ) = h a l f l i v e s ( i ) ;
61 d a t a ( p +1: p+nu , 4 ) = peps ( i ) . p r o t c l e a v e ;
62 d a t a ( p +1: p+nu , 5 ) = peps ( i ) . p s t a r t ;
63 d a t a ( p +1: p+nu , 6 ) = peps ( i ) . pend ;
64 seq ( p +1: p+nu ) = peps ( i ) . p e p t i d e ;
65 p r o t I D ( p +1: p+nu ) = i p i ( i ) ;
66 r e s i d u e ( p +1: p+nu , 1 ) = r e s ( i , 1 ) ;
67 r e s i d u e ( p +1: p+nu , 2 ) = r e s ( i , 2 ) ;
68 r e s i d u e ( p +1: p+nu , 3 ) = r e s ( i , 3 ) ;
69 r e s i d u e ( p +1: p+nu , 4 ) = r e s ( i , 4 ) ;




74 d i s p ( ’ Trimming p e p t i d e s wi th l a r g e o f f−r a t e s ’ )
75 uMax = 1e−2;
76 l o c s = f i n d ( d a t a ( : , 1 )<=uMax ) ;
77 d a t a = d a t a ( l o c s , : ) ;
78 seq = seq ( l o c s ) ;
79 n0 = l e n g t h ( d a t a ( : , 1 ) ) ;
80 r e s i d u e = r e s i d u e ( l o c s , : ) ;
81 %% P r e p a r e p a r a m e t e r s
82 l o a d bOpt % l o a d p a r a m e t e r s p and p v a r s
83 p1 . b = 2 .755 e−10;% p1 . bs ( a l l e l e ) ; %Ass ign p e p t i d e b i n d i n g r a t e
a c c o r d i n g t o a l l e l e
84 nTAP = 10000; %Number o f TAP m o l e c u l e s p e r c e l l
85 p0 = p1 ; p0 . gT = 0 ;
86 P t o t = 2*nTAP / p1 . dP ; % T o t a l p e p t i d e
87
88 %% S i m u l a t e t h e f u l l sys tem
89 d i s p ( ’ S i m u l a t i n g ODEs ’ )
90 x I n i t 0 = z e r o s (4+3* n0 , 1 ) ;
91 o d e o p t s = o d e s e t ( ’ J a c o b i a n ’ , @JacobianFixP newND ) ;
92 t i c
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93 [ t0 , x0 ] = ode15s ( @PLodesFixP newND , [ 0
10*24*3600] , x I n i t 0 , odeop t s , p1 , da t a , n0 , P t o t ) ;
94 t o c
95 MeP0 = x0 ( end ,4+2* n0 :3+3* n0 ) ;
96 %S o r t d a t a and save
97 [ sor t MeP0 , i n ] = s o r t ( MeP0 , ’ descend ’ ) ;
98 s o r t p r o t I D = p r o t I D ( i n ) ;
99 s o r t s e q = seq ( i n ) ;
100 s o r t c o p i e s = d a t a ( in , 2 ) ;
101 s o r t o f f r a t e s = d a t a ( in , 1 ) ;
102 s o r t d e g = d a t a ( in , 3 ) ;
103 s o r t p r o t = d a t a ( in , 4 ) ;
104 s o r t s t a r t = d a t a ( in , 5 ) ;
105 s o r t e n d = d a t a ( in , 6 ) ;
106 s o r t r e s i d u e = r e s i d u e ( in , : ) ;
107 o u t p u t s o r t = t a b l e ( sor t MeP0 ’ , s o r t s e q , s o r t p r o t I D , s o r t c o p i e s ,
s o r t o f f r a t e s , s o r t d e g , s o r t p r o t , s o r t s t a r t ,
s o r t e n d , s o r t r e s i d u e ) ;
108 w r i t e t a b l e ( o u t p u t s o r t , [ a l l e l e S t r { a l l e l e } ’ m u t s o r t n e w . t x t ’ ] ) ;
109
110 r e t u r n
Appendix C
HIV Project: Matlab Code
1 f u n c t i o n
[ t , x , n S e l f , n , genes , Sequence ]= H I V A l l c v o d e s o l d ( a l l e l e )%, a l l e l e s )
2
3 %READ IN TOP 1% DATA FOR EACH ALLELE
4 name = [ ’ t o p ’ a l l e l e ] ;
5 f i l e n a m e = [ ’ p a t h \ t o \ a l l e l e \ f i l e ’ a l l e l e ’ . x l s x ’ ] ;
6 [ da t a , t x t , raw ]= x l s r e a d ( f i l e n a m e , ’ S he e t1 ’ ) ;
7 raw ( c e l l f u n (@( x ) ˜ i s e m p t y ( x ) && i s n u m e r i c ( x ) && i s n a n ( x ) , raw ) ) = { ’ ’ } ;
8 c e l l V e c t o r s = raw ( : , [ 1 , 5 , 6 ] ) ;
9 %ASSIGN DATA FROM FILE
10 A l l e l e = c e l l V e c t o r s ( 2 : end , 1 ) ;
11 S t a r t = d a t a ( : , 1 ) ;
12 End = d a t a ( : , 2 ) ;
13 Length = d a t a ( : , 3 ) ;
14 Sequence = c e l l V e c t o r s ( 2 : end , 2 ) ;
15 genes = c e l l V e c t o r s ( 2 : end , 3 ) ;
16 P r o t e a s o m e S c o r e = d a t a ( : , 6 ) ;
17 TAPScore = d a t a ( : , 7 ) ;
18 MHCScore = d a t a ( : , 8 ) ;
19 P r o c e s s i n g S c o r e = d a t a ( : , 9 ) ;
20 T o t a l S c o r e = d a t a ( : , 1 0 ) ;
21 MHCIC50nM = d a t a ( : , 1 1 ) ;
22 Abundance = d a t a ( : , 1 2 ) ;
23 %% C r e a t e o u t p u t v a r i a b l e
24 %% C l e a r t e m p o r a r y v a r i a b l e s
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25 c l e a r v a r s d a t a raw c e l l V e c t o r s ;
26 %CALCULATE PARAMETER VECTORS
27 p r o t e i n s = { ’REV ’ , ’TAT ’ , ’NEF ’ , ’GAG’ , ’POL ’ , ’ENV’ , ’ VIF ’ , ’VPR ’ , ’VPU ’ } ;
28 u = MHCIC50nM*1 e3 / 1 0 ˆ 9 ;
29 u=u *3600 ;
30 n= l e n g t h ( u ) ;
31 g= z e r o s ( n , 1 ) ;
32 g ( : ) =0 . 08 * 3 60 0 ;
33 bP =3600*2.8871 e−9;
34 bPeps= z e r o s ( n , 1 ) ; bPeps ( : ) =bP ;
35 Abundance = 1 0 . ˆ P r o t e a s o m e S c o r e ;
36 ps = Abundance / 1 0 0 0 ;
37 p e p f i l e n a m e = [ a l l e l e ’ dPc . x l s x ’ ] ;
38 [ pepda ta , ˜ , pepraw ] = x l s r e a d ( p e p f i l e n a m e ) ;
39 pepraw ( c e l l f u n (@( x ) ˜ i s e m p t y ( x ) && i s n u m e r i c ( x ) && i s n a n ( x ) , pepraw ) ) =
{ ’ ’ } ;
40 p e p c e l l V e c t o r s = pepraw ( : , 1 ) ;
41 %C a l c u l a t e p e p t i d e d e g r a d a t i o n
42 P e p t i d e 1 = p e p c e l l V e c t o r s ( 2 : end , 1 ) ;
43 p5 = p e p d a t a ( : , 1 ) ;
44 p30 = p e p d a t a ( : , 2 ) ;
45 p2 = p e p d a t a ( : , 3 ) ;
46 c l e a r v a r s p e p d a t a pepraw p e p c e l l V e c t o r s ;
47
48 dPeps = p e p t i d e d e g ( p5 , p30 , p2 ) ;
49 dPeps=dPeps ( : ) *3600 ;
50 %ASSIGN SELF PEPTIDE PARAMETERS
51 u l l =60*60*1 e−2;
52 u l =60*60*1 e−3;
53 um=60*60*1 e−4;
54 uh =60*60*1 e−5;
55 u S e l f =[ u l l ; u l ; um ; uh ] ;
56 G=20000;
57
58 g l l =60*60*G* 0 . 5 / 1 0 0 ;
59 g l =60*60*G* 9 8 . 5 / 1 0 0 ;
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60 gm=60*60*G* 0 . 5 / 1 0 0 ;
61 gh =60*60*G* 0 . 5 / 1 0 0 ;
62 g S e l f =[ g l l ; g l ; gm ; gh ] ;
63 p S e l f = [ 0 . 0 3 ; 0 . 0 3 ; 0 . 0 3 ; 0 . 0 3 ] ;
64 n S e l f = l e n g t h ( u S e l f ) ;
65
66 ns9 =4+(5* n S e l f ) +9 ;
67 TP=6+(12* n S e l f ) ;
68 TP2=4+(5* n S e l f ) ;
69 n s s =TP+147+n ;
70 NN= n s s +n ;
71 pv =0;
72 % ASSIGN INITIAL CONCENTRATIONS
73 % HOWEVER IF PV=0 THEN THESE ARE ALL SET TO 0
74 x0= z e r o s ( 1 , TP2 +49+(5* n ) ) ;
75 x0 ( 1 , TP2 +35) =2000* pv ; %Gag
76 x0 ( 1 , TP2 +36) = ( 2 0 0 0 / 2 0 ) *pv ; %GagPol
77 x0 ( 1 , TP2 +37) =33* pv ;%282;%Env
78 x0 ( 1 , TP2 +38) =101* pv ;%Vif
79 x0 ( 1 , TP2 +39) =285* pv ; %Vpr
80 x0 ( 1 , TP2 +40) =2000*0.01* pv ;%Vpu
81 x0 ( 1 , TP2 +41) =150* pv ;%2000*0.01;% Nef
82 x0 ( 1 , TP2 +5) =0;%2000*0.01;% Rev
83 x0 ( 1 , TP2 +6) =0;%2000*0.01;% Tat
84 %DEFINE ODE OPTIONS TO INCLUDE JACOBIAN
85 o p t i o n s = o d e s e t ( ’ J a c o b i a n ’ , @jacobian Cvodes ) ;
86 % DEFINE START AND END TIMES OF SIMULATON
87 t s t a r t =0 ;
88 t f i n a l =72;
89 %SOLVE SYSTEM OF ODES
90 [ t , x ]= ode15s ( @HIV1 ALLeff old , [ t s t a r t ,
t f i n a l ] , x0 , o p t i o n s , u , g , ps , genes , u S e l f , p S e l f , g S e l f , n S e l f , dPeps , bPeps ) ;
91 sim = t a b l e ( t , x ) ;
92 %f i l e n a m e = [ a l l e l e ’ s im ’ ] ;




96 f u n c t i o n dxd t =
HIV1 ALLeff old ( t , x , u , g , ps , genes , u S e l f , p S e l f , g S e l f , n S e l f , dPeps , bPeps )
97
98 [ uT , bT , gT , dT , q , c , uTv , e , gM, dM, dMe , dPc , dP , bP ]= MHC parameters ;
99 %P a r a m e t e r s%
100
101 pv =1;%number o f p r o v i r u s e s
102 t b =15; %b a s a l r a t e o f t r a n s c r i p t i o n p e r hour
103 t a d d =1485; %i n c r e a s e i n v i r a l RNA t r a n s c r i p t i o n by Ta t t r a n s a c t i v a t i o n
p e r hour
104
105 aTa t = 2 8 . 5 7 ;%A s s o c i a t i o n c o n s t a n t o f Ta t w i th TAT ( /muM)
106 ka1 = 0 . 0 1 3 2 ; %high a f f i n i t y Rev b i n d i n g ( a s s o c i a t i o n c o n s t a n t )
107 kd1 =60*60*(3 .0 e−5) ; %h igh a f f i n i t y Rev b i n d i n g d i s s o c i a t i o n c o n s t a n t
( h ) ˆ−1
108 k a i = 0 . 0 2 3 3 ; %low a f f i n i t y Rev b i n d i n g a s s o c i a t i o n c o n s t a n t
109 k d i =60*60*(3 .8 e−2) ; %low a f f i n i t y Rev b i n d i n g d i s s o c i a t i o n c o n s t a n t
( h ) ˆ−1
110 sn =12; %maximum number o f Rev p e r RRE
111 t h =7 ; %t h r e s h o l d l e v e l o f Rev f o r mRNA n u c l e a r e x p o r t
112 sp = 2 . 5 ; %s p l i c i n g r a t e c o n s t a n t
113 kexp = 2 . 0 8 2 ; %e x p o r t r a t e c o n s t a n t
114 kimp = 2 0 . 8 2 0 0 ; %i m p o r t r a t e c o n s t a n t
115 kdeg = 0 . 1 7 4 0 ; %r a t e c o n s t a n t o f RNA d e g r a d a t i o n i n n u c l e u s and c y t o p l a s m
116 t r =270; %s t e a d y−s t a t e t r a n s l a t i o n r a t e
117 kRevn = 0 . 0 4 3 2 ; %d e g r a d a t i o n r a t e o f Rev i n n u c l e u s
118 kRevc = 0 . 0 1 7 4 ; %d e g r a d a t i o n r a t e o f Rev i n c y t o p l a s m
119 kTa tc = 0 . 0 1 7 4 ; %d e g r a d a t i o n r a t e o f Ta t i n c y t o p l a s m
120 fRNAr = 0 . 1 9 ; %f r a c t i o n o f r e v mRNA i n f u l l y s p l i c e d mRNA
121 fRNAt = 0 . 0 5 ; %f r a c t i o n o f t a t mRNA i n s i n g l y and f u l l y s p l i c e d mRNAs
122 fRev = 0 . 5 ; %p r o b a b i l i t y f o r r e v mRNA t o encode Rev
123 f T a t =1 ; %p r o b a b i l i t y f o r t a t mRNA t o encode Ta t
124 d = 0 . 8 ; %s p l i c i n g d e l a y f a c t o r
125 f a c t o r =0 .000014687 ; %c o n v e r s i o n from muMˆ−1 t o / m o l e c u l e
126 f a c t o r 2 =1; %c o n v e r s i o n from Mˆ−1 t o / m o l e c u l e
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127 kbud = 0 . 0 8 ; %budding r a t e
128 fGag = 0 . 9 5 ; %f r a c t i o n o f Gag t r a n s l a t e d from FC
129 f P o l = 0 . 0 5 ; %f r a c t i o n o f Po l t r a n s l a t e d from FC
130 n G a g v i r i o n =2000; %number o f Gag i n v i r i o n ( t h i s i s a c t u a l l y f o r 4900
b u t was s e t a s t h i s i n t h e Wang and LuHa model )
131 kTat = 0 . 1 7 3 3 ; %Rate o f d e g r a d a t i o n o f Ta t p e r hour
132 kGag = 0 . 1 0 5 4 ; %Rate o f d e g r a d a t i o n o f Gag p e r hour
133 kVif = 0 . 4 6 7 3 ; %Rate o f d e g r a d a t i o n o f Vi f p e r hour
134 kEnv = 0 . 0 2 ; %Rate o f d e g r a d a t i o n o f Env p e r hour
135 kVpr = 0 . 0 3 4 6 ; %Rate o f d e g r a d a t i o n o f Vpr p e r hour
136 kVpu = 0 . 0 8 6 6 4 ; %Rate o f d e g r a d a t i o n o f Vpu p e r hour
137 aGagVif =2e−6; %A s s o c i a t i o n c o n s t a n t o f Gag wi th Vi f ( / m o l e c u l e )
138 n= l e n g t h ( u ) ; %number o f p e p t i d e s
139 %GET PROTEINS FROM WHICH PEPTIDES COME FROM
140 [ nGag , nVpu , nVpr , nVif , nRev , nTat , nGagPol , nEnv , nNef ]= l e n g t h g e n e s ( genes ) ;
141
142 ns9 =4+(5* n S e l f ) +9 ;
143 TP=6+(12* n S e l f ) ;
144 TP2=4+(5* n S e l f ) ;
145 n s s =TP+147+n ;
146 NN= n s s +n ;
147
148 r = z e r o s (NN+(10* n ) , 1 ) ;
149 %P r o d u c t i o n / d e g r a d a t i o n o f M and T
150
151 r ( 1 ) = gM; % s u p p l y o f M
152 r ( 2 ) = dM*x ( 1 ) ; % d e g r a d a t i o n o f M where x ( 1 ) =M
153 r ( 3 ) = gT ; % s u p p l y o f T
154 r ( 4 ) =dT*x ( 2 ) ; % d e g r a d a t i o n o f T
155 r ( 5 ) = bT*x ( 1 ) *x ( 2 ) ; % b i n d i n g o f T t o M where x ( 2 ) i s T
156 r ( 6 ) = uT*x ( 3 ) ; % u n b i n d i n g of T from M where x ( 3 ) =M−T
157 r ( 7 : 6 + n S e l f ) =0 ;%%p S e l f ( : ) * p r t * S e l f P r o t ; %p r o d u c t i o n o f s e l f p e p t i d e s
i n t h e c y t o p l a s m ( may need t o be tweeked )
158 r (6+ n S e l f +1 :6+(2* n S e l f ) ) =0 ;%%dPc*x ( 5 : 4 + n S e l f ) ; %x ( 1 : n S e l f ) = S e l f
P e p t i d e s i n c y t o p l a s m
159 r (6+ (2* n S e l f ) +1 :6+(3* n S e l f ) ) = g S e l f ( : ) ;%. * x ( 5 : 4 + n S e l f ) ; %
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t r a n s p o r t a t i o n o f s e l f p e p t i d e s t o t h e ER from t h e c y t o p l a s m
160 r (6+ (3* n S e l f ) +1 :6+(4* n S e l f ) ) =dPc ( : ) . * x (4+ n S e l f +1 :4+(2* n S e l f ) ) ; %
d e g r a d a t i o n o f s e l f p e p t i d e s i n t h e ER ,
x (4+ n S e l f +1:4+2* n S e l f ) = s e l f p e p t i d e s i n t h e ER
161 r (6+ (4* n S e l f ) +1 :6+(5* n S e l f ) ) =bP*x (4+ n S e l f +1 :4+(2* n S e l f ) ) *x ( 1 ) ;
%b i n d i n g of s e l f p e p t i d e s t o M, x ( 1 ) =M
162 r (6+ (5* n S e l f ) +1 :6+(6* n S e l f ) ) = u S e l f ( : ) . * x (4+(2* n S e l f ) +1 :4+(3* n S e l f ) ) ;
%u n b i n d i n g where x (4+(2* n S e l f ) +1:4+3* n S e l f ) =M−S e l f P e p
163 r (6+ (6* n S e l f ) +1 :6+(7* n S e l f ) ) =c *x (4+ n S e l f +1 :4+(2* n S e l f ) ) *x ( 3 ) ; %s e l f
pep b i n d i n g t o MT, where x ( 3 ) =M−T FOR NOW THIS WILL CHANGE
164 r (6+ (7* n S e l f ) +1 :6+(8* n S e l f ) ) =q* u S e l f ( : ) . * x (4+(3* n S e l f ) +1 :4+(4* n S e l f ) ) ;
% u n b i n d i n g of s e l f P e p from M−T , where
x (4+(3* n S e l f +1:4+4* n S e l f ) ) =M−T−S e l f P e p
165 r (6+ (8* n S e l f ) +1 :6+(9* n S e l f ) ) =uTv*x (4+(3* n S e l f ) +1 :4+(4* n S e l f ) ) ; %
u n b i n d i n g of T from M−T−S e l f P e p
166 r (6+ (9* n S e l f ) +1 :6+(10* n S e l f ) ) =e *x (4+(2* n S e l f ) +1 :4+(3* n S e l f ) ) ;
%e g r e s s i o n o f M−S e l f P e p where x ( ( 2 * n S e l f ) +1:3* n S e l f ) =M−S e l f P e p
167 r (6+(10* n S e l f ) +1 :6+(11* n S e l f ) ) = u S e l f ( : ) . * x (4+(4* n S e l f ) +1 :4+(5* n S e l f ) ) ;
%u n b i n d i n g of S e l f P e p on c e l l s u r f a c e
x ( ( 4 * n S e l f ) +1:5* n S e l f ) =Me−S e l f P e p
168 r (6+(11* n S e l f ) +1 :6+(12* n S e l f ) ) =0 ;% dMe*x ( 4 ) ; % where x ( 4 ) = Me
169
170 %V i r a l P r o t e i n s− t h e i r i n t i a l l e v e l s w i l l be s e t
171 %SP=6+(12* n S e l f ) ;
172 TP=6+(12* n S e l f ) ;%SPN+(11* n ) ;
173 TP2=4+(5* n S e l f ) ;
174 r ( TP+1)= t b +( t a d d * aTa t * f a c t o r *x ( TP2 +8) / ( 1 + aTa t * f a c t o r *x ( TP2 +8) ) ) *pv ;
%t r a n s c r i p t i o n o f FN
175 r ( TP+2)=sp *x ( TP2 +1) ; %s p l i c i n g o f FN
176 r ( TP+3)=kdeg *x ( TP2 +1) ; %d e g r a d a t i o n o f FN
177 r ( TP+4)=sp *x ( TP2 +2) ; %s p l i c i n g o f SN
178 r ( TP+5)=kdeg *x ( TP2 +2) ; %d e g r a d a t i o n o f SN
179 r ( TP+6)=kexp *x ( TP2 +3) ; %e x p o r t o f MN
180 r ( TP+7)=kdeg *x ( TP2 +3) ; %d e g r a d a t i o n o f MN
181 r ( TP+8)=kdeg *x ( TP2 +4) ; %d e g r a d a t i o n o f MC
182 r ( TP+9)=fRNAr* t r * fRev *x ( TP2 +4) ; %t r a n s l a t i o n o f Rev p r o t e i n
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183 r ( TP+10)=kRevc*x ( TP2 +5) ; %d e g r a d a t i o n o f Rev i n c y t o p l a s m
184 r ( TP+11)=kimp*x ( TP2 +5) ; %i m p o r t o f Rev t o n u c l e u s
185 r ( TP+12)=fRNAt* t r * f T a t *x ( TP2 +4) ; %t r a n s l a t i o n o f Ta t p r o t e i n
186 r ( TP+13)=kRevc*x ( TP2 +6) ; %d e g r a d a t i o n o f Ta t i n c y t o p l a s m
187 r ( TP+14)=kimp*x ( TP2 +6) ; %i m p o r t o f Ta t t o n u c l e u s
188 r ( TP+15)=kRevn*x ( TP2 +7) ; %d e g r a d a t i o n o f Revn
189 r ( TP+16)=kRevn*x ( TP2 +8) ; %d e g r a d a t i o n o f Tatn
190 r ( TP+17)=kexp *x ( TP2 +7) ; %e x p o r t o f Revn
191 r ( TP+18)=ka1 * f a c t o r 2 *x ( TP2 +1) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FN
192 r ( TP+19)=kd1*x ( TP2 +9) ; %u n b i n d i n g of Rev from FNR1
193 r ( TP+20) =(1−d ) * sp *x ( TP2 +9) ; %s p l i c i n g o f FNR1
194 r ( TP+21)=kdeg *x ( TP2 +9) ; %d e g r a d a t i o n o f FNR1 and r e l e a s e o f 1 Rev
195 r ( TP+22) =(1−d ) * sp *x ( TP2 +10) ; %s p l i c i n g o f SNR1 t o produced MN and
r e l e a s e 1 Rev
196 r ( TP+23)=kdeg *x ( TP2 +10) ; %d e g r a d a t i o n o f SNR1 t o r e l e a s e 1 Rev
197 r ( TP+24)=ka1 * f a c t o r 2 *x ( TP2 +2) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SN
198 r ( TP+25)=kd1*x ( TP2 +10) ; %u n b i n d i n g of Rev from SNR1
199 r ( TP+26)= k a i * f a c t o r 2 *x ( TP2 +9) *x ( TP2 +7) ; % b i n d i n g of Rev t o FNR1 t o
produce FNR2
200 r ( TP+27)= k d i *x ( TP2 +11) ; %u n b i n d i n g of Rev from FNR2
201 r ( TP+28) =(1−d ) * sp *x ( TP2 +11) ; %s p l i c i n g o f FNR2 t o produce SNR2
202 r ( TP+29)=kdeg *x ( TP2 +11) ; %d e g r a d a t i o n o f FNR2 t o r e l e a s e 2 Revs
203 r ( TP+30) =(1−d ) * sp *x ( TP2 +12) ; %s p l i c i n g o f SNR2 t o produce MN and 2* Revs
204 r ( TP+31)=kdeg *x ( TP2 +12) ; %d e g r a d a t i o n o f SNR2 t o r e l e a s e 2 Revs
205 r ( TP+32)= k a i * f a c t o r 2 *x ( TP2 +10) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR1 t o
produce SNR2
206 r ( TP+33)= k d i *x ( TP2 +12) ; %u n b i n d i n g of 1 Rev from SNR2
207 r ( TP+34)= k a i * f a c t o r 2 *x ( TP2 +11) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR2 t o
produce FNR3
208 r ( TP+35)= k d i *x ( TP2 +13) ; %u n b i n d i n g of Rev from FNR3
209 r ( TP+36) =(1−d ) * sp *x ( TP2 +13) ; %s p l i c i n g o f FNR3 t o produce SNR3
210 r ( TP+37)=kdeg *x ( TP2 +13) ; %d e g r a d a t i o n o f SNR3 t o r e l e a s e 3 Revs
211 r ( TP+38) =(1−d ) * sp *x ( TP2 +14) ; %s p l i c i n g o f SNR3 t o produce MN and 3* Revs
212 r ( TP+39)=kdeg *x ( TP2 +14) ; %d e g r a d a t i o n o f SNR3 t o r e l e a s e 3 Revs
213 r ( TP+40)= k a i * f a c t o r 2 *x ( TP2 +12) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR2 t o
produce SNR3
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214 r ( TP+41)= k d i *x ( TP2 +14) ; %u n b i n d i n g of 1 Rev from SNR3
215 r ( TP+42)= k a i * f a c t o r 2 *x ( TP2 +13) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR3 t o
produce FNR4
216 r ( TP+43)= k d i *x ( TP2 +15) ; %u n b i n d i n g of Rev from FNR4
217 r ( TP+44) =(1−d ) * sp *x ( TP2 +15) ; %s p l i c i n g o f FNR4 t o produce SNR4
218 r ( TP+45)=kdeg *x ( TP2 +15) ; %d e g r a d a t i o n o f FNR4 t o r e l e a s e 4 Revs
219 r ( TP+46) =(1−d ) * sp *x ( TP2 +16) ; %s p l i c i n g o f SNR4 t o produce MN and 4 Revs
220 r ( TP+47)=kdeg *x ( TP2 +16) ; %d e g r a d a t i o n o f SNR4 t o produce 4 Revs
221 r ( TP+48)= k a i * f a c t o r 2 *x ( TP2 +14) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR3 t o
produce SNR4
222 r ( TP+49)= k d i *x ( TP2 +16) ; %u n b i n d i n g of Rev from SNR4 t o produce SNR3
223 r ( TP+50)= k a i * f a c t o r 2 *x ( TP2 +15) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR4 t o
produce FNR5
224 r ( TP+51)= k d i *x ( TP2 +17) ; %u n b i n d i n g of Rev from FNR5 t o produce FNR4
225 r ( TP+52) =(1−d ) * sp *x ( TP2 +17) ; %s p l i c i n g o f FNR5 t o produce SNR5
226 r ( TP+53)=kdeg *x ( TP2 +17) ; %d e g r a d a t i o n o f FNR5 t o r e l e a s e 5 Revs
227 r ( TP+54) =(1−d ) * sp *x ( TP2 +18) ; %s p l i c i n g o f SNR5 t o produce MN and 5 Revs
228 r ( TP+55)=kdeg *x ( TP2 +18) ; %d e g r a d a t i o n o f SNR5 t o produce 5 Revs
229 r ( TP+56)= k a i * f a c t o r 2 *x ( TP2 +16) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR4 t o
produce SNR5
230 r ( TP+57)= k d i *x ( TP2 +18) ; %u n b i n d i n g of Rev from SNR5 t o produce SNR4
231 r ( TP+58)= k a i * f a c t o r 2 *x ( TP2 +17) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR5 t o
produce FNR6
232 r ( TP+59)= k d i *x ( TP2 +19) ; %u n b i n d i n g of Rev from FNR6
233 r ( TP+60) =(1−d ) * sp *x ( TP2 +19) ; %s p l i c i n g o f FNR6 t o produce SNR6
234 r ( TP+61)=kdeg *x ( TP2 +19) ; %d e g r a d a t i o n o f FNR6 t o produce 6 Revs
235 r ( TP+62) =(1−d ) * sp *x ( TP2 +20) ; %s p l i c i n g o f SNR6 t o produce MN and 6 Revs
236 r ( TP+63)=kdeg *x ( TP2 +20) ; %d e g r a d a t i o n o f SNR6 t o produce 6 Revs
237 r ( TP+64)= k a i * f a c t o r 2 *x ( TP2 +18) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR5 t o
produce SNR6
238 r ( TP+65)= k d i *x ( TP2 +20) ; %u n b i n d i n g of Rev from SNR6 t o produce SNR5
239 r ( TP+66)= k a i * f a c t o r 2 *x ( TP2 +19) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR6 t o
produce FNR7
240 r ( TP+67)= k d i *x ( TP2 +21) ; %u n b i n d n i g o f Rev from FNR7 t o produce FNR6
241 r ( TP+68) =(1−d ) * sp *x ( TP2 +21) ; %s p l i c i n g o f FNR7 t o produce SNR7
242 r ( TP+69)=kdeg *x ( TP2 +21) ; %d e g r a d a t i o n o f FNR7 t o r e l e a s e 7 Revs
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243 r ( TP+70)=kexp *x ( TP2 +21) ; %e x p o r t o f FNR7 t o produce FC and 7 Revs i n
c y t o p l a s m
244 r ( TP+71) =(1−d ) * sp *x ( TP2 +22) ; %s p l i c i n g o f SNR7 t o produce MN and 7 Revs
245 r ( TP+72)=kdeg *x ( TP2 +22) ; %d e g r a d a t i o n o f SNR7 t o produce 7 Revs
246 r ( TP+73)= k a i * f a c t o r 2 *x ( TP2 +20) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR6 t o
produce SNR7
247 r ( TP+74)= k d i *x ( TP2 +22) ; %u n b i n d i n g of Rev from SNR7 t o produce SNR6
248 r ( TP+75)=kexp *x ( TP2 +22) ; %e x p o r t o f SNR7 t o produce SC and 7 Revs i n
c y t o p l a s m
249 r ( TP+76)= k a i * f a c t o r 2 *x ( TP2 +21) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR7 t o
produce FNR8
250 r ( TP+77)= k d i *x ( TP2 +25) ; %u n b i n d i n g of Rev from FNR8 t o produce FNR7
251 r ( TP+78) =(1−d ) * sp *x ( TP2 +25) ; %s p l i c i n g o f FNR8 t o produce SNR8
252 r ( TP+79)=kdeg *x ( TP2 +25) ; %d e g r a d a t i o n o f FNR8 t o r e l e a s e 8 Revs
253 r ( TP+80)=kexp *x ( TP2 +25) ; %e x p o r t o f FNR8 t o produce FC and 8 Revs i n
c y t o p l a s m
254 r ( TP+81) =(1−d ) * sp *x ( TP2 +26) ; %s p l i c i n g o f SNR8 t o produce MN and 8 Revs
255 r ( TP+82)=kdeg *x ( TP2 +26) ; %d e g r a d a t i o n o f SNR8 t o r e l e a s e 8 Revs
256 r ( TP+83)= k a i * f a c t o r 2 *x ( TP2 +22) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR7 t o
produce SNR8
257 r ( TP+84)= k d i *x ( TP2 +26) ; %u n b i n d i n g of Rev from SNR8 t o produce SNR7
258 r ( TP+85)=kexp *x ( TP2 +26) ; %e x p o r t o f SNR8 t o produce SC and 8 Revs i n
c y t o p l a s m
259 r ( TP+86)= k a i * f a c t o r 2 *x ( TP2 +25) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR8 t o
produce FRN9
260 r ( TP+87)= k d i *x ( TP2 +27) ; %u n b i n d i n g of Rev from FNR9 t o produce FNR8
261 r ( TP+88) =(1−d ) * sp *x ( TP2 +27) ; %s p l i c i n g o f FNR9 t o produce SNR9
262 r ( TP+89)=kdeg *x ( TP2 +27) ; %d e g r a d a t i o n o f FNR9 t o r e l e a s e 9 Revs
263 r ( TP+90)=kexp *x ( TP2 +27) ; %e x p o r t o f FNR9 t o produce FC and 9 Revs i n
c y t o p l a s m
264 r ( TP+91) =(1−d ) * sp *x ( TP2 +28) ; %s p l i c i n g o f SNR9 t o produce MN and 9 Revs
265 r ( TP+92)=kdeg *x ( TP2 +28) ; %d e g r a d a t i o n o f SNR9 t o produce 9 Revs
266 r ( TP+93)= k a i * f a c t o r 2 *x ( TP2 +26) *x ( TP2 +7) ; %b i n d i n g o f Rev t o SNR8 t o
produce SNR9
267 r ( TP+94)= k d i *x ( TP2 +28) ; %u n b i n d i n g of Rev from SNR9 t o produce SNR8
268 r ( TP+95)=kexp *x ( TP2 +28) ; %e x p o r t o f SNR9 t o produce SC and 9 Revs i n
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c y t o p l a s m
269 r ( TP+96)= k a i * f a c t o r 2 *x ( TP2 +27) *x ( TP2 +7) ; %b i n d i n g o f Rev t o FNR9 t o
produce FNR10
270 r ( TP+97)= k d i *x ( TP2 +29) ; %u n b i n d i n g of Rev from FNR10 t o p roduce FNR9
271 r ( TP+98) =(1−d ) * sp *x ( TP2 +29) ; %s p l i c i n g o f FNR10 t o p roduce SNR10
272 r ( TP+99)=kdeg *x ( TP2 +29) ; %d e g r a d a t i o n o f FNR10 t o r e l e a s e 10 Revs
273 r ( TP+100)=kexp *x ( TP2 +29) ; %e x p o r t o f FNR10 t o p roduce FC and 10 Revs
i n c y t o p l a s m
274 r ( TP+101) =(1−d ) * sp *x ( TP2 +30) ; %s p l i c i n g o f SNR10 t o p roduce MN and 10
Revs
275 r ( TP+102)=kdeg *x ( TP2 +30) ; %d e g r a d a t i o n o f SNR10 t o r e l e a s e 10 Revs
276 r ( TP+103)= k a i * f a c t o r 2 *x ( TP2 +28) *x ( TP2 +7) ; %b i n d i n g of Rev t o SNR9 t o
produce SNR10
277 r ( TP+104)= k d i *x ( TP2 +30) ; %u n b i n d i n g o f Rev from SNR10 t o p roduce SNR9
278 r ( TP+105)=kexp *x ( TP2 +30) ; %e x p o r t o f SNR10 t o p roduce SC and 10 Revs
i n c y t o p l a s m
279 r ( TP+106)= k a i * f a c t o r 2 *x ( TP2 +29) *x ( TP2 +7) ; %b i n d i n g of Rev t o FNR10 t o
p roduce FNR11
280 r ( TP+107)= k d i *x ( TP2 +31) ; %u n b i n d i n g o f Rev from FNR11 t o p roduce FNR10
281 r ( TP+108) =(1−d ) * sp *x ( TP2 +31) ; %s p l i c i n g o f FNR11 t o p roduce SNR11
282 r ( TP+109)=kdeg *x ( TP2 +31) ; %d e g r a d a t i o n o f FNR11 t o r e l e a s e 11 Revs
283 r ( TP+110)=kexp *x ( TP2 +31) ; %e x p o r t o f FNR11 t o p roduce FC and 11 Revs
i n c y t o p l a s m
284 r ( TP+111) =(1−d ) * sp *x ( TP2 +32) ; %s p l i c i n g o f SNR11 t o p roduce MN and 11
Revs
285 r ( TP+112)=kdeg *x ( TP2 +32) ; %d e g r a d a t i o n o f SNR11 t o r e l e a s e 11 Revs
286 r ( TP+113)= k a i * f a c t o r 2 *x ( TP2 +30) *x ( TP2 +7) ; %b i n d i n g of Rev t o SNR10 t o
p roduce SNR11
287 r ( TP+114)= k d i *x ( TP2 +32) ; %u n b i n d i n g of Rev from SNR11 t o p roduce SNR10
288 r ( TP+115)=kexp *x ( TP2 +32) ; %e x p o r t o f SNR11 t o p roduce SC and 11 Revs
i n c y t o p l a s m
289 r ( TP+116)= k a i * f a c t o r 2 *x ( TP2 +31) *x ( TP2 +7) ; %b i n d i n g of Rev t o FNR11 t o
p roduce FNR12
290 r ( TP+117)= k d i *x ( TP2 +33) ; %u n b i n d i n g of Rev from FNR12 t o p roduce FNR11
291 r ( TP+118) =(1−d ) * sp *x ( TP2 +33) ; %s p l i c i n g o f FNR12 of p roduce SNR12
292 r ( TP+119)=kdeg *x ( TP2 +33) ; %d e g r a d a t i o n o f FNR12 t o r e l e a s e 12 Revs
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293 r ( TP+120)=kexp *x ( TP2 +33) ; %e x p o r t o f FNR12 t o p roduce FC and 12 Revs
i n c y t o p l a s m
294 r ( TP+121) =(1−d ) * sp *x ( TP2 +34) ; %s p l i c i n g o f SNR12 t o p roduce MN and 12
Revs
295 r ( TP+122)=kdeg *x ( TP2 +34) ; %d e g r a d a t i o n o f SNR12 t o r e l e a s e 12 Revs
296 r ( TP+123)= k a i * f a c t o r 2 *x ( TP2 +32) *x ( TP2 +7) ; %b i n d i n g of Rev t o SNR11 t o
p roduce SNR12
297 r ( TP+124)= k d i *x ( TP2 +34) ; %u n b i n d i n g o f Rev from SNR12 t o p roduce SNR11
298 r ( TP+125)=kexp *x ( TP2 +34) ; %e x p o r t o f SNR12 t o p roduce SC and 12 Revs
i n c y t o p l a s m
299 r ( TP+126)=fGag * t r *x ( TP2 +23) ; %t r a n s l a t i o n o f Gag p r o t e i n from
f u l l −l e n g t h mRNA i n c y t o p l a s m
300 r ( TP+127)=kGag*x ( TP2 +35) ; %d e g r a d a t i o n o f Gag p r o t e i n
301 r ( TP+128)=kbud *x ( TP2 +35) ; %e x p o r t o f Gag due t o budding
302 r ( TP+129) =2*( kbud *( x ( TP2 +35) ) ) / n G a g v i r i o n ; %e x p o r t o f 2 gmRNA due t o
budding
303 r ( TP+130)= t r *0 .05* x ( TP2 +23) ;%t r a n s l a t i o n o f GagPol from FC
304 r ( TP+131)=kGag * 1 .1* x ( TP2 +36) ; %d e g r a d a t i o n o f GagPol i n c y t o p l a s m ??
305 r ( TP+132)=kbud *x ( TP2 +36) ; %budding of GagPol
306 r ( TP+133) =0 .15* t r *x ( TP2 +24) ; %t r a n s l a t i o n o f gp160 from SC
307 r ( TP+134)=kEnv*x ( TP2 +37) ; %d e g r a d a t i o n o f gp160 i n c y t o p l a s m
308 r ( TP+135)=kbud *x ( TP2 +37) ; %budding o f gp160
309 CGagVif=aGagVif *x ( TP2 +35) *x ( TP2 +38) ;
310 r ( TP+136) =0 .1* t r *x ( TP2 +24) ; %t r a n s l a t i o n o f Vi f from SC
311 r ( TP+137)= kVif *x ( TP2 +38) ; %d e g r a d a t i o n o f Vi f
312 r ( TP+138)=kbud *CGagVif ;%budding of Vi f
313 r ( TP+139)= t r *0 .27* x ( TP2 +24) ;%t r a n s l a t i o n o f Vpr
314 r ( TP+140)=kVpr*x ( TP2 +39) ;%d e g r a d a t i o n o f Vpr
315 r ( TP+141)=kbud *x ( TP2 +39) ; %budding o f Vpr
316 r ( TP+142) =0 .1* t r *x ( TP2 +24) ; % t r a n s l a t i o n o f Vpu
317 r ( TP+143)=kVpu*x ( TP2 +40) ; % d e g r a d a t i o n o f Vpu
318 r ( TP+144)=kbud *x ( TP2 +40) ; %budding o f Vpu
319 r ( TP+145) = ( 0 . 5 * t r ) *x ( TP2 +4) ; %T r a n s l a t i o n o f Nef
320 r ( TP+146) =( kRevc*x ( TP2 +41) ) ; %d e g r a d a t i o n o f Nef x ( TP2 +41)=Nef
321 r ( TP+147)=kbud *x ( TP2 +41) ; %budding o f Nef
322 %P r o d u c t i o n o f Rev p e p t i d e s
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323 r ( TP+147+1:TP+147+nRev ) = ps ( 1 : nRev ) *kRevc*x ( TP2 +5) ; %where
x ( TP2 +5)=Revc
324 %P r o d u c t i o n o f Ta t P e p t i d e s
325 r ( TP+147+nRev +1: TP+147+nRev+ nTat ) =ps ( nRev +1: nRev+ nTat ) * kTat *x ( TP2 +6) ;
%x ( TP2 +6)= Ta t c
326 %P r o d u c t i o n o f Nef P e p t i d e s
327 r ( TP+147+nRev+ nTat +1: TP+147+nRev+ nTat +nNef ) =ps ( nRev+ nTat +1: nRev+ nTat +nNef )
328 *kRevc*x ( TP2 +41) ; %x ( TP2 +41)=Nefc
329 %P r o d u c t i o n o f Gag P e p t i d e s
330 nRTN=nRev+ nTat +nNef ;
331 r ( TP+147+nRTN+1: TP+147+nRTN+nGag ) =ps (nRTN+1:nRTN+nGag ) *kGag*x ( TP2 +35) ;
% x ( TP2 +35)=Gag
332 %P r o d u c t i o n o f GagPol P e p t i d e s
333 nRTNG=nRTN+nGag ;
334 r ( TP+147+nRTNG+1: TP+147+nRTNG+nGagPol ) =ps (nRTNG+1:nRTNG+nGagPol )
335 *kGag * 1 .1* x ( TP2 +36) ; % x ( TP2 +36)=GagPol
336 %P r o d u c t i o n o f Env P e p t i d e s
337 nRTNGP=nRTNG+nGagPol ;
338 r ( TP+147+nRTNGP+1: TP+147+nRTNGP+nEnv ) =ps (nRTNGP+1:nRTNGP+nEnv )
339 *kEnv*x ( TP2 +37) ; % x ( TP2 +37)=Env
340 %P r o d u c t i o n o f Vi f P e p t i d e s
341 nRTNGPE=nRTNGP+nEnv ;
342 r ( TP+147+nRTNGPE+1: TP+147+nRTNGPE+ nVif ) =ps (nRTNGPE+1:nRTNGPE+ nVif )
343 * kVif *x ( TP2 +38) ; %x ( TP2 +38)= Vif
344 %P r o d u c t i o n o f Vpr P e p t i d e s
345 nRTNGPEV=nRTNGPE+ nVif ;
346 r ( TP+147+nRTNGPEV+1: TP+147+nRTNGPEV+nVpr ) =ps (nRTNGPEV+1:nRTNGPEV+nVpr )
347 *kVpr*x ( TP2 +39) ; %x ( TP2 +39)=Vpr
348 %P r o d u c t i o n o f Vpu P e p t i d e s
349 nRTNGPEVV=nRTNGPEV+nVpr ;
350 r ( TP+147+nRTNGPEVV+1: TP+147+nRTNGPEVV+nVpu ) =ps (nRTNGPEVV+1:nRTNGPEVV+nVpu )
351 *kVpu*x ( TP2 +40) ; % x ( TP2 +40)=Vpu
352 %D e g r a d a t i o n o f p e p t i d e s i n t h e c y t o p l a s m
353 n s s =TP+147+n ;
354 r ( n s s +1: n s s +n ) =dPeps ( : ) . * x ( TP2 +49+1: TP2+49+n ) ; %dP = d e g r a d a t i o n o f
p e p t i d e s i n c y t o p l a s m x ( TP2 +49+1: TP2+49+n ) =CPi
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355 NN= n s s +n ;
356 r (NN+1:NN+n , 1 ) =g ( : ) . * x ( TP2 +49+1: TP2+49+n ) ; %p e p t i d e s u p p l y =
g ( 1 : n ) . * ( CP1 : CPn )
357 r (NN+n +1:NN+(2* n ) ) =dP*x ( TP2+49+n +1: TP2+49+(2* n ) ) ; % p e p t i d e
d e g r a d a t i o n where P=x ( TP2+49+n +1: TP2+49+2*n ) ;
358 r (NN+(2* n ) +1:NN+(3* n ) ) = bPeps ( : ) . * x ( TP2+49+n +1: TP2+49+(2* n ) ) *x ( 1 ) ; %
b i n d i n g o f P i t o M where x ( 1 ) =M
359 r (NN+(3* n ) +1:NN+(4* n ) ) = u ( : ) . * x ( TP2+49+(2* n ) +1: TP2+49+(3* n ) ) ; %
u n b i n d i n g of P i from M where x ( TP2+49+2*n +1: TP2+49+3*n ) =M−Pi .
360 r (NN+(4* n ) +1:NN+(5* n ) ) =c *x ( TP2+49+n +1: TP2+49+(2* n ) ) *x ( 3 ) ; % p e p t i d e
b i n d i n g t o M−T where x ( 3 ) =M−T
361 r (NN+(5* n ) +1:NN+(6* n ) ) = q*u ( : ) . * x ( TP2+49+(3* n ) +1: TP2+49+(4* n ) ) ;
%u n b i n d i n g of p e p t i d e from M−T , where
x ( TP2+49+(3* n ) +1: TP2+49+4*n ) =M−T−Pi
362 r (NN+(6* n ) +1:NN+(7* n ) ) = uTv*x ( TP2+49+(3* n ) +1: TP2+49+(4* n ) ) ; %u n b i n d i n g
of T from M−Pi
363 r (NN+(7* n ) +1:NN+(8* n ) ) = e *x ( TP2+49+(2* n ) +1: TP2+49+(3* n ) ) ; %e g r e s s i o n
o f Me−Pi where x ( TP2+49+2*n +1: TP2+49+3*n ) =M−Pi
364 r (NN+(8* n ) +1:NN+(9* n ) ) = u ( : ) . * x ( TP2+49+(4* n ) +1: TP2+49+(5* n ) ) ; %
u n b i n d i n g of P i from Me where x ( TP2+49+(4* n ) +1: TP2+49+5*n ) = MePi
365 r (NN+(9* n ) +1:NN+(10* n ) ) = 0 ;% dMe*x ( 4 ) ; % where x ( 4 ) = Me
366 dxd t = z e r o s ( TP2 +49+(5* n ) , 1 ) ;
367 dMdt1= −r (NN+(2* n ) +1:NN+(3* n ) ) + r (NN+(3* n ) +1:NN+(4* n ) ) ;
368 dMdt2=−r (6+ (4* n S e l f ) +1 :6+(5* n S e l f ) ) + r (6+(5* n S e l f ) +1 :6+(6* n S e l f ) ) ;
369 dxd t ( 1 ) =sum ( dMdt1 ) +sum ( dMdt2 ) + r ( 1 )− r ( 2 ) −r ( 5 ) + r ( 6 ) ; %dM/ d t
370 dTdt1= r (NN+(6* n ) +1:NN+(7* n ) ) ;
371 dTdt2= r (6+(8* n S e l f ) +1 :6+(9* n S e l f ) ) ;
372 dxd t ( 2 ) =sum ( dTdt1 ) +sum ( dTdt2 ) + r ( 3 )−r ( 4 ) −r ( 5 ) + r ( 6 ) ; %dT / d t
373 dMTdt1= −r (NN+(4* n ) +1:NN+(5* n ) ) + r (NN+(5* n ) +1:NN+(6* n ) ) ;
374 dMTdt2=−r (6+ (6* n S e l f ) +1 :6+(7* n S e l f ) ) + r (6+(7* n S e l f ) +1 :6+(8* n S e l f ) ) ;
375 dxd t ( 3 ) =sum ( dMTdt1 ) +sum ( dMTdt2 ) + r ( 5 ) − r ( 6 ) ; %dMT/ d t
376 dMedt= r (NN+(8* n ) +1:NN+(9* n ) )− r (NN+(9* n ) +1:NN+(10* n ) ) ;
377 dMedtSe l f = r (6+(10* n S e l f ) +1 :6+(11* n S e l f ) )−r (6+(11* n S e l f ) +1 :6+(12* n S e l f ) ) ;
378 dxd t ( 4 ) = sum ( dMedt ) +sum ( dMedtSe l f )−dMe*x ( 4 ) ; % dMe / d t
379 dxd t ( 5 : 4 + n S e l f ) =0 ;%r ( 7 : 6 + n S e l f )−r (6+ n S e l f +1 :6+(2* n S e l f ) )
380 −r (6+ (2* n S e l f ) +1 :6+(3* n S e l f ) ) ; % d S e l f P e p C y t / d t
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381 dxd t (4+ n S e l f +1 :4+(2* n S e l f ) ) = r (6+(2* n S e l f ) +1 :6+(3* n S e l f ) )
382 −r (6+ (3* n S e l f ) +1 :6+(4* n S e l f ) )−r (6+ (4* n S e l f ) +1 :6+(5* n S e l f ) )
383 + r (6+(5* n S e l f ) +1 :6+(6* n S e l f ) )−r (6+ (6* n S e l f ) +1 :6+(7* n S e l f ) )
384 + r (6+(7* n S e l f ) +1 :6+(8* n S e l f ) ) ; %dSelfER / d t
385 dxd t (4+(2* n S e l f ) +1 :4+(3* n S e l f ) ) = r (6+(4* n S e l f ) +1 :6+(5* n S e l f ) )
386 −r (6+ (5* n S e l f ) +1 :6+(6* n S e l f ) ) + r (6+(8* n S e l f ) +1 :6+(9* n S e l f ) )
387 −r (6+ (9* n S e l f ) +1 :6+(10* n S e l f ) ) ; %dM−S e l f P e p / d t
388 dxd t (4+(3* n S e l f ) +1 :4+(4* n S e l f ) ) = r (6+(6* n S e l f ) +1 :6+(7* n S e l f ) )
389 −r (6+ (7* n S e l f ) +1 :6+(8* n S e l f ) )−r (6+ (8* n S e l f ) +1 :6+(9* n S e l f ) ) ;
%dM−T−S e l f P e p / d t
390 dxd t (4+(4* n S e l f ) +1 :4+(5* n S e l f ) ) = r (6+(9* n S e l f ) +1 :6+(10* n S e l f ) )
391 −r (6+(10* n S e l f ) +1 :6+(11* n S e l f ) ) ; %dMe−S e l f P e p / d t
392 i f t <8.5
393 dxd t ( TP2 +1: TP2 +4) =0;
394 e l s e
395 dxd t ( TP2 +1)= r ( TP+1)−r ( TP+2)−r ( TP+3)−r ( TP+18)+ r ( TP+19) ;%FN
396 dxd t ( TP2 +2)= r ( TP+2)−r ( TP+4)−r ( TP+5)−r ( TP+24)+ r ( TP+25) ;%SN
397 dxd t ( TP2 +3)= r ( TP+4)−r ( TP+6)−r ( TP+7)+ r ( TP+22)+ r ( TP+30)+ r ( TP+38)+ r ( TP+46)
398 + r ( TP+54)+ r ( TP+62)+ r ( TP+71)+ r ( TP+81)+ r ( TP+91)+ r ( TP+101)+ r ( TP+111)
399 + r ( TP+121) ;%MN
400 dxd t ( TP2 +4)= r ( TP+6)−r ( TP+8) ; %MC
401 end
402 i f t <8.5
403 dxd t ( TP2 +5)=−kRevc*x ( TP2 +5) ;
404 dxd t ( TP2 +6)=−kTat *x ( TP2 +6) ;
405 e l s e
406 dxd t ( TP2 +5)= r ( TP+9)−r ( TP+10)−r ( TP+11)+ r ( TP+17) +(7* r ( TP+70) ) +(7* r ( TP+75) )
407 +(8* r ( TP+80) ) +(8* r ( TP+85) ) +(9* r ( TP+90) ) +(9* r ( TP+95) ) +(10* r ( TP+100) )
408 +(10* r ( TP+105) ) +(11* r ( TP+110) ) +(11* r ( TP+115) ) +(12* r ( TP+120) )
409 +(12* r ( TP+125) ) ; %Rev Cytoplasm
410 dxd t ( TP2 +6)= r ( TP+12)−r ( TP+13)−r ( TP+14)+fRNAt* t r * f T a t *x ( TP2 +24) ; %Tat
Cytoplasm
411 end
412 i f t <8.5
413 dxd t ( TP2 +7: TP2 +34) =0;
414 e l s e
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415 dxd t ( TP2 +7)= r ( TP+11)−r ( TP+15)−r ( TP+17)−r ( TP+18)+ r ( TP+19)+ r ( TP+21)+ r ( TP+22)
416 + r ( TP+23)−r ( TP+24)+ r ( TP+25)−r ( TP+26)+ r ( TP+27) +(2* r ( TP+29) ) +(2* r ( TP+30) )
417 +(2* r ( TP+31) )−r ( TP+32)+ r ( TP+33)−r ( TP+34)+ r ( TP+35) +(3* r ( TP+37) ) +(3* r ( TP+38) )
418 +(3* r ( TP+39) )−r ( TP+40)+ r ( TP+41)−r ( TP+42)+ r ( TP+43) +(4* r ( TP+45) ) +(4* r ( TP+46) )
419 +(4* r ( TP+47) )−r ( TP+48)+ r ( TP+49)−r ( TP+50)+ r ( TP+51) +(5* r ( TP+53) ) +(5* r ( TP+54) )
420 +(5* r ( TP+55) )−r ( TP+56)+ r ( TP+57)−r ( TP+58)+ r ( TP+59) +(6* r ( TP+61) ) +(6* r ( TP+62) )
421 +(6* r ( TP+63) )−r ( TP+64)+ r ( TP+65)−r ( TP+66)+ r ( TP+67) +(7* r ( TP+69) ) +(7* r ( TP+71) )
422 +(7* r ( TP+72) )−r ( TP+73)+ r ( TP+74)−r ( TP+76)+ r ( TP+77) +(8* r ( TP+79) ) +(8* r ( TP+81) )
423 +(8* r ( TP+82) )−r ( TP+83)+ r ( TP+84)−r ( TP+86)+ r ( TP+87) +(9* r ( TP+89) ) +(9* r ( TP+91) )
424 +(9* r ( TP+92) )−r ( TP+93)+ r ( TP+94)−r ( TP+96)+ r ( TP+97) +(10* r ( TP+99) ) +(10* r ( TP+101) )
425 +(10* r ( TP+102) )−r ( TP+103)+ r ( TP+104)−r ( TP+106)+ r ( TP+107) +(11* r ( TP+109) )
426 +(11* r ( TP+111) ) +(11* r ( TP+112) )−r ( TP+113)+ r ( TP+114)−r ( TP+116)+ r ( TP+117)
427 +(12* r ( TP+119) ) +(12* r ( TP+121) ) +(12* r ( TP+122) )−r ( TP+123)+ r ( TP+124) ;
%Revn
428 dxd t ( TP2 +8)= r ( TP+14)−r ( TP+16) ; %Tatn
429 dxd t ( TP2 +9)= r ( TP+18)−r ( TP+19)−r ( TP+20)−r ( TP+21)−r ( TP+26)+ r ( TP+27) ;
%FNR1
430 dxd t ( TP2 +10)= r ( TP+20)−r ( TP+22)−r ( TP+23)+ r ( TP+24)−r ( TP+25)−r ( TP+32)+ r ( TP+33) ;
%SNR1
431 dxd t ( TP2 +11)= r ( TP+26)−r ( TP+27)−r ( TP+28)−r ( TP+29)−r ( TP+34)+ r ( TP+35) ;
%FNR2
432 dxd t ( TP2 +12)= r ( TP+28)−r ( TP+30)−r ( TP+31)+ r ( TP+32)−r ( TP+33)−r ( TP+40)+ r ( TP+41) ;
%SNR2
433 dxd t ( TP2 +13)= r ( TP+34)−r ( TP+35)−r ( TP+36)−r ( TP+37)−r ( TP+42)+ r ( TP+43) ;
%FNR3
434 dxd t ( TP2 +14)= r ( TP+36)−r ( TP+38)−r ( TP+39)+ r ( TP+40)−r ( TP+41)−r ( TP+48)+ r ( TP+49) ;
%SNR3
435 dxd t ( TP2 +15)= r ( TP+42)−r ( TP+43)−r ( TP+44)−r ( TP+45)−r ( TP+50)+ r ( TP+51) ;
%FNR4
436 dxd t ( TP2 +16)= r ( TP+44)−r ( TP+46)−r ( TP+47)+ r ( TP+48)−r ( TP+49)−r ( TP+56)+ r ( TP+57) ;
%SNR4
437 dxd t ( TP2 +17)= r ( TP+50)−r ( TP+51)−r ( TP+52)−r ( TP+53)−r ( TP+58)+ r ( TP+59) ;
%FNR5
438 dxd t ( TP2 +18)= r ( TP+52)−r ( TP+54)−r ( TP+55)+ r ( TP+56)−r ( TP+57)−r ( TP+64)+ r ( TP+65) ;
%SNR5
439 dxd t ( TP2 +19)= r ( TP+58)−r ( TP+59)−r ( TP+60)−r ( TP+61)−r ( TP+66)+ r ( TP+67) ;
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%FNR6
440 dxd t ( TP2 +20)= r ( TP+60)−r ( TP+62)−r ( TP+63)+ r ( TP+64)−r ( TP+65)−r ( TP+73)+ r ( TP+74) ;
%SNR6
441 dxd t ( TP2 +21)= r ( TP+66)−r ( TP+67)−r ( TP+68)−r ( TP+69)−r ( TP+70)−r ( TP+76)+ r ( TP+77) ;
%FNR7
442 dxd t ( TP2 +22)= r ( TP+68)−r ( TP+71)−r ( TP+72)+ r ( TP+73)−r ( TP+74)−r ( TP+75)−r ( TP+83)
443 + r ( TP+84) ; %SNR7
444 dxd t ( TP2 +23)= r ( TP+70)+ r ( TP+80)+ r ( TP+90)+ r ( TP+100)+ r ( TP+110)+ r ( TP+120)
445 −kdeg *x ( TP2 +23)−r ( TP+129) ; %FC
446 dxd t ( TP2 +24)= r ( TP+75)+ r ( TP+85)+ r ( TP+95)+ r ( TP+105)+ r ( TP+115)+ r ( TP+125)
447 −kdeg *x ( TP2 +24) ; %SC
448 dxd t ( TP2 +25)= r ( TP+76)−r ( TP+77)−r ( TP+78)−r ( TP+79)−r ( TP+80)−r ( TP+86)+ r ( TP+87) ;
%FNR8
449 dxd t ( TP2 +26)= r ( TP+78)−r ( TP+81)−r ( TP+82)+ r ( TP+83)−r ( TP+84)−r ( TP+85)−r ( TP+93)
450 + r ( TP+94) ; %SNR8
451 dxd t ( TP2 +27)= r ( TP+86)−r ( TP+87)−r ( TP+88)−r ( TP+89)−r ( TP+90)−r ( TP+96)+ r ( TP+97) ;
%FNR9
452 dxd t ( TP2 +28)= r ( TP+88)−r ( TP+91)−r ( TP+92)+ r ( TP+93)−r ( TP+94)−r ( TP+95)−r ( TP+103)
453 + r ( TP+104) ; %SNR9
454 dxd t ( TP2 +29)= r ( TP+96)−r ( TP+97)−r ( TP+98)−r ( TP+99)−r ( TP+100)−r ( TP+106)+ r ( TP+107) ;
%FNR10
455 dxd t ( TP2 +30)= r ( TP+98)−r ( TP+101)−r ( TP+102)+ r ( TP+103)−r ( TP+104)−r ( TP+105)
456 −r ( TP+113)+ r ( TP+114) ; %SNR10
457 dxd t ( TP2 +31)= r ( TP+106)−r ( TP+107)−r ( TP+108)−r ( TP+109)−r ( TP+110)−r ( TP+116)
458 + r ( TP+117) ; %FNR11
459 dxd t ( TP2 +32)= r ( TP+108)−r ( TP+111)−r ( TP+112)+ r ( TP+113)−r ( TP+114)−r ( TP+115)
460 −r ( TP+123)+ r ( TP+124) ; %SNR11
461 dxd t ( TP2 +33)= r ( TP+116)−r ( TP+117)−r ( TP+118)−r ( TP+119)−r ( TP+120) ; %FNR12
462 dxd t ( TP2 +34)= r ( TP+118)−r ( TP+121)−r ( TP+122)+ r ( TP+123)−r ( TP+124)−r ( TP+125) ;
%SNR12
463 end
464 i f t <8.5
465 dxd t ( TP2 +35)=−kGag*x ( TP2 +35) ;
466 dxd t ( TP2 +36)=−kGag * 1 .1* x ( TP2 +36) ;
467 dxd t ( TP2 +37)=−kEnv*x ( TP2 +37) ;
468 dxd t ( TP2 +38)=−kVif *x ( TP2 +38) ;
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469 dxd t ( TP2 +39)=−kVpr*x ( TP2 +39) ;
470 dxd t ( TP2 +40)=−kVpu*x ( TP2 +40) ;
471 dxd t ( TP2 +41)=−kRevc*x ( TP2 +41) ;
472 dxd t ( TP2 + 4 2 : 4 9 ) =0;
473 e l s e
474 dxd t ( TP2 +35)= r ( TP+126)−r ( TP+127)−r ( TP+128) ; %Gag
475 dxd t ( TP2 +36)= r ( TP+130)−r ( TP+131)−r ( TP+132) ; %GagPol
476 dxd t ( TP2 +37)= r ( TP+133)−r ( TP+134)−r ( TP+135) ; %Env
477 dxd t ( TP2 +38)= r ( TP+136)−r ( TP+137)−r ( TP+138) ; %Vif
478 dxd t ( TP2 +39)= r ( TP+139)−r ( TP+140)−r ( TP+141) ; %Vpr
479 dxd t ( TP2 +40)= r ( TP+142)−r ( TP+143)−r ( TP+144) ; %Vpu
480 dxd t ( TP2 +41)= r ( TP+145)−r ( TP+146)−r ( TP+147) ; %Nef
481 dxd t ( TP2 +42) =( kbud *( x ( TP2 +35) ) ) / n G a g v i r i o n ; %Vi r ion ’
482 dxd t ( TP2 +43)= r ( TP+128) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %GagVir ion
483 dxd t ( TP2 +44)= r ( TP+132) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %GagPo lVi r ion
484 dxd t ( TP2 +45)= r ( TP+135) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %EnvVir ion
485 dxd t ( TP2 +46)= r ( TP+138) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %V i f V i r i o n
486 dxd t ( TP2 +47)= r ( TP+141) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %VprVi r ion
487 dxd t ( TP2 +48)= r ( TP+144) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %VpuVir ion
488 dxd t ( TP2 +49)= r ( TP+147) ;%/ ( ( kbud *( x ( 3 5 ) ) ) / n G a g v i r i o n ) ; %N e f V i r i o n
489 end
490 dxd t ( TP2 +49+1: TP2+49+n ) = r ( TP+147+1:TP+147+n )−r (NN+1:NN+n )−r ( n s s +1: n s s +n ) ;
% dCPi / d t = p r o d u c t i o n−s u p p p l y t o ER − d e g r a d a t i o n i n c y t o p l a s m
491 dxd t ( TP2+49+n +1: TP2 +49+(2* n ) ) = r (NN+1:NN+n )−r (NN+n +1:NN+(2* n ) )
492 −r (NN+(2* n ) +1:NN+(3* n ) ) + r (NN+(3* n ) +1:NN+(4* n ) )
493 − r (NN+(4* n ) +1:NN+(5* n ) ) + r (NN+(5* n ) +1:NN+(6* n ) ) ; %dPi / d t
494 dxd t ( TP2 +49+(2* n ) +1: TP2+49+(3* n ) ) = r (NN+(2* n ) +1:NN+(3* n ) )
495 − r (NN+(3* n ) +1:NN+(4* n ) ) + r (NN+(6* n ) +1:NN+(7* n ) )
496 − r (NN+(7* n ) +1:NN+(8* n ) ) ; %dMPi / d t
497 dxd t ( TP2 +49+(3* n ) +1: TP2+49+(4* n ) ) = r (NN+(4* n ) +1:NN+(5* n ) )
498 − r (NN+(5* n ) +1:NN+(6* n ) ) − r (NN+(6* n ) +1:NN+(7* n ) ) ; % dMTPi / d t
499 dxd t ( TP2 +49+(4* n ) +1: TP2+49+(5* n ) ) = r (NN+(7* n ) +1:NN+(8* n ) ) −
r (NN+(8* n ) +1:NN+(9* n ) ) ; % dMePi / d t
500 end
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